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Summary
Small non-coding RNAs like microRNAs (miRNAs) are important regulators of gene expres-
sion. miRNAs bind to a member of the Argonaute (Ago) protein family and guide them to partially
complementary sequences on target messenger RNAs (mRNAs). Argonaute-miRNA complexes
silence target mRNAs by inducing translational repression and mRNA decay. To mediate these
effects, Argonaute proteins interact with a member of the TNRC6 protein family, which recruit
deadenylase and decapping complexes to the mRNA.
Post-transcriptional gene regulation by miRNAs has been implicated in central processes like
differentiation, development and cell proliferation. Consequently, miRNAs also play important roles
in diseases including cancer. In cancer, miRNAs can regulate both tumor suppressors and onco-
genes. To get deeper insights into the role of miRNAs in cancer, we analyzed the role of miRNAs
in cancer stem cells. Cancer stem cells are an undifferentiated subpopulation of cancer cells
with properties of normal tissue stem cells including self-renewal and multipotency. Interestingly,
it is thought that cancer stem cells drive tumor growth, contribute significantly to therapy resis-
tance and cause tumor recurrence after therapy. We therefore isolated cancer stem cells and
non cancer stem cells from Glioblastoma multiforme, an highly malignant brain tumor, which is
thought to be driven by a cancer stem cell population. We analyzed miRNA expression between
cancer stem cells and their non stem cell counterpart and identified miRNAs including miR-9,
miR-9* and miR-17 to be preferentially expressed in glioblastoma stem cells. Inhibition of these
miRNAs led to significantly reduced tumor growth in vitro, decreased the cancer stem cell pool
and stimulated cell differentiation. To further characterize the function of miR-9*, we identified
target genes including the putative transcription factor Calmodulin-binding transcription activator
1 (CAMTA1). CAMTA1 was validated as novel tumor suppressor in Glioblastoma multiforme, as
overexpression of CAMTA1 led to strongly reduced tumor growth in vitro and in vivo and CAMTA1
expression correlated with patient survival. As CAMTA1 is a putative transcription factor, we fur-
ther characterized potential CAMTA1 regulated genes. We identified the anti-proliferative cardiac
hormone natriuretic peptide A (NPPA), which might at least in part mediate the tumor suppressive
effects of CAMTA1. Therefore, these findings provide deep insights into novel players in Glioblas-
toma multiforme and cancer stem cell biology and could provide a basis for therapeutic strategies.
Although miRNAs, Ago and TNRC6 proteins are expected to function in the cytoplasm by reg-
ulating mRNAs, they have also been identified in the cell nucleus. However, whereas the post-
transcriptional mechanisms in the cytoplasm are well understood, not much is known on their
nuclear functions. Furthermore, it is totally unknown how they reach the nucleus to fulfill their nu-
clear functions. To better understand these processes, we characterized nuclear transport path-
ways of Ago and TNRC6 proteins. We show that Ago and TNRC6 proteins mainly localize to the
cytoplasm but can be also identified in the nucleus of human cells. We provide direct evidence for
nuclear import of Ago proteins and show that both Ago and TNRC6 shuttle between the nucleus
and cytoplasm. We suggest that Ago proteins are imported by multiple redundant importins and
show that TNRC6 proteins are imported via Importin-beta (Impβ). Therefore, both protein families
are imported via different import routes. Nuclear export of both Ago and TNRC6 proteins was de-
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pendent on Crm1. Finally, we show that both protein families can regulate each others import by
a cytoplasmic retention mechanism. In this mechanism, Ago-TNRC6 interaction prevents nuclear
import, whereas free Ago and TNRC6 pools can be imported into the nucleus. We further provide
evidence that Ago prevents the nuclear import of TNRC6 proteins by masking nuclear localization
signals in TNRC6. We therefore suggest that nuclear import balances cytoplasmic Ago-TNRC6
levels, a mechanism that might be important for cytoplasmic miRNA-mediated gene silencing as
well as possible nuclear Ago and TNRC6 functions.
Part I.
General introduction
1. Small non-coding RNAs
Whether genes are transcribed and translated is strictly regulated by diverse transcriptional and
post-transcriptional mechanisms. Transcriptional mechanisms include epigenetic regulation by
chromatin modification and binding of transcription factors. Whether the transcribed gene is in-
deed translated into a protein is additionally regulated on the post-transcriptional level. These
mechanisms determine the stability of the messenger RNA (mRNA) and can repress transla-
tion by the ribosome. Of these variable post-transcriptional mechanisms, especially the biology
of post-transcriptional gene silencing (PTGS) by small non-coding RNAs (ncRNA) caught special
interest and is a major topic of this work.
Small ncRNAs were originally identified in Caenorhabditis elegans (C. elegans). Victor Ambros
and Gary Ruvkun discovered that the unusual lin-4 gene produces a small ncRNA, that can
suppress lin-14 protein translation via a proposed ’antisense RNA-RNA interaction’ mechanism
(Lee et al., 1993, Wightman et al., 1993). Andrew Fire and Craig Mello then made the observa-
tion that long double-stranded RNAs (dsRNA) can function as highly potent triggers that silence
complementary genes (Fire et al., 1998). This process, called RNA interference (RNAi) made
it theoretically possible to knockdown each gene with known sequence in C. elegans. The first
RNAi experiments in mammalian cells were carried out years later in the Tuschl lab using shorter
dsRNAs, overcoming the interferon response of mammalian cells against long dsRNAs (Elbashir
et al., 2001). The actual boost in the field came with the discovery of another small ncRNA let-7
(Reinhart et al., 2000). Strikingly, it was found that let-7 is not restricted to nematodes but is rather
conserved throughout animals, including humans (Pasquinelli et al., 2000). The same was true for
lin-4 and subsequently, other small ncRNAs were identified in diverse organisms (Lagos-Quintana
et al., 2001).
The minimal triggers for RNAi are called small interfering RNAs (siRNA) (Elbashir et al., 2001).
siRNAs are approximately 21 nucleotides long and double-stranded. They bind to perfect com-
plementarity target sites on mRNAs and function through induction of endonucleolytic cleav-
age. Small ncRNAs like let-7 and lin-4 on the other side are called micro RNAs (miRNAs) (Lagos-
Quintana et al., 2001, Lau et al., 2001, Lee and Ambros, 2001). miRNAs are approximately 21 to
24 nucleotides long and double-stranded, i.e. very similar to siRNAs. The difference however
is their mode of target RNA binding, as miRNAs bind to only partially complementary target
sites. In mammals, miRNA binding sites are located within 3’ untranslated regions (UTR) of the
target mRNA and binding induces either translational repression or exonucleolytic degradation
(Huntzinger and Izaurralde, 2011). Of note, during PTGS of mRNAs in mammals, small ncRNAs
generally function as miRNAs and not as siRNAs, i.e. they do not mediate target mRNA cleavage
(Fabian et al., 2010). How mammalian miRNAs are generated will be described in part I section 2.
Both siRNAs and miRNAs need associated proteins to mediate their effects. These protein
components are targeted sequence-specifically to the miRNA or siRNA binding site on the tar-
get mRNA. Argonaute proteins are the key players in siRNA- and miRNA-mediated gene silenc-
ing processes (Meister, 2013). Argonautes and siRNAs form an RNA-induced silencing complex
(RISC), with Argonaute being the catalytically active component that mediates target RNA cleav-
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age. Gene silencing by miRNAs is mediated by the miRNA-induced silencing complex (miRISC). To
mediate silencing, miRISC contains not only the miRNA and Argonaute, but additionally another
key protein component, which are the so-called TNRC6 proteins (Braun et al., 2013). TNRC6
proteins recruit downstream factors including deadenylase and decapping complexes, which then
mediate both translational repression and mRNA degradation. How Argonaute and TNRC6 pro-
teins function and how translational repression and mRNA degradation are induced will be pre-
sented in part I sections 3 and 4 of this introduction.
Since their discovery, small RNA-mediated gene silencing processes have been identified in
many organisms including C. elegans, mammals, plants and yeast (Bartel, 2004). The cellular
functions that are under miRNA control are broad and include central processes like differentia-
tion, cell proliferation, metabolism and apoptosis (Peters and Meister, 2007, Bushati and Cohen,
2007). Consequently, miRNAs have also been identified to play important roles in disease pro-
cesses including cancer (Esquela-Kerscher and Slack, 2006). How miRNAs regulate cancerous
processes is one major part of the this thesis and will be presented in part I section 1.1.
While it became obvious that miRNAs regulate important cellular processes by mediating PTGS
of target mRNAs, the small ncRNA world has been further expanded by the discovery of novel
small RNA classes. One example are Piwi-interacting RNAs (piRNAs), which are exclusively ex-
pressed in the germ line where they silence transposons (Weick and Miska, 2014). Major contri-
butions to the discovery of novel miRNAs had the availability of the complete genomic sequences
of model organisms like C. elegans, Drosophila, human and mouse, allowing annotation of novel
small RNA species (Bartel, 2004). Furthermore, the applicability of deep-sequencing technolo-
gies enabled fast and simultaneous sequencing of complete RNomes. Along with the discovery of
new small ncRNA classes, also other mechanisms have been identified by which the small RNA
mediates its gene regulatory effects. One example is transcriptional gene silencing, in which small
RNAs travel into the nucleus bound to Argonaute proteins and induce epigenetic chromatin modi-
fications (Castel and Martienssen, 2013). As nuclear small RNA-mediated functions will introduce
to the second major part of this thesis, they will be presented in part I section 1.1.
2. Biogenesis of miRNAs in mammals
The processes described in this section generate miRNAs in an ordered multistep biogenesis
pathway. The generated miRNAs are then loaded onto Argonaute proteins to build up miRISC,
which can bind to target mRNAs to induce silencing. Of note, only the mammalian miRNA bio-
genesis pathway will be described here, as all work during this study has been done in the human
cells. In addition, it will be shown how siRNAs are loaded onto Argonaute and where siRNAs can
originate from in the mammalian system.
miRNA genes and transcription
Most mammalian miRNA genes are transcribed by RNA polymerase II (RNAP II) (Lee et al.,
2004). The primary transcripts of miRNA-containing genes are called primary miRNA (pri-miRNA).
These pri-miRNA transcripts are capped and polyadenylated and of variable length (Cai et al.,
2004). The miRNA sequence is part of a stem-loop structure within the pri-miRNA, which serves
as substrate for a sequential processing pathway (Figure 1.2.1).
miRNA genes can be found in diverse patterns of genomic organization. Intragenic miRNAs
are mostly located within introns or rarely exons of protein-coding or non-coding host genes that
have additional functions beyond miRNA expression (Rodriguez et al., 2004). They are mostly
transcribed as part of the host gene but can also be expressed from own independent promoters
(Ramalingam et al., 2014). Intergenic miRNAs are encoded in previously unannotated regions of
the human genome and do require an own promoter. Of note, a clear differentiation between in-
tergenic and intragenic miRNAs is sometimes problematic, especially regarding non-coding hosts
genes. In these cases, it is often not clear whether the non-coding transcript solely encodes the
miRNA (i.e. intergenic miRNA gene) or has additional functions (i.e. intragenic miRNA gene).
Many miRNAs are multiply encoded within the genome (Kim et al., 2009). One example is
hsa-miR-9 (hsa, Homo sapiens), which is highly expressed in human brain and encoded in three
separate loci miR-9-1, miR-9-2 and miR-9-3. Another important property of genomic miRNA or-
ganization are so-called miRNA clusters, i.e. one miRNA transcription unit gives rise to several
different miRNAs. Indeed, most mammalian miRNAs are encoded within those clusters, which
are expressed as a common polycistronic transcript, are presumably coregulated but indepen-
dently processed (Altuvia et al., 2005, Lagos-Quintana et al., 2001, Chaulk et al., 2011). One of
Figure 1.2.1. (following page) Biogenesis pathway of miRNAs in mammals. A, pri-miRNA transcripts are capped
(Cap) and polyadenylated and contain single or clustered miRNA stem-loops. B, The microprocessor complex comprising
Drosha and DGCR8 bind the pri-miRNA stem-loop and Drosha cleaves near the stem to release the pre-miRNA. The 5p
arms is indicated in red, the 3p arms in blue. C, Exp5 bound to RanGTP binds the pre-miRNA and exports as trimeric
complex to the cytoplasm. In the cytoplasm, Exp5 and RanGDP release the pre-miRNA. D, Dicer and one of its cofactors
TRBP and PACT bind the pre-miRNA and Dicer cleaves near the pre-miRNA loop. The product is a mature miRNA het-
eroduplex. E, The RISC loading complex senses the guide (here: 5p arm) and passenger strand and mediates handover
of the miRNA to one of the four human Argonaute proteins (Ago1-4). The passenger strand is removed and degraded,
whereas the guide strand stays within Argonaute. F, Functional miRISC minimally contains the miRNA guide strand, one
Argonaute protein and a member of the TNRC6 family proteins. TSS, transcriptional start site; I, endonucleolytic cleavage
site.
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the best characterized examples is the miR-17~92 cluster. It is expressed as a single intergenic
polycistronic pri-miRNA that contains six tandem stem-loop structures yielding miR-17, miR-18a,
miR-19a, miR-20a, miR-19b-1 and miR-92-1. Furthermore, most of the mammalian miRNAs are
assigned to so-called miRNA families, which are miRNAs with the same seed sequence (Kim
et al., 2009). The seed sequence of a miRNA includes nucleotides 2 to 8 and base pairing of
this seed sequence has been shown to be sufficient for miRNA-mRNA binding (Lewis et al.,
2003). It is expected that members of a miRNA family have redundant or partially redundant func-
tions. Members of one miRNA family are marked with an alphabetical character suffix, as for
example miR-18a and miR-18b.
Primary miRNA processing by Drosha
The first step of the miRNA processing pathway is catalyzed by the so called microprocessor com-
plex (Figure 1.2.1 B). In this step, the stem-loop structure that harbors the miRNA sequence is cut
out from the pri-miRNA transcript. The microprocessor complex consists of the RNaseIII enzyme
Drosha and its cofactor DiGeorge Syndrome Critical Region Gene 8 (DGCR8) (Gregory et al.,
2004, Denli et al., 2004, Han et al., 2004, Landthaler et al., 2004). DGCR8 harbors two double-
stranded RNA-binding domains (dsRBDs) and senses the junction of double-stranded and single-
stranded (ds, ss) sequences at the base of the pri-miRNA hairpin. DGCR8 seems to recruit and
position Drosha on the hairpin, whose RNase III domains mediate cleavage about 11 nucleotides
away from the junction (Han et al., 2006b). This cleavage releases the so-called precursor miRNA
(pre-miRNA), which has a median length of 70 nucleotides and comprises a single stem-loop.
Drosha processing occurs cotranscriptionally and seems to be linked to splicing (Morlando
et al., 2008, Pawlicki and Steitz, 2008, Siomi and Siomi, 2010). In case of intronic miRNAs, pri-
miRNA processing is thought to occur before splicing and indeed, splicing is not prerequisite for
pri-miRNA processing (Kim and Kim, 2007). However, both processes seem to be highly inter-
connected, as introns with a miRNA hairpin are spliced more slowly and the early spliceosome
complex seems to tether introns during Drosha cleavage (Kataoka et al., 2009). However, the
molecular mechanisms that link transcription, splicing and pri-miRNA processing are not charac-
terized in detail. While processing of intronic miRNAs does not obviously affect the expression
levels of the host gene (Kim and Kim, 2007), exonic miRNAs processing should affect host gene
expression. However, this has not been characterized comprehensively.
Precursor miRNA export by Exp5 and processing by Dicer
The pre-miRNA is exported from the nucleus by the karyopherin Exp5 in a RanGTP-dependent
manner (Yi et al., 2003, Bohnsack et al., 2004, Lund et al., 2004, Figure 1.2.1 C). The crys-
tal structure of Exp5 in complex with RanGTP and pre-miR-30a has been resolved and shows
that the Exp5-RanGTP complex recognizes the two nucleotide 3’-overhang generated by Drosha
cleavage and parts of the hairpin stem (Okada et al., 2009, Figure 1.2.1 C right panel). After
transition of the pre-miRNA-Exp5-RanGTP complex through the nuclear pore complex, RanGTP
hydrolysis occurs which releases the pre-miRNA.
In the cytoplasm, the pre-miRNA is bound by Dicer and one of its cofactors TAR RNA bind-
ing protein 2 (TRBP) and protein activator of PKR (PACT) (Haase et al., 2005, Chendrimada
et al., 2005, Lee et al., 2006c). Dicer is, similar to Drosha, an RNaseIII enzyme, i.e. it cleaves
dsRNA. TRBP and PACT are dsRNA binding proteins (dsRBPs) with three dsRBDs. TRBP in-
teracts directly with the helicase domain of Dicer and functions in substrate binding and product
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length determination (Fukunaga et al., 2012). The exact role of PACT and whether PACT directly
contacts Dicer is not known (Lee et al., 2013, Kim et al., 2014a). Both components, Dicer and
TRBP contact the pre-miRNA loop and stem and Dicer’s RNase III domains mediate cleavage
(Zhang et al., 2004, Macrae et al., 2006, Taylor et al., 2013, Wilson et al., 2015, Figure 1.2.1 D
right panel). The product of this step is a short dsRNA of about 21 nucleotides with 2 nucleotides
3’-overhangs, a 5’-phosphate and a 3’-hydroxyl group, i.e. a mature miRNA heteroduplex. The
two strands within the miRNA heteroduplex are called miR-X-5p and miR-X-3p, with 5p and 3p
defining the respective 5’ and 3’ arm of the pre-miRNA where the strand derives from (X is any
miRNA).
miRNA-loading onto Argonaute proteins
To function in PTGS, miRNAs are loaded onto Argonaute proteins (Figure 1.2.1 E). Interest-
ingly, isolated Argonaute proteins hardly bind dsRNAs, indicating that loading of miRNAs onto
Argonaute is an assisted mechanism (Meister et al., 2005, Lima et al., 2009, Hauptmann and
Meister, 2013). In addition, Argonaute proteins associate with only one strand of the miRNA het-
eroduplex. Therefore it must be somehow decided which strand stays associated with Argonaute
and the other strand must be displaced.
The proteins that assist miRNA-loading include the microprocessor components Dicer and
TRBP and a multi-protein chaperone machinery (Dueck and Meister, 2014). Dicer and TRBP di-
rectly associate with Argonaute proteins to form the so-called RISC loading complex (Figure 1.2.1
E). Both loading and strand selection occurs within this complex. TRBP is thought to sense the
correct strand, whereas Dicer hands over the miRNA heteroduplex to Argonaute (Maniataki and
Mourelatos, 2005, Gregory et al., 2005, Noland et al., 2011). Furthermore, Argonaute proteins as-
sociate with the chaperone heat shock protein 90 (Hsp90) and the FK506-binding immunophilins
Fkbp4/5, which can function as co-chaperones (Frohn et al., 2012, Martinez et al., 2013, Pare
et al., 2013). It has been suggested from the investigation of Argonaute loading in plants and
flies, that these chaperones keep Argonaute in an open conformation that can accommodate
the miRNA duplex (Iki et al., 2010, Iwasaki et al., 2010, Johnston et al., 2010, Martinez et al.,
2013). By a not completely understood mechanism, the miRNA duplex is unwound and one
miRNA strand is removed (Dueck and Meister, 2014). By definition, the miRNA strand that re-
sides in Argonaute is the guide strand, whereas the discarded strand is the passenger strand,
also often referred to as miRNA* (star) strand.
One important determinant for strand selection is the stability of miRNA ends. The so-called
asymmetry rule describes that the strand with the less thermodynamically stable 5’-end is pref-
erentially loaded (Khvorova et al., 2003, Schwarz et al., 2003). Furthermore, Ago proteins have
a strong preference for uridine and adenosine at the 5’-position, which might also contribute to
strand selection (Frank et al., 2010). Whether other determinants of strand selection exist or if
strand selection has a randomized component is not well understood.
Formation of functional silencing complexes
Ago proteins are part of larger effector complexes also known as miRNA-induced silencing com-
plex (miRISC). Although the exact composition of miRISC is still a matter of debate, miRISC is
commonly defined by its minimal components consisting of the miRNA guide strand, one Ago
protein and one TNRC6 protein (Kim et al., 2009). Whether miRISC assembly follows an ordered
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sequence and which mechanisms regulate the assembly of miRISC are not known in detail. De-
tails on Argonaute and TNRC6 proteins and their function within miRISC are described in part I
section 3. Furthermore, section 4 will discuss the current knowledge on miRISC assembly and
target mRNA binding.
Origins and mode of function of siRNAs
Whereas miRNAs mediate gene silencing by inducing translational repression and mRNA degra-
dation, siRNAs function by inducing endonucleolytic cleavage of the target RNA. In the mam-
malian system, siRNAs either originate from endogenous sources or enter the cell from exoge-
nous sources as experimentally transfected siRNAs or viral siRNAs for example.
Endogenous siRNAs (endo-siRNAs) have been identified in mouse oocytes and embryonic
stem cells, however their detailed function is not clear (Tam et al., 2008, Babiarz et al., 2008,
Watanabe et al., 2008). Endo-siRNAs can originate from various genomic sources, which include
hybridized sense-antisense transcripts, transcripts from inverted repeat regions and spliced tran-
scripts from protein-coding genes that hybridize with antisense transcripts from homologous pseu-
dogenes (Figure 1.2.2 A, Tam et al., 2008, Watanabe et al., 2008). The resulting longer dsRNAs
are then processed by Dicer into 21 nucleotide long siRNAs (Figure 1.2.2 B). After loading onto
Argonaute, endo-siRNAs are thought to induce endonucleolytic cleavage of target RNAs.
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Figure 1.2.2. Sources of siRNAs in mammalians. A, Endogenous siRNAs can originate from various sources, that
generate long dsRNAs. These include sense-antisense transcription, transcription of inverted repeat regions and tanscrip-
tion from gene-pseudogene pairs. B, Long dsRNAs are cleaved by Dicer proteins into short siRNAs, that are loaded onto
Argonaute. C, Exogenous experimentally transfected siRNAs are phosphorylated at the 5’ end by Clp1 and loaded onto
Argonaute in a Dicer-dependent manner. TSS, transcriptional start site; I, endonucleolytic cleavage site.
For experimental RNAi, siRNAs are synthesized and supplied as 21 nucleotide long RNA
duplexes (Elbashir et al., 2001). These chemically synthesized siRNAs generally possess a 5’-
hydroxyl moiety and consequently, must get first phosphorylated for stable Argonaute interaction
(Figure 1.2.2 C). Indeed, immediately after entry into the cell, the siRNA 5’-hydroxyl groups are
phosphorylated by the human RNA kinase Clp1 (Weitzer and Martinez, 2007). Loading of siRNAs
seems to depend on Dicer and also follows the asymmetry rule (Khvorova et al., 2003, Schwarz
et al., 2003, Sakurai et al., 2011). The resulting RISC, minimally consisting of an siRNA and an
Argonaute protein then binds the mRNA and induces mRNA cleavage. The cleavage products
are degraded by the exosome from their 3’ ends or by the exonuclease Xrn1 from their 5’ ends
(Orban and Izaurralde, 2005). Of note, the long dsRNAs that have been used in the first effec-
tive RNAi experiments in C. elegans (part I section 1, Fire et al., 1998) are processed by the
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C. elegans dicer protein DCR-1 into siRNAs, which then associate with Argonaute (Parrish et al.,
2000, Zamore et al., 2000, Hammond et al., 2000, Ketting et al., 2001).
In nematodes, plants and insects, RNAi can function as an antiviral defense mechanism, that
generates siRNAs from and consequently against viral genomes or their dsRNA intermediates
(Ding and Voinnet, 2007). This mechanism however does not seem to be active in mammals,
although conflicting reports show that this is still under debate (Jeang, 2012, Maillard et al., 2013,
Li et al., 2013).
3. Argonaute and TNRC6 proteins
3.1. Argonaute proteins are key players in miRNA-mediated
gene silencing
Argonaute proteins are the key protein components in all sRNA-mediated gene silencing pro-
cesses that have been characterized so far (Meister, 2013). Argonaute proteins are the direct
binding partners of small ncRNAs, which target the Argonaute protein to complementary or par-
tially complementary target RNAs.
Argonaute proteins are highly conserved from prokaryotes to eukaryotes. All eukaryotes ana-
lyzed so far contain minimally one Argonaute protein, with the exception of Saccharomyces cere-
visiae (S. cerevisiae) (Swarts et al., 2014). Phylogenetically, Argonaute genes cluster into three
distinct clades: the Ago clade, Piwi clade and the worm-specific Wago clade (Meister, 2013). Ago
clade members interact with miRNAs and siRNAs and are components of miRISC and RISC. Piwi
clade members bind to a distinct small ncRNA class, called Piwi-interacting RNAs (piRNAs). Both
Piwi and piRNAs are specifically expressed in testes, are mainly nuclear and repress transpos-
able elements in the male germ line (Siomi et al., 2011). Wago proteins bind diverse small ncRNA
classes and have similarly diverse functions including siRNA-guided gene silencing and epige-
netic transcriptional silencing (Ketting, 2011). The number of Argonaute proteins varies substan-
tially between organisms. Mammals contain four Ago and four Piwi clade members, Arabidopsis
thaliana (A. thaliana) contains ten Ago proteins, Schizosaccharomyces pombe (S. pombe) one
Ago protein, C. elegans 23 Ago and three Piwi clade proteins and Drosophila melanogaster con-
tains two Ago and three Piwi proteins (Peters and Meister, 2007, Tolia and Joshua-Tor, 2007,
Hutvagner and Simard, 2008, Höck and Meister, 2008).
The four human Ago clade members are Ago1, Ago2, Ago3 and Ago4. Of central importance,
only Ago2 is able to cleave target mRNAs, whereas Ago1, Ago3 and Ago4 are catalytically inac-
tive (Meister et al., 2004b, Liu et al., 2004). Therefore, only Ago2 mediates siRNA-guided gene
silencing by endonucleolytic cleavage. The reason for this functional divergence of Ago2 and
Ago1/3/4 is not known in detail. The largely uniform expression pattern of human Ago1-4 would
suggest largely redundant functions. Furthermore, experiments in mouse embryonic stem cells
suggested redundancy at least in this cellular system, as each Ago protein is able to rescue the
phenotype of Ago1-4 deficient cells (Su et al., 2009). Interesting hints towards non-redundant
functions came from the analysis of Ago knockout mice. Whereas Ago2 knockouts are embry-
onic lethal, Ago1, Ago3 and Ago4 knockouts as well as Ago1/3 double knockouts are viable (Liu
et al., 2004, Morita et al., 2007, Cheloufi et al., 2010, Van Stry et al., 2012, Modzelewski et al.,
2012). During embryonic development, Ago2 has an essential function in extra-embryonic tissue
independent of its cleavage activity (Cheloufi et al., 2010). In addition, Ago2 cleavage activity is
important for hematopoiesis, as Ago2 knockout mice which carry a transgene with a cleavage
deficient Ago2 mutant, overcome the early embryonic lethality but die shortly after birth due to
anemia (Cheloufi et al., 2010). This might at least in part result from the erythropoietic miR-451,
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which is Dicer-independently processed by Ago2-mediated cleavage of the precursor (Yang et al.,
2010, Cheloufi et al., 2010, Cifuentes et al., 2010, Rasmussen et al., 2010). Ago4 has been at-
tributed with non-redundant functions in the male germ line, as Ago4 knockouts have defects in
spermatogenesis although the other Ago proteins are expressed in the germ line (Modzelewski
et al., 2012). Taken together, both redundant and non-redundant functions seem to be attributed
to mammalian Ago clade members with cell type and developmental stage-specific effects.
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Figure 1.3.1. Structure of human Ago2 and binding to TNRC6 proteins. A, Structure of human Ago2 bound to
miRNA. Ago2 consists of N (green), PAZ (violet), MID (light blue), and PIWI (brown) domain. The PAZ and MID domain bind
to the 3’- and 5’-ends of the miRNA (miR-20a is shown in red). Of note, nucleotides 11 to 15 of miR-20a were not resolved
in the crystal. The active center of Ago2 is indicated with a broken circle. The lower panel shows the domain architecture
of human Ago2 (hAgo2). B, Active center of Ago2 with DEDH catalytic tetrad and the miRNA guide strand. C, Modeling of
the Ago2-binding peptide of TNRC6B with two tryptophans (depicted as line-angle formula) binding to tryptophan binding
pockets of the Ago2 PIWI domain. Figure adapted from Schraivogel and Meister, 2014.
Ago proteins are characterized by a unique domain architecture, which is highly conserved be-
tween species. Functional studies of Ago proteins have been complicated in the past as truncation
and even point mutations in most cases lead to partial or complete loss-of-function and severely
affect expression levels and protein stability. The crystal structure of human Ago2 was solved re-
cently and provided important insights into Ago protein function and the mechanisms of miRNA-
mediated PTGS (Schirle and MacRae, 2012, Elkayam et al., 2012, Schirle et al., 2014). The Ago
protein adopts a bilobal structure with an N-terminal and C-terminal lobe and a nucleic acid bind-
ing channel between the two lobes (Figure 1.3.1 A). Beginning at the amino terminal end, Ago
proteins are built of a N domain, the Piwi-Argonaute-Zwille (PAZ) domain, the middle (MID) do-
main and the PIWI domain (Meister, 2013). The PAZ domain anchors the 3’-end of the sRNA,
whereas the MID domain anchors the 5’-phosphorylated end. The Piwi domain possesses cleav-
age activity, and is structurally similar to RNaseH, which cleaves the RNA strand of an RNA-DNA
duplex. Cleavage by Ago2 is achieved by the residues DEDH (D597, E637, D669, and H807),
which form a catalytic tetrad in the active center of Ago2 (Figure 1.3.1 B). Linker domains, desig-
nated as L1 to L3, are located between N, PAZ, MID and PIWI domains, interconnect the domains
and also contribute to RNA binding (Schirle and MacRae, 2012).
How do miRNAs bind the target mRNA within the Ago complex? Some nucleotides of the
miRNA sequence are more important for target recognition than others. The so-called seed
region, which comprises nucleotides 2 to 8 from the 5’ end of the miRNA must form perfect
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Watson-Crick base pairs, whereas the surrounding nucleotides are not essential for target mRNA
recognition (Schirle et al., 2014). Interestingly, the crystal structure of hAgo2 revealed that the
seed nucleotides 2 to 6 are conformationally prearranged within Ago2 for pairing with the target
mRNA, whereas the nucleotides outside the seed region are not accessible. Only after formation
of the ternary complex by binding to the target RNA, a conformational change in Ago2 makes
nucleotides 14 to 18 accessible for pairing. However it still remains to be answered how the non-
seed nt contribute to target recognition, specificity and silencing. The remaining nt at the 3’- and
5’-end are not accessible to the target but are associated with Ago2.
How does Ago2 mediate endonucleolytic cleavage? Endonucleolytic cleavage occurs in the
phosphodiester bond opposite of nucleotides 10 and 11 of the siRNA guide, which form the ac-
tive center together with the catalytic tetrad (Figure 1.3.1 B). Perfect complementarity inside and
outside of the seed seems to be necessary to properly orient the scissile phosphate for cleavage
(Ipsaro and Joshua-Tor, 2015). Cleavage is catalyzed by a Mg2+-dependent, not fully understood
mechanism (Schwarz et al., 2004, Tolia and Joshua-Tor, 2007, Schirle et al., 2014). The cleav-
age step leaves a 5’-phosphate and a 3’-hydroxylated end, whereas the siRNA guide strand itself
remains unaffected.
3.2. TNRC6 proteins are the effector proteins recruited by
Argonaute
During miRNA-mediated PTGS, Ago proteins interact with a member of the TNRC6 protein fam-
ily, also known as GW proteins or GW182 family proteins. Drosophila contains one GW protein
(GW182), C. elegans contains two paralogs (AIN-1 and AIN-2) and mammals contain three par-
alogs referred to as TNRC6 (trinucleotide repeat containing 6) A, B and C (Pfaff and Meister,
2013). TNRC6A is the closest mammalian homolog of Drosophila GW182. Here, the domain
structure of TNRC6 proteins will be presented together with the binding mechanism of Ago and
TNRC6 proteins.
TNRC6 proteins contain an N-terminal Ago-binding domain and a C-terminal silencing domain
(Figure 1.3.2). The N-terminal domain, also designated as GW domain, mediates interaction
with Ago clade proteins. This domain is characterized by multiple GW (Glycine-Tryptophan) re-
peats. The interaction between Ago and TNRC6 proteins is mediated by specific tryptophans
of these GW-repeats, that bind into tryptophan binding pockets on the surface of the Ago Piwi
domain (Figure 1.2.1 A and C) (Till et al., 2007, Eulalio et al., 2009a, Baillat and Shiekhattar,
2009, Chekulaeva et al., 2010, Pfaff et al., 2013). Although the GW domain of TNRC6 proteins
contains multiple tryptophans, studies suggest that only a limited set of tryptophans mediate in-
teraction. Furthermore, Ago2 and eventually Ago1/3/4 contain two distinct tryptophan binding
pockets and indeed, binding of two tryptophans is required for stable Ago2-TNRC6 interaction
(Baillat and Shiekhattar, 2009, Chekulaeva et al., 2010, Pfaff et al., 2013). Furthermore, it has
been shown for Ago2, that the two tryptophan binding pockets require a tryptophan distance of
about 10 amino acids, which might at least in part mediate specificity of the interaction (Pfaff
et al., 2013). TNRC6B for example contains two tryptophans pairs that can mediate Ago2 inter-
action (Figure 1.3.2). One is located in the central part of the GW domain, the second one, also
referred to as ’Ago2-hook’, is located in the C-terminal part close to the end of the GW domain
(Till et al., 2007, Pfaff et al., 2013). Regarding TNRC6A, three possible Ago2 binding hot spots
have been identified that partially overlap with those in TNRC6B, indicating similar binding mech-
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anisms (Nishi et al., 2013). Whether multiple tryptophan pairs function cooperatively by a not yet
identified mechanism or whether there are regions with high and low Ago2 affinity remains to
be investigated. In addition, many tryptophans within TNRC6 are separated by 10 amino acids
distance. Therefore, it is not yet known which mechanisms further determine specificity of this
interaction.
TNRC6A v1 1962 aa
TNRC6A v2 1709 aa
TNRC6B 1723 aa
TNRC6C 1690 aa
UBA PAM2 RRMQ-rich GW
Ago2-hook
GW domain silencing domain
Q-rich
Figure 1.3.2. Domain organization of human TNRC6A-C with indicated tryptophan residues. A, Domain organiza-
tion of human TNRC6A variant v1 (NP_055309), TNRC6A v2 (NP_001136112), TNRC6B (NM_001162501) and TNRC6C
(NP_001136112). Starting from the N-terminus, TNRC6 proteins contain a GW domain (green), UBA domain (violet), Q-
rich domain (grey), PAM2 motif (light blue) and RRM (brown). For abbreviations, please refer to the main text. TNRC6A
v1 contains an additional Q-rich domain at the N-terminus. Vertical lines indicate the exact positions for each tryptophan
residue. Validated Ago2 binding sites in TNRC6A and TNRC6B were mapped to amino acid position (red vertical line) or
region (red horizontal line). In TNRC6A, three possible Ago2 binding hot spots have been identified (Takimoto et al., 2009,
Nishi et al., 2013), whereas TNRC6B contain two possible Ago2 binding regions (Till et al., 2007, Pfaff et al., 2013). The
four schemes were aligned to the Ago2-hook (Till et al., 2007).
The C-terminal silencing domain consists of a ubiquitin-associated (UBA)-like domain, a glu-
tamine (Q)-rich domain, a poly-A binding protein interacting motif 2 (PAM2) and an RNA-recognition
motif (RRM). The UBA-like domain as well as the RRM domain are the only structured sequences
in this large 180 kDa protein (Huntzinger and Izaurralde, 2011, Eulalio et al., 2009b). How this hall-
marking unstructured conformation contributes to TNRC6 function remains to be answered. UBA
domains are usually present in proteins involved in the ubiquitin-proteasome system. However,
a function for the TNRC6 UBA domain has not been identified yet and it seems to be dispens-
able for silencing (Lazzaretti et al., 2009). The RRM of Drosophila GW182 seems to lack RNA
binding activity but contributes to miRNA-mediated gene silencing by a yet unknown mechanism
(Eulalio et al., 2009b). In human TNRC6B, the RRM seems to be important for protein function as
well, however the underlying mechanism is unknown as well (Baillat and Shiekhattar, 2009). The
PAM2 is responsible for the interaction with PABP (Huntzinger et al., 2010, Jinek et al., 2010). The
Q-rich region is necessary for P-body localization but dispensable for silencing (Lazzaretti et al.,
2009). How the C-terminal silencing domain functions during PTGS will be described in part I
section 4.
TNRC6 proteins are thought to function redundantly during miRNA-mediated PTGS. Indeed,
knockdown of one or two of the three human TNRC6 paralogs does not have severely affect
PTGS, whereas depletion of all three proteins results in a strong derepression of miRNA-reporter
constructs (Zipprich et al., 2009, Chekulaeva et al., 2011, Hannus et al., 2014). Furthermore, arti-
ficial tethering of the C-terminal domains of TNRC6A-C showed that all three TNRC6 proteins are
capable of activating PTGS (Lazzaretti et al., 2009). TNRC6A, TNRC6B and TNRC6C associate
with all four human Ago proteins and a common set of miRNA targets and miRNAs (Landthaler
et al., 2008, Baillat and Shiekhattar, 2009, Lazzaretti et al., 2009). However, whether indeed all
12 possible Ago-TNRC6 combinations are formed and functional in vivo, and whether some Ago-
TNRC6 combinations are predominantly formed, remains to be investigated.
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3.3. Intracellular localization of gene silencing components
mRNAs are localized in the cytoplasm and consequently, Ago proteins as well as TNRC6 proteins
have also been shown to be mainly localized within the cytoplasm (Jakymiw et al., 2005, Liu et al.,
2005b, Sen and Blau, 2005, Leung et al., 2006, Rüdel et al., 2008). In addition, the miRNA load-
ing machinery has been exclusively found in the cytoplasm, indicating that Ago loading is also a
cytoplasmic process (Ohrt et al., 2008, Gagnon et al., 2014). Ago and TNRC6 proteins show a
granular and equally distributed signal pattern in the cytoplasm when stained with antibodies de-
tecting the endogenous protein (Rüdel et al., 2008, Gagnon et al., 2014). Of importance, different
cell lines, antibodies and staining protocols lead to different Ago2 patterns and localization (Rüdel
et al., 2008, Azuma-Mukai et al., 2008, Benhamed et al., 2012, Gagnon et al., 2014).
Biochemical fractionations confirm this cytoplasmic Ago and TNRC6 pool, however also de-
tect significant amounts of Ago protein in nuclear fractions of mammalian cells (Robb et al.,
2005, Rüdel et al., 2008, Chu et al., 2010, Gagnon et al., 2014). Of note, impurities of nucleo-
cytoplasmic fractionations might partially falsify the amount of nuclear Ago2 and therefore have to
be interpreted carefully. Within nuclear fractions, Ago2 was found in soluble as well as chromatin-
associated fractions, indicating a chromatin-bound and free nuclear Ago2 pool (Ameyar-Zazoua
et al., 2012). The exact amount of nuclear Ago2 is not characterized in detail. Nuclear Ago2 is es-
timated to be approximately five times lower in concentration compared to cytoplasmic Ago2, as
determined by fluorescence correlation spectroscopy of overexpressed eGFP-Ago2 (Ohrt et al.,
2008). Functions have been attributed to nuclear Ago2 and will be discussed in part I section 1.1.
The intracellular distribution of TNRC6 proteins is far less clear. In biochemical fractionations,
endogenous TNRC6A has been identified to be enriched in the cytoplasm but also in the nucleus,
using different antibodies and unknown amounts of extracts in Western Blots (Nishi et al., 2013,
Gagnon et al., 2014). By immunofluorescence, overexpressed TNRC6A-C are almost exclusively
cytoplasmic (Lazzaretti et al., 2009). A similar predominantly cytoplasmic localization has been
observed for TNRC6A, however without clear validation of antibody specificity (Eystathioy et al.,
2002, Eystathioy et al., 2003a Jakymiw et al., 2005, Li et al., 2014). Taken together, the exact
intracellular localization of TNRC6 proteins is not clear.
P-bodies and stress granules as cytoplasmic sites of miRNA-mediated PTGS
It is not yet fully understood how miRISC finds target mRNAs in the cytoplasm. RNA granules,
such as P-bodies, have been implicated in this process, however they are not essential for miRNA-
mediated PTGS as well as for RNAi (Chu and Rana, 2006, Eulalio et al., 2007a, Eulalio et al.,
2009a). P-bodies are thought to be sites where central processes like mRNA decay, nonsense-
mediated decay and PTGS by miRNAs come together, because they contain proteins associated
with those processes (Eulalio et al., 2007a). Of importance, P-bodies are visible especially under
conditions of an overexpressed P-body component and are almost absent without overexpres-
sion. Different reports, cell lines and antibodies lead to conflicting results regarding the presence
of P-bodies without protein overexpression (Eulalio et al., 2007b, Rüdel et al., 2008). Vice versa,
the formation of P-bodies seems to depend on the presence of factors including TNRC6, miRNAs,
Lsm1, DCP1 and DDX6 (Liu et al., 2005a, Rehwinkel et al., 2005, Chu and Rana, 2006, Pauley
et al., 2006, Eulalio et al., 2007b).
It has been proposed that within P-bodies, Ago2 is bound to translationally repressed and tem-
porally stored mRNAs (Kulkarni et al., 2010, Brengues et al., 2005, Cougot et al., 2013). P-body
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localized mRNAs are not bound by ribosomes but can reenter polyribosomes; in addition, mRNA
degradation seems to be active in P-bodies (Bhattacharyya et al., 2006, Eulalio et al., 2007a). Only
a very minor pool of human Ago2 seems to localize to visible P-bodies and in addition, only a
minor pool of P-bodies are Ago2-positive. Therefore the major portion of Ago2 is present in a
free cytoplasmic pool in the above mentioned granular pattern (Leung et al., 2006, Leung and
Sharp, 2013). The proportion of TNRC6 proteins within P-bodies has not been quantified com-
prehensively, but similar P-body associated and free TNRC6 pools can be expected (Yang et al.,
2004). Ago2 seems to be trapped within P-bodies as only a very slow exchange of Ago2 between
the P-body localized and the free Ago2 pool was observed (Aizer et al., 2008). In contrast to this
invariable Ago2 association, P-bodies are of dynamic size and seem to be disassembled during
mitosis, however, a direct interconnection between these dynamics and Ago protein function has
not been shown yet (Yang et al., 2004). Of note, not only Ago2, but also Ago1, Ago3 and Ago4 are
localized to P-bodies when the proteins are overexpressed (Liu et al., 2005b, Pillai et al., 2005,
Sen and Blau, 2005). Similar to human Ago proteins, TNRC6A-C overexpression leads to the for-
mation of P-bodies as well (Meister et al., 2005, Jakymiw et al., 2005, Pillai et al., 2005, Lazzaretti
et al., 2009). The frequently mentioned GW-bodies, which are also visible upon overexpression of
TNRC6 proteins, are very probably identical to P-bodies (Eystathioy et al., 2003b).
Stress granules (SGs) are another type of cytoplasmic bodies, which appear under stress con-
ditions. Stress conditions are for example induced by heat shock or oxidative stress and are ex-
pected to at least in part resemble stress conditions in vivo. The detailed function of SGs during
stress reponse is not known, but similar to P-bodies, SGs are enriched in non-translating mRNAs
(Anderson and Kedersha, 2008). Therefore, it has been supposed that SGs might function as stor-
age centers for untranslated mRNAs, which can be activated again after stress relieve (Anderson
and Kedersha, 2008). Interestingly, Ago2 has been found to localize in SGs during stress condi-
tions and quantifications revealed that about 1 to 10 % of Ago2 is present in SGs (Leung et al.,
2006, Leung and Sharp, 2013). Furthermore, miRNA-mediated repression was relieved upon
stress induction while mRNA stability consequently increased, which is in line with the hypothe-
sized mRNA storage function of SGs (Detzer et al., 2011). Whether Ago2 is still associated with
mRNA in SGs is not known, as well as whether TNRC6 proteins localize to SG.
Of note, the physiological significance of P-bodies and SGs has not been shown and is difficult
to prove experimentally. Therefore, these bodies might still be experimental artifacts, eventually
created by protein aggregation or precipitation under completely unphysiological conditions (see
also discussion in part III section 4). On the other side, it might be thinkable that the granularity of
the Ago2 immunofluorescent signal might present submicroscopical P-body like structures. This
hypothesis also includes, that submicroscopical P-body like structures might result in visible P-
bodies under special conditions like protein expressions. However, whether this is indeed the
case, has not been investigated so far.
miRISC loading, function and degradation can be associated with the endomembrane
system
miRNA-mediated post-transcriptional gene silencing components have been associated with the
endomembrane system (Kim et al., 2014b). The main components of the animal endomembrane
system are the endoplasmic reticulum (ER), Golgi complex, trans-Golgi network, endosomes and
lysosomes. Cytoplasmic fractionations and immunofluorescence experiments identified a signifi-
cant proportion of Ago2 protein being associated with the rough ER, together with siRNA guide
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strand and target mRNAs (Cikaluk et al., 1999, Stalder et al., 2013). Interestingly, the remaining
components of the RISC loading complex Dicer, TRBP and PACT, were also associated with the
rough ER (Stalder et al., 2013). This suggested that both miRISC loading as well as miRNA-
mediated PTGS can be associated with the ER.
miRISC turnover has been associated with other components of the endomembrane system. Au-
tophagy is a degradation pathway for components such as proteins and organelles in the cyto-
plasm. These components are sequestered within autophagosomes, that fuse with lysosomes
forming an organelle in which proteins and organelles are degraded. Ago2, miRNAs and Dicer,
but not TNRC6, have been found to associate within autophagosomes in which they are subjected
to degradation (Gibbings et al., 2012, Martinez and Gregory, 2013).
The proportion of the described gene silencing components that are associated with the ER
and how much Ago is degraded via autophagy is not known so far. It would be conceivable that
there are target-specific effects, as mRNAs exist that are preferentially translated at the rough
ER. In addition, external stimuli like for example serum and nutrient starvation, strongly regulate
the extend of autophagy, which also might have implications for Ago turnover.
4. Post-transcriptional gene silencing
processes
miRNAs mediate post-transcriptional gene silencing by translational repression and mRNA de-
cay. Both processes are induced by TNRC6 proteins, which are guided to 3’ UTRs via inter-
action with Ago proteins. Interestingly, it has been shown that the C-terminal silencing domain
of TNRC6A-C is able to mediate translational repression and mRNA degradation alone (Eulalio
et al., 2009c, Lazzaretti et al., 2009, Zipprich et al., 2009). Therefore, all downstream processes
described here are mediated by this C-terminal domain.
To induce translational repression and mRNA decay, miRISC binds miRNA-target sites in a
sequence-specific manner. The miRNA-binding sites are mostly located in the 3’-UTR of target
mRNAs (Figure 1.4.1 A). miRNA binding sites within the open reading frame (ORF) or the 5’
UTR seem to exist and some seem to be functional, however, they are controversially discussed
especially regarding the silencing mechanism (Lytle et al., 2007, Orom et al., 2008, Hafner et al.,
2010, Hausser et al., 2013). Whether Ago binds TNRC6 prior or after mRNA binding is not known
in detail and observations differ between reports (Baillat and Shiekhattar, 2009, Rüdel et al., 2011,
Frohn et al., 2012, Schirle et al., 2014).
Upon association with the target mRNA, translational repression and mRNA degradation are
induced. Translational repression seems acts on the initiation phase of translation. To understand
the underlying processes, the mechanism of canonical translation initiation will be described in
short. During translation initiation, 5’-Cap and poly(A) tail cooperate to recruit the 43S pre-initiation
complex. The pre-initiation complex then scans for the start codon and initiates translation (Jack-
son et al., 2010). The Cap structure is recognized by eIF4F, a complex that consists of the cy-
toplasmic Cap-binding protein eIF4E, the scaffolding protein eIF4G and the RNA helicase eIF4A
(Figure 1.4.1 A, eIF4A not shown). The poly-(A) tail is bound by the cytoplasmic poly(A)-binding
protein PABPC. PABPC binding regulates both poly(A) tail length and translation initiation. For
effective translation initiation, PABPC interacts with eIF4G, bringing both mRNA termini together
to form a closed loop state (Jackson et al., 2010).
PABPC is one important interaction partner of TNRC6 proteins (Zekri et al., 2013). The PAM2
of TNRC6 proteins directly associates with the PABC domain in PABPC (Fabian et al., 2009,
Figure 1.4.1 A). The corresponding crystal structure of human TNRC6 PAM2 peptide in complex
with the PABC domain of PABPC has been solved (Jinek et al., 2010). For fly GW182, additional
contacts between tryptophan motifs in the silencing domain and PABPC have been identified
(Chekulaeva et al., 2011). Despite the importance of these interactions, the detailed mechanism
of PABPC function in miRNA-mediated PTGS is not yet clear. One controversially discussed sce-
nario suggests that TNRC6 inhibits interaction between PABPC and eIF4G, therefore prevent-
ing closed loop formation (Fabian et al., 2009, Zekri et al., 2009). Alternative scenarios propose
that translational repression functions independent of PABPC, eventually by recruitment of the
CCR4-NOT complex (see below). Indeed, some studies suggest that TNRC6-PABPC interaction
is dispensable for silencing and CCR4-NOT can induce translational repression independent of
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its deadenylase activity (Braun et al., 2011, Chekulaeva et al., 2011, Huntzinger et al., 2013). This
might be mediated via recruitment of DDX6, a known translational repressor and decapping factor
(Mathys et al., 2014, Chen et al., 2014). Whether DDX6 mainly mediates translational repression
or decapping is still unclear. Additionally to PABPC-dependent and CCR4-NOT-dependent trans-
lational repression, mRNA deadenylation might contribute to translational repression, as succes-
sive poly(A) tail shortening diminishes PABPC interaction and consequently translation initiation
(Fabian and Sonenberg, 2012, Subtelny et al., 2014).
PABPC
RRM (x4) PABC
TNRC6B
UBA Q-richGW PAM2 RRM
TNRC6
Ago
TNRC6
Ago
TNRC6
Ago
PABPC
eIF4E eIF4E
deadenylation
decay
Xrn1
5’    3’
translational repression storage in P-bodiesmRNA closed loop
A
B
CCR4-NOT complex
decapping complex
decapping complex
DCP2
DCP1
EDC4
DDX6
PAN2-PAN3 complex
AA
AAAAAAA
AAAAAAA
AAAA
AAAA
AAAA
AAAA
A
A A
A
eIF4G
TNRC6
Ago
decapping
AA
AA
60S
40S
CCR4-NOT complex
CNOT1
3
10
9
CCR4
2
Caf1
PAN2-PAN3 complex
PAN3
PAN2
Figure 1.4.1. Mechanisms of miRNA-mediated PTGS in mammals. A, Multistep process of PTGS in mam-
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Degradation of mRNAs is mediated by deadenylation, which causes mRNAs to undergo decap-
ping and finally 5’→3’ decay (Behm-Ansmant et al., 2006, Chen et al., 2009). Deadenylation is
mediated primary by the CCR4-NOT complex and to a lesser extend by the PAN2-PAN3 complex,
whereas decapping is catalyzed by the decapping-complex (Figure 1.4.1 A and B, Fabian et al.,
2010, Huntzinger and Izaurralde, 2011). It is not yet clear whether both deadenylase complexes
are redundant or fulfill separate functions, which so far have not been functionally dissected (Braun
et al., 2013). Via their C-terminal silencing domain, TNRC6 proteins act as docking platform for
both deadenylase complexes (Braun et al., 2011). A direct interaction of the decapping complex
with TNRC6 proteins has not been identified so far, instead it seems to be recruited by CCR4-
NOT (Chen et al., 2014, Mathys et al., 2014). The CCR4-NOT complex is a multimodular complex
composed of several independent modules. Modules bind to the CNOT1 subunit, which functions
as a scaffold for complex assembly. The catalytic active components are the two deadenylases
CAF1 and CCR4a. Two redundant modes of CCR4-NOT interaction with mammalian TNRC6 pro-
teins have been suggested so far. First, the silencing domain of TNRC6 can interact directly with
the scaffold protein CNOT1 via its tryptophan residues (Fabian et al., 2011, Braun et al., 2011,
Chekulaeva et al., 2011). Second, TNRC6 can contact CNOT9 via a tandem tryptophan motif in
its C-terminal silencing domain, between the PAM2 motif and the RRM domain (Chen et al., 2014,
Mathys et al., 2014). CNOT9 is bound to CNOT1 and therefore mediates CCR4-NOT recruitment
by TNRC6 proteins (Figure 1.4.1). Both interactions rely on tryptophan insertion into binding pock-
ets on the respective protein partner, similar to the mechanism of Ago-TNRC6 interaction. The
two-subunit PAN2-PAN3 deadenylation complex contains Pan3 and the exonuclease component
Pan2. Pan3 mediates association with RNA, either by directly binding poly-(A) RNA or indirectly
via PABPC (Siddiqui et al., 2007, Wolf et al., 2014). During miRNA-mediated PTGS, TNRC6 pro-
teins have been shown to recruit the PAN2-PAN3 complex by direct interaction of Pan3 with the
TNRC6 silencing domain (Braun et al., 2011, Christie et al., 2013).
While mediating deadenylation, the CCR4-NOT complex component CNOT1 recruits the DEAD-
box ATPase DDX6 (also known as p54/RCK), a known general activator of decapping (Chu and
Rana, 2006, Mathys et al., 2014, Chen et al., 2014). DDX6 interacts with the DCP1-DCP2 de-
capping complex, which consists of the catalytic subunit DCP2 and additional activators including
DCP1, EDC4 and DDX6 (Huntzinger and Izaurralde, 2011). After decapping, mRNAs are rapidly
degraded by the 5’→3’ exonuclease Xrn1 (Figure 1.4.1 A). 5’→3’ degradation is the predominant
degradation pathway of miRNA silenced transcripts (Huntzinger and Izaurralde, 2011). Depletion
of Xrn1 results in defective miRNA silencing and deadenylated miRNA target mRNAs accumulate
when decapping is blocked (Behm-Ansmant et al., 2006, Nishihara et al., 2013). The recruitment
of the decapping complex is thought to occur before completion of deadenylation, which might
explain why degradation does not occur from the 3’ end by the exosome.
Alternatively to mRNA degradation, miRNA-mediated PTGS can result in storage of translation-
ally repressed mRNAs (Figure 1.4.1 A right, Fabian et al., 2010). Stored mRNAs dissociate from
ribosomes and have been shown to contain shorter poly(A) tails, indicating deadenylation prior to
mRNA storage (not indicated in Figure 1.4.1 A). Storage of mRNAs is thought to be reversible, i.e.
translationally repressed mRNAs can be activated again upon external stimuli. What regulates a
possible degradation-or-storage decision is not characterized so far, as well as how much mRNA
is stored and degraded (Kulkarni et al., 2010).
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Relative contribution of translational repression and mRNA decay
Whether translational repression or mRNA decay might be the dominant effect of miRNA-guided
regulation is still under discussion (Wilczynska and Bushell, 2015). Initial evidence from C. elegans
suggested that mammalian miRNAs mediate target repression on the level of translation, with little
or no influence on mRNA stability (Wightman et al., 1993, Olsen and Ambros, 1999). However, re-
cent studies suggest that mRNA degradation might be the dominant effect of mammalian miRNAs
(Huntzinger and Izaurralde, 2011, Fabian and Sonenberg, 2012). The overall effect of translational
repression in these studies was relatively weak, so that around 70 to 80 % of the effects on pro-
tein expression are attributed to mRNA destabilization (Eichhorn et al., 2014). However this has
been challenged again by other studies, which suggest a more significant role for translational
repression (Larsson and Nadon, 2013).
There is strong evidence that translational repression and mRNA decay are timely ordered
processes (Djuranovic et al., 2012, Bazzini et al., 2012, Béthune et al., 2012, Eichhorn et al.,
2014). Translational repression seems to be activated rapidly after miRISC binding and to occur
before mRNA destabilization. Indeed, translational repression has been shown to be independent
of deadenylation and decapping (Bazzini et al., 2012). One important determinant, which results
in the shift from translational repression to mRNA decay could be the poly(A) tail length. In mam-
malian cells, intermediate poly(A) tail length is approximately 80 nt and translation rate correlates
with poly(A) tail length (Subtelny et al., 2014). Within this model, deadenylation might start imme-
diately after miRISC binding, resulting in initial translational repression, but with ongoing succes-
sive poly(A) shortening, decapping and consequently destabilization are induced (Subtelny et al.,
2014).
Part II.
miR-9/9* regulate CAMTA1 in
glioblastoma stem cells
1. Introduction
In this study, we analyze miRNA functions in cancer stem cells. As a model system, we use
Glioblastoma multiforme, a highly aggressive brain tumor that is thought to be driven by a cancer
stem cell population. Here, I will first present how miRNAs function in cancerous processes in
general. To get insights into the biology of Glioblastoma multiforme and cancer stem cells, I will
then give a short overview on important aspects of Glioblastoma multiforme and how cancer stem
cells are thought to drive tumor growth.
1.1. Small RNA-mediated gene regulatory pathways in cancer
The identification and characterization of miRNA-target pairs have shown that miRNAs regulate
the expression of proteins implicated in diverse biological processes, including cell proliferation,
differentiation and metabolism. Consequently, miRNAs have also been implicated in disease pro-
cesses including cancer (Esquela-Kerscher and Slack, 2006). There they regulate important tu-
morigenic processes like apoptosis, invasion, vascularization, metastasis and proliferation. Fur-
thermore, due to the ability to regulate various target mRNAs, the deregulation of one or a few
miRNA genes could potentially promote diverse cancer-associated processes (Di Leva et al.,
2014). As is the case for proteins, miRNAs can function as oncogenic miRNAs (oncomiRs) or
tumor suppressors, depending on the respective target proteins: A miRNA functions as tumor
suppressor, when a major target mRNA has oncogenic function; or it functions as oncogene,
when a major target mRNA is a tumor suppressor.
The diverse mechanisms by which miRNAs support tumor-formation and growth will be rep-
resented here in short, along with the most prominent cancer-related miRNAs. These miRNAs
include let-7, miR-21, miR-9, miR-29, miR-34 and miR-155 and the miRNA clusters miR-17~92,
miR-15a~16 and miR-221~222 (Esquela-Kerscher and Slack, 2006, Croce, 2009, Jansson and
Lund, 2012, Di Leva et al., 2014). Of note, many of these miRNAs have been reported to function
as tumor suppressor in one cancer type but as oncogene in another. In the coming sections, the
different mechanisms that affect miRNA function in cancer will be presented along with the most
prominent cancer-related miRNAs.
Abnormal miRNA expression by genetic aberration of miRNA genes
miRNA genes are frequently deleted or amplified in cancers. The first evidence for a deleted
miRNA gene was the miR-15a~16 cluster in chronic lymphocytic leukemia (CLL) (Calin et al.,
2002). In CLL, miR-15a and miR-16 function as tumor suppressors by regulating the oncogene
BCL2, which is consequently derepressed. Interestingly, deletion of the miR-15a~16-1 cluster
locus is sufficient for CLL development in mice (Croce, 2009). Further prominent tumor suppressor
miRNAs come from the let-7 family, whose members are frequently deleted in various types of
cancer (Di Leva et al., 2014). Members of the let-7 family regulate the important oncogenes RAS,
MYC and HMGA2, which are overexpressed when let-7 is lost (Johnson et al., 2005, Lee and
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Dutta, 2007). Amplification of miRNA genes has been reported for the oncomiRs miR-155 and
miR-17~92 cluster in various types of cancer (Di Leva et al., 2014). Members of the miR-17~92
cluster regulate tumor suppressors including PTEN, P21 and components of the TGF-β tumor
suppressor pathway (Di Leva et al., 2014). Translocation of miRNA genes into different genomic
contexts has been reported and could potentially increase or decrease miRNA expression (Di
Leva et al., 2014). However, so far there is no reported evidence for an ultimate tumorigenic effect
of these miRNA translocations.
Point mutations within mature miRNA sequences have only been very sporadically reported
and recent large scale sequencing studies in various types of cancer did not identify mutated
miRNAs (Jansson and Lund, 2012). One exception is miR-142, which is frequently mutated in B-
cell lymphomas (Kwanhian et al., 2012). Point mutations within the pri- and pre-miRNA sequences
which result in reduced miRNA processing have also been reported. One example is the miR-
15a~16-1 cluster, which can show reduced processing efficiency by a single base substitution
immediately downstream of the miR-16-1 sequence (Calin et al., 2005).
Aberrant regulation of miRNA expression by transcriptional and epigenetic mechanisms
It has been shown that cancer-related transcription factors can modulate miRNA expression. The
tumor suppressor TP53, for example, can induce expression of the miR-34 family by direct binding
to miR-34 family promoters in various types of cancer (Chang et al., 2007, He et al., 2007, Tarasov
et al., 2007). Therefore, at least a part of the TP53 tumor suppressive effects could be mediated
by this miRNA family. The miR-34 family represses well known oncogenes like for example BCL2,
HMGA2 and MYC (Di Leva et al., 2014). The oncogene MYC has been shown to transactivate
the miR-17~92 cluster and to repress the miR-15a~16-1 cluster in different types of cancer.
Epigenetic silencing of miRNA loci has been reported as well. A large proportion of miRNA
genes are associated with CpG islands, indicating regulation by DNA methylation. One example
is the CpG island controlled let-7a-3 locus, which is hypomethylated in some lung cancers and
consequently let-7a expression is increased (Brueckner et al., 2007). Of note, let-7a had onco-
genic function in the investigated lung cancer cases.
Deregulation of miRNA expression by miRNA biogenesis defects
Reported evidence for single miRNAs that are downregulated or lost in cancer is more frequent
than overexpressed miRNAs. Similarly, losing of a (protein) tumor suppressor seems to be a more
frequent event in cancer than the acquisition of an oncogene (Hanahan and Weinberg, 2011). Sur-
prisingly, some studies also showed that global downregulation of mature miRNAs occurs with
high incidence in various cancer types (Lu et al., 2005). The underlying mechanisms seem to
be aberrations in the miRNA processing machinery including Drosha, Dicer, DGCR8, TRBP and
Exp5 (Jansson and Lund, 2012). The most frequently observed aberration is a heterozygous loss
of Dicer, which occurs in almost one third of tumors of various tissue origins (Kumar et al., 2009,
Lambertz et al., 2010). Another example is a functional loss of Exp5 by a premature stop codon,
resulting in a C-terminally truncated protein that cannot bind pre-miRNAs any more (Melo et al.,
2010). Consequently, inactivation of Exp5 resulted in globally nuclear trapped pre-miRNAs and
derepressed oncogenes including BCL2 (Melo et al., 2010).
Numerous factors have been shown to regulate miRNA biogenesis in a general way or by affect-
ing the processing of single miRNAs (Ha and Kim, 2014). Aberrations of these miRNA biogenesis
regulators have also been reported in cancer. One example is the RNA-binding protein LIN28,
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which binds pri-let-7 and pre-let-7 at the terminal loop and suppress Drosha- and Dicer-processing
(Ha and Kim, 2014). In malignant germ cell tumors, LIN28 has been found to be highly expressed
and to downregulate let-7 expression, which contributed significantly to malignancy (Murray et al.,
2013).
Reports that show cancer-related deregulation of the miRISC components Ago and TNRC6 are
rare. In malignant melanomas for example, Ago2 expression seems to be strongly decreased by
a so far unidentified post-transcriptional mechanism (Völler et al., 2013). However, how increased
Ago2 levels might influence tumorigenicity of malignant melanomas is unknown.
Aberrant miRNA function by altered miRNA binding sites
In various types of cancers, rearrangements within 3’ UTRs have been identified and directly
linked to miRNA-mediated regulation of the affected mRNA. In almost all cases reported so far,
these rearrangements result in a loss of miRNA-mediated repression of an oncogene. In many
cancers, 3’ UTRs seem to be frequently shortened, mainly resulting from the choice of alterna-
tive polyadenylation signals (Mayr and Bartel, 2009). 3’ UTR shortening directly affected miRNA-
mediated regulation, which partially explained the observed increase in protein expression. Re-
cent large scale sequencing efforts also revealed translocations, interchanges or deletions of 3’
UTRs of specific genes (Brennan et al., 2013). For example, translocations within the 3’ UTR
of HMGA2 oncogene remove functional let-7 seed-match sequences (Mayr et al., 2007, Lee and
Dutta, 2007). This has been found to explain overexpression of the HMGA2 oncoprotein in various
types of cancer (Mayr et al., 2007).
In addition to 3’ UTR rearrangements, mechanisms exist that affect single miRNA binding sites
in cancers (Ryan et al., 2010). One example is a single nucleotide polymorphism (SNP) within a
let-7 miRNA binding site of the KRAS 3’ UTR in lung cancers (Chin et al., 2008). miRNA target
sites can also be regulated by diverse RNA binding proteins. The ubiquitously expressed RNA-
binding protein Pumilio (PUM1), for example, binds the mRNA of the p27 tumor suppressor and
is mutated in various cancers (Jansson and Lund, 2012). By binding, it favors association of miR-
221 and miR-222, resulting in a suppression of p27 and consequently a decrease in cell cycle
progression (Kedde et al., 2010).
1.2. Glioblastoma multiforme
Brain tumors include a large variety of different tumor types and although incidence is fairly low
compared to other types of cancer, the vast majority of brain tumors are highly malignant. Brain
tumors start either in the brain as primary tumors or can spread into the brain from a cancer
somewhere else in the body as secondary metastatic tumors. Gliomas are the most common
type of brain tumor and are defined as tumors that display histological and immunohistochemical
evidence of glial differentiation. However, from which cellular origins gliomas derive from is indeed
unknown.
Glioblastoma multiforme, also referred to as glioblastoma, grade IV astrocytoma or short GBM
is the most common and simultaneously the most malignant and lethal type of primary brain
tumor. GBM occurs in both child age as well as adults with an incidence of about three cases
per 100,000 people (Siegel et al., 2014). Without therapy, median survival is about 4 months
after initial diagnosis, whereas current multimodal therapy by surgical resection, irradiation and
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chemotherapy increases median survival in selected therapy studies to about 13 months (Stupp
et al., 2005, Gilbert, 2011).
GBMs either develop as primary or secondary GBM. 90 % of GBM cases are primary GBM
which develop rapidly de novo and mainly in older patients. The remaining cases are secondary
GBM which arise within 5 to 10 years from lower-grade gliomas in younger patients (Ohgaki and
Kleihues, 2007). Despite their different pathology, primary and secondary GBM are clinically and
histochemically not distinguishable, however, they accumulate partially different sets of mutations
and genomic aberrations (Brennan et al., 2013).
Important pathological properties of GBM include high infiltrative growth patterns (Cloughesy
et al., 2014, Cuddapah et al., 2014). Tumor cells migrate deeply into adjacent non-neoplastic
brain tissue, thereby preventing complete surgical resection. Furthermore, GBM is among the
most vascularized of all solid tumors and tumor growth strongly depends on vascularization (Jain
et al., 2007). Another hallmarking property of GBM is its cellular and morphological heterogeneity
and the parallel detection of cell populations with different grades of differentiation (Chen et al.,
2012b). This heterogeneity has been shown to contribute to tumor growth and therapy resistance.
1.2.1. Molecular pathology
GBM, and cancer in general, is a disease of accumulated genetic and epigenetic aberrations
(Hanahan and Weinberg, 2011). Recent studies integrating large scale genome, exome and RNA
sequencing data, as well as copy-number, transcriptomic, epigenomic and targeted proteomic
profiling provided deep insight into alterations associated with GBM (TCGA, 2008, Brennan et al.,
2013). In addition to the presented data from the TCGA consortium, molecular analysis and clas-
sification of GBM patient samples have been performed in other studies not presented here in
detail (Gravendeel et al., 2009, Li et al., 2009, Parsons et al., 2008).
These studies revealed that recurrent genetic alterations occur in a limited number of three core
pathways: Receptor tyrosine kinase (RTK), TP53 and RB1 signaling pathways (Figure 2.1.1). Com-
ponents within these pathways show a statistical tendency towards mutual exclusivity, i.e. in GBM
patients, only a single component within each of the three pathways is affected. Furthermore,
most tumors show aberrations in all three pathways, suggesting that deregulation of these path-
ways is a core requirement for GBM pathogenesis (TCGA, 2008). Consistently, transgenic and
knockout mouse models developed GBM-like tumors after cooperative lesion in minimally two of
the three presented core pathways (Chen et al., 2012b).
The RTK pathways integrate extracellular signals and activate transcriptional programs that
affect proliferation, migration and survival. Frequent aberrations of RTK pathways in GBM are mu-
tation and amplification of EGFR or PDGFRA and mutation or deletion of PTEN, less frequent are
deletion or mutation of NF1 itself (Figure 2.1.1 B left panel). The TP53 pathway regulates senes-
cence and apoptosis and integrates signals from various upstream pathways like DNA repair
mechanisms. Inactivation of the TP53 pathway most frequently occurs via deletion or mutation of
ARF or TP53 itself (Figure 2.1.1 B middle panel). The RB pathway regulates cell cycle arrest and
G1/S progression. In most cases, the CDKN2A/B locus is deleted or CDK4 amplified. Deletion of
mutation of RB1 itself is not frequent (Figure 2.1.1 B right panel).
Clustering of the TCGA data revealed different subclasses of GBM that, interestingly, resem-
ble stages in neurogenesis and mesenchymal lineage (Phillips et al., 2006, Verhaak et al., 2010,
Huse et al., 2011). This means, that gene expression programs typically active in those lineages
are activated in the different subtypes in addition to their glial expression profiles, as for example
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Figure 2.1.1. Alterations in RTK, TP53 and RB signaling pathways in GBM. Shown are recurrent genetic aberrations
in RTK, TP53 and RB signaling pathways. Genetic aberrations either lead to decreased (blue) or increased (red) func-
tion. Most frequent aberrations affect EGFR, PDGFRA or PTEN in RTK signalling, ARF or TP53 in TP53 signalling and
CDKN2A/B or CDK4 in RB signalling. In RTK signaling pathways, effects are mediated in large part through downstream
Akt- and MAPK-signaling pathways, which themselves are only rarely direct targets of mutational events in GBM. Figure
was partially adapted from Brennan et al., 2013.
shown by GFAP expression (Brennan et al., 2013). These subclasses include proneural, neural,
classical and mesenchymal lineage which are shown with representative genetic aberrations and
lineage signature genes in Figure 2.1.2 A. The proneural subclass exhibits frequent PDGFRA,
TP53 and IDH1 mutation and expresses genes associated with neurogenesis. The mesenchy-
mal subclass shows frequent aberration of NF1 and increased expression of components in the
NFκB pathway. Mesenchymal GBM displays expression of mesenchymal and astrocytic signa-
ture genes. Interestingly, increased expression of two transcription factors C/EBPβ and STAT3
has been identified as potential driver for mesenchymal transformation in GBM (Carro et al.,
2010). GBM of the classical subclass is associated with exceptionally high rates of EGFR am-
plification and mutation or loss of CDKN2A. The neural subclass is characterized by aberrations
in many of the genes also found in other groups and cannot be clearly separated. It shows gene
expression signatures that resemble those of neurons. Despite these deep insights, the prognos-
tic value of the different subclasses is low. Only the proneural subclass correlated with marginally
improved patient survival (Figure 2.1.2 B) but seems to be largely resistant to temozolomide, an
alkylating agent used as chemotherapy drug in GBM patients (Stupp et al., 2005). On the other
hand, mesenchymal and classical subclasses show increased necrosis and vascularization and
increased therapy response, which might be a result of higher proliferation rate observed in these
classes.
Due to the lack of efficient therapies for GBM, these molecular profiling and classification studies
are an important basis for development of targeted therapy strategies, i.e. towards unique gene
changes for patient specific treatment (Cloughesy et al., 2014).
1.2.2. miRNAs regulate hallmarks of GBM
The presented large-scale genomic and transcriptomic datasets gained deep insight into the mu-
tational landscape underlying GBM. However, despite epigenetic, genomic and transcriptomic
abnormalities, also post-transcriptional and even post-translational regulatory mechanisms have
strong impact on protein outcome and function. As this thesis investigates post-transcriptional
gene regulation by miRNAs, important roles of miRNAs in GBM will be presented here.
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Figure 2.1.2. Molecular subclasses of GBM. A, Four different subclasses of GBM as identified in Verhaak et al., 2010
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A tremendous number of studies tried to identify differentially expressed miRNAs in GBM and
to link those to GBM pathogenesis and molecular pathways (reviewed in Mizoguchi et al., 2012,
Møller et al., 2013, Henriksen et al., 2014). A selection of miRNAs that repeatedly appeared
to be differentially expressed in GBM include miR-21, miR-10b, miR-26a, miR-34a, miR-124,
miR-128, miR-181b and the miR-221~222 and miR-17~92 cluster. Therefore, also typical cancer-
associated miRNAs like miR-21, miR-34a and the two clusters miR-221~222 and miR-17~92
seem affected in GBM (see part I section 1.1). However, conflicting results have for example been
reported for the oncomiR cluster miR-221~222, which was repeatedly identified to be down- as
well as upregulated in different GBM profiling studies. Whether this might depend on different
GBM subclasses and tumor heterogeneity is not known so far. Thus, despite the high number of
published miRNA expression data, an exhaustive as well as reliable profile of GBM-associated
miRNAs is still lacking.
Many of the identified miRNAs have been implicated into central cancerous processes includ-
ing cell cycle control, growth suppressor signaling, apoptosis, regulation of immune responsive
signaling, angiogenesis and invasion. In addition, some of those miRNAs can target components
of the three GBM core pathways including RTK signaling, TP53 signaling and RB signaling (Mi-
zoguchi et al., 2012, Møller et al., 2013, Henriksen et al., 2014). Although this shows principal
importance of miRNAs for GBM, only very few studies comprehensively and reliably analyzed
how single miRNAs influence these cancer-associated processes. miR-26a for example pro-
motes GBM growth by targeting PTEN, RB1 and MAP3K2/MEKK2 (Huse et al., 2009, Kim et al.,
2010). miR-10b is a miRNA not expressed in non-neoplastic brain tissue, but highly expressed in
GBM; miR-10b might contribute to GBM tumorigenicity by directly targeting the tumor suppres-
sors TP53, NOTCH1, CDKN1A and CDKN2A (Gabriely et al., 2011, Lin et al., 2012). miR-21 was
the first miRNA identified as an oncomiR in GBM and was elevated in cancer tissue (Chan et al.,
2005). miR-21 targets include multiple important components of the TP53 tumor suppressor path-
ways (Zhou et al., 2010). miR-18, a miRNA of the miR-17~92 cluster which is lower expressed in
GBM, targets oncogenic Smad3 which is consequently increased and positively regulates TGF-β
signaling (Fox et al., 2013).
A recent study used miRNA expression profiles from the TCGA network to classify human
GBM (Kim et al., 2011b). According to their miRNA expression profiles which resembled different
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neural precursors at multiple stages of differentiation, patient samples were separated into five
classes: Neural, oligoneural, multipotent, astrocytic and neuromesenchymal GBM. Interestingly,
miRNA expression-derived subclasses showed stronger correlation with patient survival than the
above presented mRNA subclasses presented in II section 1.2.1. A comparison of the five miRNA-
derived GBM classes with the four mRNA-derived GBM classes revealed only partial overlap. For
example, the neural miRNA class contains a mixture of all four mRNA classes, whereas the
oligoneural miRNA class matches well with the proneural mRNA class (Kim et al., 2011b). It is
however not clear, why for example tumors with neural miRNA expression profiles do not similarly
show neural mRNA expression profiles.
1.3. Cancer stem cell hypothesis
As detailed knowledge on cancer development is often lacking, models have been formulated
that implement known aspects and processes of tumor-formation. Cancers are thought to be of
monoclonal origin, i.e. a founding driver mutation occurs in a single cell-of-origin (Hanahan and
Weinberg, 2011). This cell undergoes clonal expansion and accumulates further aberrations by
increased genome instability (Figure 2.1.3 A). Therefore cancerous diseases preclude a multistep
progression with intermediate stages of increasing aggressiveness (Greaves and Maley, 2012). Of
note, recent evidence also suggested that complex genomic rearrangements frequently observed
in many cancers can occur in a single cellular catastrophe and not by accumulation of aberrations,
a process referred to as chromothripsis (Stephens et al., 2011).
The cancer stem cell model, also described as the hierarchical model, assumes that some
cancers are additionally organized in a hierarchical manner with cells of different grades of differ-
entiation that resemble the hierarchical structure of non-neoplastic tissues (Figure 2.1.3 B and C,
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mitotic cells. C, Schematic representation of the cancer stem cell model including founding aberrations, that might occur
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2013.
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Kreso and Dick, 2014). Adult stem cells of non-neoplastic tissues are essential for tissue home-
ostasis and have been identified in diverse tissues like hematopoietic lineages, digestive tract,
muscle, brain and skin. They carry long-term self-renewal capacity and multipotency and divide
by relatively rare, periodic and asymmetric divisions or give rise to more committed progeny by
symmetric cell divisions. In a simplified view, the resulting progenitor cells proliferate by many
symmetrical divisions before becoming fully differentiated and eventually post-mitotic (Figure 2.1.3
B). Cancer stem cells, from now on referred to as CSCs, are defined by self-renewal and multipo-
tency as well. CSCs are isolated by cell sorting using cell surface markers of normal tissue stem
cells. Stem cell characteristics are then experimentally tested by repeated xenotransplantations,
clonogenic assays in vitro and expression of marker proteins typically expressed in non-neoplastic
stem cells, progenitor cells or differentiated cells.
Cancer stem and progenitor cells have been implicated in various aspects of tumor-formation
and growth: First, they are thought to be essential for tumor growth, as differentiated cells of many
tumors do not proliferate any more and like in normal tissues, self-renewal of stem cells might also
ensure life long feed with proliferative cells in tumors as well. Second, processes like formation of
metastases and relapse after therapy might depend on cancer stem cells in some cancers. Third,
it has been proposed that normal stem and progenitor cells are candidates for tumor cells of ori-
gin. This however remains to be characterized and recent evidence for dedifferentiation of tumor
cells to CSCs provide an alternative explanation where CSCs might arise from. These dediffer-
entiation processes can occur from progenitor cells or even differentiated cells of various tissues
(Figure 2.1.3 C, Friedmann-Morvinski and Verma, 2014).
Although the cancer stem cell model provides explanations for various cancerous processes, it
still must be considered as a model. Indeed, the detailed function of CSCs in vivo within the patient
is still controversially discussed. However, numerous in vitro studies and in vivo animal models
provide strong evidence that CSCs might at least in part be drivers for the above mentioned
processes.
1.3.1. GBM cancer stem cells
CSCs have been identified in GBM as one of the first CSCs in solid tumors (Singh et al., 2004)
and have since then been characterized mainly phenotypically and functionally. GBM CSCs, from
now on referred to as GSCs, are thought to be implicated in GBM growth, therapy resistance and
tumor regrowth after therapy (Sundar et al., 2014). Furthermore, they have been implicated in
processes like tumor vascularization and the high infiltrative behavior of GBM (Ricci-Vitiani et al.,
2010, Wang et al., 2010). Last but not least, non-neoplastic neural stem cells (NSCs) have been
suggested as a possible cell-of-origin for GBM by generating a GSC population (Chen et al.,
2012a). However, because direct evidence for GSCs within the parent tumor is still lacking, the
extend of their contribution to the mentioned processes is still a matter of debate.
GSCs have been originally characterized to express the surface marker CD133, but since now,
various additional marker proteins have been introduced for GSCs as for example CD44, Integrin
α6 and CD36 (Singh et al., 2004, Sundar et al., 2014). Whether these markers are coexpressed
on GSCs or whether different studies isolate different GSC subpopulations has not been analyzed
comprehensively but might be possible. Furthermore, despite the broad spectrum of available
marker proteins, none of the mentioned markers has indeed been shown to be exclusively ex-
pressed on GSCs and to be expressed on all GSCs. CD133, for example, is the most frequently
used marker for GSC isolation, however, cells with GSC properties have also been identified that
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do not express CD133 (Beier et al., 2007, Lottaz et al., 2010, Beier et al., 2012).
Where are GSCs located within the tumor and how do they contribute to GBM growth? Al-
though numerous studies provide interesting insights into these important questions, only a short
overview will be given here. GSCs were initially thought to be rare within GBMs. However, due to
varying results between studies and markers used for sorting, it is not exactly known how many
cells are indeed bona fide GSCs and if all GBMs contain GSCs (Singh et al., 2004, Beier et al.,
2007, Günther et al., 2008, Chen et al., 2010). Within GBM, the GSC subpopulation has been
found to reside in two different niches, a perivascular and perinecrotic location, with extensive
regulatory crosstalk between GSCs and the respective niche cells (Calabrese et al., 2007, Seidel
et al., 2010). GSCs have been suggested to contribute to vascular proliferation through a variety
of mechanisms, including hypoxia-induced stimulation of endothelial cell growth, recruitment of
endothelial progenitor cells and transdifferentiation into endothelial cells (Ricci-Vitiani et al., 2010,
Wang et al., 2010). Although the proliferative behavior of GSCs within the primary tumor is not
characterized comprehensively, most GSCs are expected to be quiescent and only periodically
activated, and indeed, a second smaller subpopulation of proliferative GSCs has been identified
(Chen et al., 2012a, Patel et al., 2014, Codega et al., 2014). Despite this restricted proliferative
behavior of GSCs, they are thought to drive tumor growth by generating a highly proliferative
progeny, which contributes largely to tumor growth (Kreso and Dick, 2014). In addition to the pro-
posed role in tumor growth, GSCs have been implicated in rapid tumor recurrence after therapy
and show increased resistance to both radiotherapy and chemotherapy. This resistance is thought
to be ensured both by increased DNA-damage response and by the low proliferative behavior of
most GSCs, which are consequently less responsive to chemotherapy (Bao et al., 2006, Chen
et al., 2012a). In addition, recurrent tumors after chemotherapy in GBM mouse models have been
shown to largely derive from GSCs, further supporting their importance for this inevitable process
in GBM (Chen et al., 2012a).
Molecular characterization of GSCs
Whether the stem cell-like properties of GSCs are intrinsic to early founding tumor cells or whether
they are an acquired property is not clear, as well as the underlying molecular mechanisms. A
recent study provided insights into stemness maintenance mechanisms of GSCs (Suva et al.,
2014). The authors characterize epigenetic profiles and gene expression programs in GSCs ver-
sus non-GSCs. Interestingly, they identify four neurodevelopmental transcription factors POU3F2,
SOX2, SALL2 and OLIG2, that can reprogram differentiated GBM tumor cells into cells that resem-
ble bona fide GSCs regarding epigenetic marks, gene expression data, neurosphere growth and
tumor propagating potential. Strikingly, these transcription factors were more highly expressed
in CD133+ cells, indicating that the observed reprogramming might indeed occur in vivo. Simi-
lar attempts of artificial dedifferentiation have been used in induced pluripotent stem cell (iPSC)
generation from non-neoplastic cells (Takahashi and Yamanaka, 2006).
Taken together, although GSCs seem to be important for GBM tumorigenicity, a detailed and
comprehensive understanding of the molecular mechanisms that are important for GSC function
is lacking. Therefore, future studies will be needed, that for example compare GSCs with non-
GSCs from many patient samples, similar as it has been done for total GBM samples described
above in part II section 1.2.1.
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miRNAs with GSC-specific functions
miRNAs have been implicated as important regulators in stem cell biology by regulating dif-
ferentiation and stem cell maintenance (Gangaraju and Lin, 2009, Gruber and Zavolan, 2013,
Shenoy and Blelloch, 2014). Such roles for miRNAs have been identified in embryonic stem cells,
germline stem cells and various somatic tissue stem cells including those of the central nervous
system. In addition, miRNAs also regulate central processes during neurogenesis (Shen and
Temple, 2009). However, although many miRNAs have been suggested to specifically function in
CSCs and GSCs, comprehensive miRNA profiles and detailed functional analyses are still lacking
(reviewed in DeSano and Xu, 2009, Liu and Tang, 2011, Takahashi et al., 2013, Katsushima and
Kondo, 2014, Rathod et al., 2014).
The vast majority of studies investigated single miRNAs that have been previously associated
with stem cell functions in non-neoplastic brain cells. In addition, miRNA targets are mostly picked
from in silico predicted lists according to previously reported roles in NSCs or neurogenesis. This,
however, questions conclusions regarding the bona fide miRNA function in the respective cellular
context. These studies suggest for example miR-34a, miR-124, miR-128, miR-137, miR-138,
miR-451 and the miR-17~92 cluster to function in GSCs (Silber et al., 2008, Gal et al., 2008,
Godlewski et al., 2008, Ernst et al., 2010, Guessous et al., 2010, Xia et al., 2012, Chan et al.,
2012, Peruzzi et al., 2013). The identified miRNAs seem to have targets that function in stem
cell-specific processes and some of those miRNAs were also differentially expressed in GSCs.
Taken together, although miRNAs have been implicated in differentiation and stem cell main-
tenance, not much is known how miRNAs regulate GSC function and how they contribute to
GSC-driven tumor growth.
2. Aims of part II
A molecular characterization of the highly malignant brain tumor Glioblastoma multiforme (GBM)
has comprehensively been done from isolated tumor samples. Genetic programs, however, that
are specifically important in GBM cancer stem cells (GSCs) are underrepresented in those data-
sets. Additionally, conventional chemotherapeutic therapies are designed to target rapidly prolif-
erating cells, which might be a major reason why the relatively rare and periodic divisions allow
survival of GSCs after therapy. Therefore, a more detailed characterization of GSCs is necessary
to better understand their regulation and to develop novel targeted therapies.
microRNAs (miRNAs) have been shown to play important roles in cancer and normal stem cells,
however their role in cancer stem cells has not been characterized in detail. Therefore, the aim of
this thesis is to analyze miRNA expression in GSCs. miRNAs which are differentially expressed
in GSCs might be important for GSC biology and therefore GBM in general. To understand how
these miRNAs contribute to GSC maintenance and GBM growth, in vitro tumor formation assays
will be used. This should uncover miRNAs as a basis for the development of future targeted
therapy strategies by miRNA- or siRNA-based therapeutical agents.
To get deep insights into the function of the identified miRNAs, miRNA target mRNAs will be
identified. Interesting target mRNAs will be subjected to further cell biological and biochemical
analysis, with the aim to better understand how the identified miRNA-mRNA pairs contribute to
GSCs and GBM. This should finally allow the identification of novel regulatory pathways in GBM
and GSCs.
Taken together, the specific aims in part I of this work include:
1. Identification of miRNAs differentially expressed between GSCs and non-GSCs.
2. Characterization of GSC-enriched miRNAs by in vitro assays.
3. Experimental identification and validation of target mRNAs.
4. Characterization of the function of miRNA targets in vitro and in vivo.
3. Results
3.1. Small RNA profiling of GSCs
To analyze miRNA expression in GSCs and to identify differentially expressed miRNAs, glioblas-
toma cell lines were used, that derived from patients suffering from primary GBM. The R11 cell
line was cultivated in stem cell medium conditions to enrich for GSCs and to prevent rapid differ-
entiation, which would occur under serum conditions (Lottaz et al., 2010).
To separate GSCs from non-GSCs we used CD133 as surface marker for fluorescence acti-
vated cell sorting (FACS). Cluster of differentiation 133 (CD133), also known as prominin-1, is a
transmembrane glycoprotein of unknown function expressed on adult neural stem cells and di-
verse stem cells of other tissues (Cheng et al., 2009). CD133 was used for the first identification
and isolation of cancer stem cells from GBM and has been shown to effectively enrich for GSCs
from R11 (Singh et al., 2004, Beier et al., 2007). CD133+ cells were stained with a phycoerythrin
(PE) coupled anti-CD133 antibody and positive cells were gated out from negative cells to get
CD133+- and CD133--enriched subpopulations. These subpopulations were used for total RNA
isolation and miRNA deep sequencing (Figure 2.3.1 A). FACS analysis revealed a CD133+ sub-
population of 11,8 % in R11 (Figure 2.3.1 B). This GSC content was in line with published results
for CD133-sorted GSCs from R11 (Beier et al., 2007). RNA was extracted from both fractions,
cloned and analyzed by deep sequencing. Sequences from datasets were annotated and library
composition is shown in Figure 2.3.1 C.
We then identified differentially expressed miRNAs. Therefore, the number of reads for each
miRNA was normalized to the total number of miRNA reads in each sample and the log2 ratio
was calculated for each miRNA between CD133+ and CD133- cells. Candidate miRNAs were
selected from the 20 miRNAs with the highest read number and therefore highest expression and
are presented in Figure 2.3.1 D. A value above zero shows that a miRNA is more abundant in
CD133+ cells and a value below zero shows a miRNA that is more abundant in CD133- cells. The
size of the dots represents the read number. miR-17, miR-9* and miR-106b showed the strongest
upregulation and were therefore chosen for further analysis. As miR-9, the complementary strand
to miR-9*, also was one of the 20 miRNAs with the highest read number, miR-9 was also chosen
for further analysis.
The sequencing data for the selected miRNAs was further validated by Northern Blot. Signals
for miR-9, miR-9*, miR-17 and miR-106b were much stronger in CD133+ cells (Figure 2.3.1 E)
indicating that these miRNAs are indeed differentially expressed in GSCs versus non-GSCs.
miR-9 and miR-9*, from now on also referred to as miR-9/9* since they originate from the same
precursor, were both highly expressed in CD133+ cells. Therefore, the expression levels of miR-
9/9* were analyzed in CD133+ cells from a broader range of human primary GBM-derived cell
lines. R11, R28, R44 and R54 are Type I GSC lines, which were shown to contain a CD133+ cell
population with GSC properties and neurosphere growth and express proneural signature genes
(Beier et al., 2007). The additionally used cell lines R20, R40 and R52 are not characterized
in detail but were shown to contain a CD133+ cell population as well. Consistent with the data
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Figure 2.3.1. miRNA expression profiling of glioblastoma cancer stem cells versus non-cancer stem cells. A,
Schematic representation of workflow. Primary glioblastoma cell line R11 was cultivated in stem cell medium and sorted
into CD133+ and CD133- subpopulations. Small RNAs were cloned and analyzed by deep sequencing. B, Representative
FACS analysis of R11 cells shows a subpopulation of 11,8 % CD133-positive (CD133+) cells. C, Small RNA library
composition. D, Selected miRNA candidates differentially expressed in CD133+ versus CD133- cells. Positive values
indicate higher expression in CD133+ cells, negative values indicate higher expression in CD133- cells. E, Validation of
differential expression of miR-17-5p, miR-9*, miR-106b and miR-9 by Northern Blot in R11 cells. Isoleucine (Ile) tRNA was
used as loading control.
obtained from R11, miR-9/9* expression was significantly higher in CD133+ cells from almost
all cell lines tested (Figure 2.3.2 A and B). miR-34a, a miRNA which was detected in the deep
sequencing data and more highly expressed in CD133- cells, was used as control. Indeed, miR-
34a was either more highly expressed in CD133- cells or equally expressed, with the exception of
R28 (Figure 2.3.2 C).
Taken together, we sorted CD133+ and CD133- cells from the primary human GBM-derived cell
line R11 to enrich for a subpopulation that contains or lacks GSCs. We found miRNAs differen-
tially expressed in CD133+ and CD133- cells and validated miR-9/9*, miR-17 and miR-106b as
candidates to be specifically upregulated in CD133+ cells.
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Figure 2.3.2. Quantification of miR-9 and miR-9* in different GBM cell lines. miR-9 (A) and miR-9* (B) were ana-
lyzed by quantitative real-time PCR in CD133+ and CD133- GBM subpopulations. As control, miR-34a (C) was analyzed
accordingly. Data are shown as mean plus SEM. P-values are shown as *P < 0.05; **P < 0.005; ***P < 0.0005; n.s., not
significant.
3.2. miR-9/9* function as oncogenes in GBM and GSCs
3.2.1. miR-9/9* and miR-17 regulate GBM growth in vitro
To analyze the functions of the CD133+-enriched miRNAs in GBM, we blocked the activity of
miRNAs by chemically modified miRNA inhibitors or increased the abundance of these miRNAs
by introducing miRNA mimicking RNAs. We analyzed neurosphere-formation, the proportion of
CD133+ cells and differentiation markers.
The activity of a miRNA can be blocked by transfection of chemically modified oligonucleotides
which can base pair with the targeted miRNA strand. We used inhibitors with a 2’-O-methylated
ribose sugar backbone and the 21 nucleotide antisense sequence of the target miRNA strand
(Meister et al., 2004a). One broadly accepted experimental approach used to characterize GSCs
is a clonogenic assay, that quantifies the formation of so called neurospheres. Neurospheres are
a cell culture phenomenon originally observed when adult neural stem cells are cultivated un-
der defined growth factor and non-adherent conditions (Reynolds and Weiss, 1992). They are
free-floating heterogeneous cell aggregates, that are thought to develop by clonal expansion from
neural stem cells (Reynolds and Weiss, 1992). Indeed, although GSCs seem to be largely quies-
cent in vivo, the defined culture conditions in vitro result in high proliferation of GSCs. GSCs form
large neurospheres, whereas progenitor cells have restricted neurosphere-forming potential, the
more differentiated GBM cells instead do not form neurospheres (Beier et al., 2007, Singh et al.,
2004).
To characterize the role of the identified miRNAs in GBM and GSCs, we analyzed neurosphere-
formation after inhibition of miR-9/9*, miR-17 or miR-106b. As a control, an inhibitor against miR-
122 was used as miR-122 is not expressed in brain tissue but has been shown to be liver-specific
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are shown as mean plus SEM. *P < 0.05; ***P < 0.0005; n.s., not significant.
(Lagos-Quintana et al., 2002). Cells were transfected twice with miRNA inhibitors in 7 day inter-
vals and neurosphere-formation was analyzed 14 days after the second transfection (Figure 2.3.3
A). Of note, a double transfection was done to increase the duration of the transient effect of the
miRNA inhibitors. Inhibition of miR-9 and miR-9* let to a strongly reduced neurosphere-formation,
inhibition of miR-17 reduced neurosphere-formation to about 50 % and miR-106b had no effect
(Figure 2.3.3 B). Since inhibition of both miR-9/9* and miR-17 affected neurosphere-formation,
we tested whether simultaneous inhibition of two different miRNAs shows additive effects. Indeed,
the effect of simultaneous inhibition of miR-9 and miR-17 or miR-9* and miR-17 was significantly
stronger compared to samples in which only one of the three miRNAs was inhibited (Figure 2.3.3
C). Of note, only 50 % of the inhibitor concentration in Figure 2.3.3 B was used for the simultane-
ous inhibition of two miRNAs, which explains the intermediate effects of miR-9/9* in Figure 2.3.3
C. Simultaneous transfection of miR-9 and miR-9* was not tested, as both inhibitors can anneal
and would probably neutralize each other.
We next increased the amount of mature miRNA. This can for example be achieved by transfect-
ing so called miRNA mimics, which are annealed mature miRNA sense and antisense strands. We
analyzed neurosphere-formation after miR-9/9* mimic transfection in two different cell lines (R11
and R28). As expected from the miRNA inhibition experiments, the transfection of miRNA mimics
conversely increased neurosphere-formation (Figure 2.3.4).
Taken together, we have shown that inhibition of miR-9/9* and miR-17 strongly decreases
whereas overexpressing miR-9/9* enhances neurosphere-formation of GBM-derived cell lines.
Therefore, miR-9/9* and miR-17 have oncogenic function in this cellular system.
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Figure 2.3.4. Transfection of miR-9/9* mimics increases neurosphere-formation. GBM cell lines R11 (A) and R8
(B) were transfected with miR-9/9* mimics as shown in Figure 2.3.3 A. Neurosphere-formation was analyzed. As control
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3.2.2. miR-9/9* affect the CD133+ GSC pool and differentiation
Since miR-9/9* are highly expressed in CD133+ cells and strongly affect neurosphere-formation,
we analyzed whether miR-9/9* directly affect the CD133+ subpopulation. GSCs are thought to be
the major driver for the formation of neurospheres and therefore a reduced CD133+ pool could
explain the effects of miR-9/9* on neurosphere-formation. We transfected R11 cells with miR-9/9*
inhibitors as described above and analyzed the CD133+ subpopulation by flow cytometry. Indeed,
inhibition of miR-9 or miR-9* led to a reduction of the CD133+ subpopulation to about 50 to 60 %
compared to the control inhibitor, suggesting that these miRNAs are important for maintenance of
the GSCs status (Figure 2.3.4 A).
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Reduced stem cell maintenance might result in increased cell differentiation. We therefore
tested neuron-specific class II β-Tubulin (Tuj1) and glial fibrillary acidic protein (GFAP) by West-
ern Blot upon miR-9 or miR-9* inhibition. Tuj1 functions as a neuronal marker and is specifi-
cally expressed in differentiating neuronal progenitors and GFAP is a glial marker which is mainly
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expressed in differentiated astrocytes (reviewed in von Bohlen Und Halbach, 2007). A marker
for oligodendrocytes, as for example MBP, PDGFRα and Olig1/2 has not been tested. Indeed,
Tuj1 was clearly increased upon miR-9/9* inhibition, showing induced neuronal differentiation
(Figure 2.3.4 B). The glial differentiation marker GFAP instead was not increased.
Taken together, we found that miR-9/9* and miR-17 strongly affect neurosphere-formation of
primary human GBM-derived cell lines. miR-9/9* probably function in maintaining GSC-status by
preventing differentiation.
3.3. Identification of miR-9* targets
3.3.1. miR-9* mRNA target identification
As miRNAs function by regulating the expression of other genes, we identified target genes of
miR-9* by analysis of mRNA enrichment in Ago2-immunoprecipitations upon miRNA inhibition
(Beitzinger et al., 2007, Karginov et al., 2007, Easow et al., 2007). We selected miR-9*, since
it showed strong upregulation in CD133+ cells and prominent effects in neurosphere-formation
assays presented in part II section 3.2. R11 cells were transfected with miR-9* or control inhibitors
and immunoprecipitated Ago2-bound mRNAs were detected by microarray. The miRNA inhibitor
prevents mRNA binding and therefore miR-9* targets are selectively lost in the immunoprecipitates
compared to control transfections and the input RNA (Figure 2.3.6 A). The top twenty candidates
are shown in Figure 2.3.6 B. miR-9* target mRNA candidates that were more than 10-fold depleted
in the miR-9* inhibitor sample compared to the control sample were PGBD2, NEFM, MALT1,
CAMTA1, OASL and PPIP5K1.
PiggyBAC transposable element derived 2 (PGBD2) is not characterized so far, but is predicted
to encode for a transposase. Neurofilament medium polypeptide (NEFM, NF-M) is a neurofila-
ment protein of the axonal cytoskeleton and functions as neuronal differentiation marker. Mucose-
associated lymphoid tissue lymphoma translocation gene 1 (MALT1) is a caspase-like protein
and plays a role in NF-κB activation during T-cell receptor signalling (Thome, 2008). Calmodulin-
binding transcription activator 1 (CAMTA1) encodes for a potential transcription activator involved
in neuroblastoma and is located on 1p36, a region frequently deleted in GBM (Henrich et al.,
2011). 2’-5’-Oligoadenylate synthase-like (OASL) encodes for a protein which activate RNaseL
as a viral defense mechanism (Thome, 2008). Diphosphoinositol pentakisphosphate kinase 1
(PPIP5K1, HISPPD2A) encodes for a largely uncharacterized inositol kinase.
Taken together, we have identified several possible miR-9* target mRNAs. These included
CAMTA1, a transcription factor with an interesting genomic localization.
3.4. Characterization of the novel tumor suppressor CAMTA1
3.4.1. CAMTA1 is a putative tumor suppressor in 1p36 and frequently
deleted in GBM
For further analysis, we focused on CAMTA1, as it is expressed from the 1p36 locus which is
frequently deleted in gliomas, including anaplastic astrocytoma, oligodendroglioma and the unre-
lated neuroblastoma (Ichimura et al., 2007, Henrich et al., 2011). Reported frequencies of 1p36
deletions in GBM range from 1 to 20 % between different reports (Weller et al., 2009, Brennan
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Figure 2.3.6. Identification of miR-9* target mRNAs. A, Strategy to identify miR-9* target mRNAs based on Ago2
immunoprecipitation and microarray analysis. B, List of the twenty most strongly Ago2-associated transcripts in the pres-
ence of control inhibitor (inh.) with simultaneous lower abundance in the miR-9* inhibition sample. List is sorted according
to fold change as calculated by subtracting fold mRNA enrichment in miR-9* and miR-122 inhibitor samples. CAMTA1 is
shown in red.
et al., 2013, Figure 2.3.7 A). For astrocytoma and oligodendroglioma, CAMTA1 has been re-
ported to be located within a minimally deleted region of 1p36 (Dong et al., 2004, Barbashina
et al., 2005). Therefore, CAMTA1 might be important for different glioma types.
The human CAMTA1 gene spans a region of almost 1 Mb and contains 23 exons. N- and C-
terminally truncated non-coding and protein-coding transcript variants are predicted, in addition
to splice variants of the full length CAMTA1. Clear evidence for the expression of single transcript
variants is largely lacking. Human CAMTA1 mRNA has been detected in non-neoplastic adult
brain tissue as an 8 kb transcript, which corresponds to full length CAMTA1 mRNA, and an ad-
ditional 3 kb transcript, which might correspond to a C-terminally truncated variant (Barbashina
et al., 2005). Mouse CAMTA1 mRNA is strongly expressed in brain tissue and weakly in heart
(Song et al., 2006), which is in line with our own quantitative real-time PCR experiments (data not
shown).
The human CAMTA1 gene encodes for a 1673 amino acid protein with a molecular weight of
about 180 kDa (Appendix Figure A1). Domain predictions suggest a CG-1 DNA-binding domain,
a transcription factor immunoglobulin-like (TIG) domain that can mediate sequence-independent
DNA contacts, calmodulin-binding motifs (IQ), a calmodulin-binding domain (CaMBD) and ankyrin
domains that may mediate protein-protein interactions (Figure 2.3.7 B). CAMTA1 is therefore pre-
dicted to be a Calmodulin-regulated transcription factor. Additionally, CAMTA1 contains two nu-
clear localization signals and is therefore predicted to be nuclear (Figure 2.3.7 B). Evidence for
functionality of those domains and localization of the human protein is largely lacking, except for
the DNA-binding activity of the N-terminal CG-1 domain (Long et al., 2014).
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3.4.2. Validation of CAMTA1 as a miR-9/9* target mRNA
To show that CAMTA1 is indeed regulated by miR-9*, we searched for miR-9* binding sites in the
3’-UTR of CAMTA1. Interestingly, we not only identified potential binding sites for miR-9*, but also
for miR-9, miR-17 and miR-106b, which were also highly abundant in CD133+ cells (Figure 2.3.8
A). Therefore, CAMTA1 might be regulated by multiple miRNAs in GSCs.
To validate those binding sites, we cloned and fused the CAMTA1 3’-UTR to firefly luciferase
and cotransfected miRNA inhibitors. Therefore, firefly luciferase is under control of the CAMTA1
3’-UTR and its expression should be influenced by miRNA inhibitor transfection. Renilla luciferase
was detected as internal control, which is expressed from the same reporter plasmid. Inhibition
of a miRNA that regulates CAMTA1 would result in an increase in firefly signal. As control for
miR-9 and miR-9* we mutated CAMTA1 3’-UTRs in all predicted miR-9 or miR-9* binding sites,
respectively. Indeed, inhibition of miR-9 and miR-9* resulted in a significant derepression of the
wildtype CAMTA1 3’-UTR reporter but not of mutated CAMTA1 3’-UTR reporters, indicating that
the predicted miRNA binding sites are indeed functional (Figure 2.3.8 B).
Inhibition of miR-106b or miR-17 also resulted in a derepression of the CAMTA1 3’-UTR re-
porter (Figure 2.3.8 C), indicating that miR-9, miR-9*, miR-106b and miR-17 regulate CAMTA1
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expression. Of note, compared to the weak increase in CAMTA1 mRNA levels (Figure 2.3.8 D),
CAMTA1 protein was much stronger increased (Figure 2.3.8 E), suggesting that miR-9/9* may
preferentially inhibit CAMTA1 translation, rather than mRNA stability.
Taken together, we have shown that CAMTA1 is indeed regulated by miR-9/9*, miR-17 and
miR-106b.
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Figure 2.3.8. miR-9, miR-9*, miR-106 and miR-17-5p regulate CAMTA1 expression. A, Location of miR-9, miR-9*,
miR-17-5p and miR-106b binding sites in the 3’-UTR of CAMTA1 as predicted with TargetScan and manual sequence
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3.4.3. CAMTA1 impairs glioblastoma growth in vitro
Because neurosphere-formation assays suggested an oncogenic function of miR-9/9*, CAMTA1
should function as a tumor suppressor if miR-9/9* and CAMTA1 expression are functionally cou-
pled. To investigate the function of CAMTA1 in GBM growth in vitro, we first characterized the
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Figure 2.3.9. CAMTA1 has tumor suppressor activity in vitro. A, Domain organization of CAMTA1 and CAMTA1 ∆N,
in which the putative CG-1 DNA-binding domain has been deleted. B, Flag/HA-tagged (FH) CAMTA1 and CAMTA1 ∆N
were expressed in HEK 293T cells and protein expression was analyzed by Western Blot using anti-CAMTA1 antibody. C,
FH-CAMTA1 was expressed in R11 (left panel) and R28 (right panel) and neurosphere-formation was analyzed. D, FH-
CAMTA1 and FH-CAMTA1 ∆N were expressed in R11 cells and neurosphere-formation was analyzed. E, FH-CAMTA1
was expressed in R11 cells and CD133+ subpopulation was quantified by FACS analysis. An empty plasmid, expressing
FH only was used as control in C, D and E. Data are shown as mean plus SEM. *P < 0.05; ***P < 0.0005.
effects of CAMTA1 overexpression on neurosphere-formation of GBM-derived cell lines. It has
already been shown for mouse CAMTA2, that the N-terminal CG-1 domain is essential for protein
function (Song et al., 2006). Therefore, we included a N-terminally truncated mutant CAMTA1
∆N into our analyses (Figure 2.3.9 A) and tested overexpression in HEK 293T cells (Figure 2.3.9
B). Of note, endogenous CAMTA1 was not detectable in HEK293T cells (Figure 2.3.9 B).
Strikingly, expression of CAMTA1 in both GBM-derived cell lines tested led to an almost com-
plete loss of neurosphere-formation capacity (Figure 2.3.9 C). Interestingly, expression of CAMTA1
∆N had no inhibitory effect on neurosphere-formation, indicating that expression of a functional
CAMTA1 only inhibits neurosphere-formation (Figure 2.3.9 D). Of note, expression of CAMTA1
∆N resulted in a slight increase in neurosphere-formation (Figure 2.3.9 D). However, because the
effects of CAMTA1 ∆N were not reproducible in GBM cell line R28, we so far do not suggest that
CAMTA1 ∆N might exhibit dominant-negative functions (data not shown).
We have shown that miR-9/9* inhibition results in a decrease of CD133+ cells in the GBM-
derived cell line R11. To investigate whether CAMTA1 overexpression decreases the CD133+ sub-
population, we overexpressed CAMTA1 and submitted these cells for FACS analysis. Indeed we
observed a strong reduction of CD133+ cells to about 30 % of the control sample upon CAMTA1
overexpression (Figure 2.3.9 E) indicating that low CAMTA1 levels are beneficial for the CD133+
subpopulation.
Taken together, CAMTA1 functions as a tumor suppressor in GBM in vitro and affects the
CD133+ GSC pool, which might at least in part explain its tumor suppressor function.
3. RESULTS 55
3.4.4. miR-9/9* effects and CAMTA1 expression are functionally coupled
We found that miR-9 and miR-9* inhibition as well as CAMTA1 overexpression block neurosphere-
formation. Therefore, we hypothesized that miR-9/9* effects might result from induced CAMTA1
protein after miR-9/9* inhibition. If this hypothesis is correct, it should be possible to rescue the
effects of miR-9/9* inhibition on neurosphere-formation by decreasing levels of CAMTA1. Addi-
tionally, we wanted to test whether the decrease of endogenous CAMTA1 levels has the opposite
effects on neurosphere-formation compared to CAMTA1 overexpression.
We therefore depleted CAMTA1 by RNAi and validated successful reduction of the endogenous
protein with anti-CAMTA1 Western-Blot and two different siRNAs (Figure 2.3.10 A). Knockdown of
CAMTA1 alone (i.e. without miR-9/9* inhibition) only resulted in a weak increase of neurosphere-
formation for one siRNA (Figure 2.3.10 B, black bars). Therefore, we did not observe a supportive
effect of decreased CAMTA1 levels on neurosphere-formation capacity.
We subsequently transfected inhibitors against miR-9, miR-9* or a control inhibitor and knocked
down CAMTA1 simultaneously (Figure 2.3.10 B, grey bars). Indeed, reduction of neurosphere-
formation upon miR-9 and miR-9* inhibition was strongly reduced in CAMTA1 knockdown sam-
ples, although the rescue of miR-9* inhibition was not as efficient as for miR-9.
Taken together, these data show that CAMTA1 protein mediates the miR-9/9*-dependent effects
on neurosphere-formation.
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3.4.5. CAMTA1 functions as a tumor suppressor in vivo
The striking effects of CAMTA1 overexpression on neurosphere growth of GBM-derived cell lines
led us to investigate whether CAMTA1 also functions as a tumor suppressor in vivo. To do so, we
used a well established xenograft model, in which human GBM-derived cell lines are injected
orthotopically (i.e. at its naturally occuring position) into brains of nude mice NU/NU-Foxn1nu
(NU/NU) (Figure 2.3.11 A). NU/NU mice show a strong thymus dysgenesis with a severely di-
minished immune response. We used the GBM-derived cell line R28, because it showed strong
effects on CAMTA1 overexpression and has already been shown to form reproducible and fast
growing tumors when orthotopically implanted into mouse brains (Beier et al., 2007). To be able
to follow tumor growth in the living animal, R28 was transduced to stably express firefly luciferase
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and as expected, luciferase expression correlated with cell number in vitro (Figure 2.3.11 B). After
transfection with CAMTA1 plasmid or empty plasmid as control, cells were injected into mice and
tumor growth was analyzed 15 days after transfection by measuring luciferase signal after luciferin
injection. In agreement with the in vitro data, cells transfected with CAMTA1 showed strongly de-
creased tumor growth (Figure 2.3.11 C and D), whereas control cells rapidly formed tumors. Of
note, the color scale in Figure 2.3.11 C is different between both groups, making weak signals in
the CAMTA1 transfected group more intense.
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Figure 2.3.11. CAMTA1 functions as a tumor suppressor in vivo. A, Schematic representation of the used xenograft
model. B, Human GBM cell line R28 was transduced with a construct containing firefly luciferase (luc) to generate stable
R28-luc cell line. Luciferase expression was analyzed by detection of luciferase activity. C, D, R28-luc was transiently
transfected with pIRES-CAMTA1 or an empty plasmid followed by orthotopic implantation into nude mice (NU/NU-Foxn1nu)
brain. Tumor size was analyzed by bioluminescent imaging 14 d post implantation. Two representative mice of each
experimental group are shown in panel C. The color scales indicate signal intensity recorded as total photons per second,
square centimeter and steradian. Box-Whisker-Diagram of the quantified dorsal signals from both experimental groups is
shown in panel D with a significance of *P < 0.05. n represents group size. Data in D are shown as mean plus/minus SEM.
3.4.6. Initial characterization of a CAMTA1 knockout mouse model
As CAMTA1 showed striking effects on tumor growth in vitro and in vivo, we decided to use a
previously reported conditional CAMTA1 knockout mouse model (Long et al., 2014, see Appendix
Figure A2). As expected for a tumor with highly diverse and multiple genetic aberrations, sponta-
neous formation of GBM or other brain tumors has not been identified in CAMTA1 knockout mice
(Long et al., 2014). This indicates that a homozygous loss of CAMTA1 alone is not able to induce
GBM or other brain tumors. As it has been shown that GBM-like tumors can develop from neural
stem cells (NSCs), we decided to generate an inducible CAMTA1 knockout specifically in NSCs
(Sanai et al., 2005, Stiles and Rowitch, 2008, Zong et al., 2012, Chen et al., 2012b). Further-
more, we developed tools for detailed analysis of the mouse model and for future crossings with
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other GBM-prone mouse models. This should finally allow to determine whether loss of CAMTA1
increases the frequency of spontaneous GBM-like tumors together with other aberrations.
To do so, we did embryo transfers to establish two founding pairs for the CAMTA1fl/fl line. Adult
NSCs reside within the subventricular zone and the subgranular zone of the dentate gyrus and are
characterized by expression of the intermediate filament protein Nestin. Therefore, we crossed
CAMTA1fl/fl mice with Nestin-CreERT2 driver lines, which allow for tamoxifen (TAM) inducible
CAMTA1 knockouts during variable developmental stages or in adult animals (Lagace et al.,
2007). TAM application results in a nuclear translocation of the cytoplasmic Nestin-CreERT2
fusion protein and consequently knockout of CAMTA1. Five sequential administrations of TAM
intraperitoneally were used (Lagace et al., 2007). Genotyping after TAM administration did not
allow direct identification of the CAMTA1 knockout allele via brain biopsies from different brain re-
gions. However, we showed successful CAMTA1 knockout after cultivation of subventricular zone-
derived NSCs under stem cell cultivation conditions (data not shown). Whether we were able to
knockout CAMTA1 in all NSCs is probable, because no wildtype allele was visible by genotyping
after TAM administration. However, this has to be further investigated. Three month after tamoxifen
injection, mice did not show the observed long-term effects of the published CAMTA1-knockout
mice, including severe ataxia (data not shown). Furthermore, the mice did not show other obvious
behavioral abnormalities and no weight loss (data not shown). Therefore, we are able to knockout
CAMTA1 in adult NSCs without the previously observed abnormalities, which is a beneficial con-
dition for long-term observation of tumor development and growth. This provides a solid basis for
future analysis of this mouse model system.
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Figure 2.3.12. CAMTA1 expression correlates with patient survival. A, B, CAMTA1 mRNA expression was analyzed
in non-tumor brain tissue, astrocytoma (WHO grade I-III) and GBM using the indicated Affymetrix probes. C, Kaplan-
Meier survival plot for GBM patients with high (red) and normal (blue) CAMTA1 mRNA expression, as determined using
Affymetrix probe 213268. Data in A are shown as mean plus/minus SEM. Data in A and B were obtained and P-value in
C was calculated using REMBRANDT database.
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3.4.7. CAMTA1 expression correlates with patient survival
As CAMTA1 overexpression showed striking effects on GBM growth in vitro and in vivo and be-
cause 1p36 deletions are frequent in glioma patients, we asked whether CAMTA1 expression
correlates with survival of patients suffering from different classes of gliomas. As source material,
we accessed the Repository of Molecular Brain Neoplasia Data (REMBRANDT), a database that
integrates clinical data, copy number information and gene expression data from glioma patients
out of clinical trials (Madhavan et al., 2009). Here, CAMTA1 mRNA expression was decreased in
GBM and WHO grade I to III astrocytoma samples compared to healthy individuals (Figure 2.3.12
A and B). Interestingly, GBM showed lower CAMTA1 expression than the less malignant astrocy-
tomas. We next analyzed whether patients with high CAMTA1 expression might have beneficial
prognosis for a longer survival. Indeed, patients with high CAMTA1 levels in tumor tissue showed
a significantly longer survival compared to all other patients (Figure 2.3.12 C). Of note, we only
found a very low number of GBM patients with high CAMTA1 levels (data not shown), therefore
survival data were analyzed from patients suffering from GBM, astrocytomas, oligodendrogliomas
and gliomas with mixed histology. Taken together, analysis of patient data indicates that CAMTA1
might act as a tumor suppressor in GBM and other gliomas. In addition, CAMTA1 might function
as a marker with potential prognostic value.
3.5. Identification of CAMTA1 target genes
CAMTAs have been shown to function as transcription factors in various organisms (reviewed
in Finkler et al., 2007). To further characterize CAMTA1, we identified potential target genes of
CAMTA1 by CAMTA1 overexpression and target mRNA quantification.
3.5.1. CAMTA1 regulates the natriuretic peptide hormone system
It has been previously shown, that mouse CAMTA2 activates transcription of the atrial natriuretic
peptide (ANP) in the heart (Song et al., 2006). ANP belongs to the natriuretic peptides, which are
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Figure 2.3.13. CAMTA1 positively regulated NPPA and NPR-A. A, B, R28 cells were transiently transfected with
CAMTA1 or CAMTA1 ∆N expressing plasmids or an empty plasmid as control. Natriuretic peptide precursor (NPP) A, B
and C mRNA was analyzed by quantitative real-time PCR in panel A. Quantification of natriuretic peptide receptor (NPR)
A, B and C mRNA is shown in panel B. C, LN-229 cells were transfected with miR-9, miR-9* or miR-17-5p inhibitors
and NPPA and NPR-A mRNA was quantified by quantitative real-time PCR. GAPDH was used as internal control for
normalization in A, B and C. Data are shown as mean plus SEM. *P < 0.05; **P < 0.005; ***P < 0.0005; n.s., not
significant.
3. RESULTS 59
mainly secreted by the heart, but have also been found to be synthesized in the brain and other
organs (Anand-Srivastava, 2005). Two structurally related proteins brain natriuretic peptide (BNP)
and C-type natriuretic peptide (CNP) belong to the same family of peptide hormones. Despite its
name, BNP is mainly expressed in heart but has also been identified in brain, as it is the case
for ANP and CNP. ANP, BNP and CNP are expressed as inactive precursors from the natriuretic
peptide precursor (NPP) genes NPPA, NPPB or NPPC, respectively. ANP and BNP are agonists
of the natriuretic peptide receptor A and C (NPR-A, NPR-C), CNP is agonist of NPR-B. Interest-
ingly, it has been shown that ANP has antiproliferative effects on GBM cell lines in vitro (Vesely
et al., 2007). To investigate whether CAMTA1 activates the expression of NPPA in GBM-derived
cell lines, CAMTA1 or CAMTA1 ∆N was expressed in LN-229 cell line followed by quantification
of peptide hormone precurser and receptor mRNAs. CAMTA1 overexpression increased NPPA
mRNA levels, whereas transfection of CAMTA1 ∆N had a much weaker effect, however the in-
duction was still significant (Figure 2.3.13 A). NPPB did not respond to CAMTA1 overexpression,
NPPC was increased to a similar degree in CAMTA1 and CAMTA1 ∆N transfected cells; addi-
tionally, induction of NPPC was variable between biological replicates (Figure 2.3.13 A). Among
the receptors, NPR-A was strongly induced upon CAMTA1 overexpression, whereas NPR-B and
NPR-C did not increase (Figure 2.3.13 C).
Because miR-9/9* and miR-17 inhibition increased CAMTA1 expression, we asked whether
inhibition of miR-9/9* and miR-17 also increase expression of NPPA and NPR-A. Indeed, NPPA
and NPR-A mRNA levels were increased upon miR-9/9* and miR-17 inhibition, presumably by
CAMTA1 expression (Figure 2.3.13 C). Although the results were reproducible, induction of NPRA
> 2-fold downregulated> 2-fold upregulated all glioma samples
1.0
0.8
0.6
0.4
0.2
0.0
0 0 0
0 0 0
2000
Days in study
P
ro
ba
bi
lit
y 
of
 s
ur
vi
va
l
60004000
1.0
0.8
0.6
0.4
0.2
0.0
2000
Days in study
60004000
1.0
0.8
0.6
0.4
0.2
0.0
2000
Days in study
60004000
1.0
0.8
0.6
0.4
0.2
0.0
2000
Days in study
P
ro
ba
bi
lit
y 
of
 s
ur
vi
va
l
60004000
1.0
0.8
0.6
0.4
0.2
0.0
2000
Days in study
60004000
1.0
0.8
0.6
0.4
0.2
0.0
2000
Days in study
60004000
NPPA
P (up vs. all) = 0.16
P (down vs. all) = 0.0002
n (up) = 23
n (down) = 68
n (all) = 343
NPPB
P (up vs. all) = 0.13
P (down vs. all) = 0.34
n (up) = 50
n (down) = 25
n (all) = 343
NPPC
P (up vs. all) = 0.45
P (down vs. all) = 0.08
n (up) = 24
n (down) = 187
n (all) = 343
NPR-A
P (up vs. all) = 0.10
P (down vs. all) = 0.26
n (up) = 66
n (down) = 10
n (all) = 343
NPR-B
P (up vs. all) = 0.73
P (down vs. all) = 0.25
n (up) = 3
n (down) = 12
n (all) = 343
NPR-C
P (up vs. all) = 0.16
P (down vs. all) = 0.31
n (up) = 12
n (down) = 37
n (all) = 343
Figure 2.3.14. NPPA expression correlates with patient survival. NPPA, NPPB, NPPC and the receptors NPR-A,
NPR-B and NPR-C were analyzed in patient samples. Kaplan-Meier plots were generated from glioma patients including
GBM, oligodendroglioma and astrocytoma. Samples were sorted into high (red) or low (green) expression of each mRNA
and compared to survival data of all samples (blue) used for analysis. Only NPPA showed a significant correlation with
patient survival. Analyses were performed using REMBRANDT database and P-values were calculated by REMBRANDT
software. n represents group size.
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and NPR-A upon miRNA inhibition were not statistically significant.
We next analyzed whether NPPA and the other components of the natriuretic peptide hormone
system show correlation with GBM patient survival. We again used REMBRANDT database for
our analysis. Consistently with our in vitro data, low NPPA expression correlated significantly with
patient survival (Figure 2.3.14). Of note, only GBM patients have been included into the analysis,
because enough patients were available with altered NPPA expression and ANP has been previ-
ously shown to have antiproliferative function on GBM-derived cell lines (Vesely et al., 2007). All
other components NPPB, NPPC, NPR-A, NPR-B and NPR-C did not significantly correlate with
patient survival.
Because the role of the natriuretic peptide hormone system in the brain is still a matter of debate
and we did not test yet whether ANP indeed has inhibitory effects on GBM growth, we can only
state so far that ANP might play a role downstream of CAMTA1 for GBM but an exact role of the
natriuretic peptide system has to be further analyzed.
3.5.2. Transcriptome response upon CAMTA1 overexpression
To get deeper insights into CAMTA1 function, we characterized the transcriptome response after
CAMTA1 overexpression. Genes regulated directly or indirectly by CAMTA1 should be either
lower or higher expressed in the CAMTA1 transfected sample compared to an empty plasmid
transfected sample. RNA was hybridized to an Affymetrix GeneChip Human Gene 1.1 ST Ar-
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Figure 2.3.15. Transcriptome response after CAMTA1 overexpression. A, GBM cell line R28 was transiently trans-
fected with CAMTA1 or empty plasmid. RNA samples were processed and hybridized on an Affymetrix Human Gene
1.1 ST Arrays in biological duplicates. Expression ratio CAMTA1 to control was calculated for each transcript in both
duplicates (lane 1 and 2). Mean value was calculated from biological duplicates and genes were sorted according to
decreasing mean ratio. Blue indicates higher, red indicates lower expression after CAMTA1 overexpression, whereas the
value 1 corresponds to unchanged levels. B, Candidates were selected from the top up- or down-regulated mRNAs and
non-coding RNAs (ncRNAs). Additionally, previously described potential CAMTA1 target genes from Henrich et al., 2011
and the natriuretic peptide hormone system (this work) were detected in the microarray data and listed together with the
measured mean fold change.
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ray designed to cover the whole human transcriptome in two biological replicates (Figure 2.3.15
A). Analysis revealed strongly up- and downregulated genes with CAMTA1 being the most strongly
upregulated candidate. To validate the data, NPPA and NPR-A were analyzed, however, neither
NPPA nor NPR-A were elevated in the microarray (Figure 2.3.15 B), although an increase of NPPA
and NPR-A mRNA was confirmed by quantitative real-time PCR in the same biological replicates
(data not shown). We therefore included possible CAMTA1 transcriptional targets from Henrich
et al., 2011 into our analysis, and consistently, putative targets from Henrich et al., 2011 were
also elevated or reduced in our microarray (Figure 2.3.15 B). Of note, whether the up- and down-
regulated genes are direct transcriptional targets or indirectly regulated is not known. Interestingly,
the top-downregulated gene castor zinc finger 1 (CASZ1) has been shown to function as tumor
suppressor in neuroblastoma and will be an interesting candidate for further analysis (Liu et al.,
2011, Virden et al., 2012).
4. Discussion of Part II
MiRNAs have been implicated in all types of cancer analyzed so far by regulating important tumor
suppressors and oncogenes. In addition, they play pivotal roles in stem cell biology, differentiation
and neurogenesis. Although this immediately suggests that miRNAs also regulate stemness and
differentiation in cancer stem cells (CSCs), comprehensive analyses of miRNAs in CSCs have not
been done so far. However, this is of central interest, as CSCs can drive tumor growth, therapy
resistance and tumor relapse after therapy. To get a deeper insight into these processes, we have
chosen to study GBM, a highly malignant brain tumor that lacks effective therapy strategies and
which is thought to be driven by a GBM cancer stem cell (GSC) subpopulation.
miR-9/9* are differentially expressed in GSCs and may function as oncomiRs
To obtain GSC and non-GSC subpopulations for miRNA deep sequencing, we used the primary
GBM patient-derived cell line R11. Previous studies have shown that CD133-positive (CD133+)
cells of R11 indeed correspond largely to the bona fide GSC subpopulation, allowing efficient
enrichment of GSC and non-GSC subpopulations. Of note, the identification of a small CD133-
GSC subpopulation has been reported, however, we did not try to further separate these cells
from the non-GSC subpopulation used for our analysis (Beier et al., 2007). R11 forms well-defined
neurospheres and previously determined transcriptome data showed that R11 is genetically and
transcriptionally stable, allowing in depth downstream analyses (Beier et al., 2007, Beier et al.,
2008).
We found that miR-9 and its corresponding miR-9* are strongly expressed in GSCs compared
to the non-GSC subpopulation, as shown by miRNA deep sequencing and Northern Blot anal-
ysis. miR-9/9* is almost exclusively expressed in brain and both strands have been shown to
be functional (Landgraf et al., 2007). Interestingly, miR-9/9* has been found to be highly ex-
pressed in diverse primary brain tumors including astrocytomas, oligodendrogliomas and GBM
(Nass et al., 2009, Huse et al., 2009, Malzkorn et al., 2010, Kim et al., 2011a). This indicates
that miR-9/9* might be important for a broad spectrum of brain tumors. Furthermore, it has been
shown that miR-9/9* play important roles during neurogenesis, neural stem cell (NSC) fate de-
termination and for proliferation and migration of neural progenitor cells (Sempere et al., 2004,
Yoo et al., 2009, Zhao et al., 2009, Delaloy et al., 2010). In addition to GBM, miR-9/9* expression
is increased in other cancer types including lymphomas, breast cancers, cervical cancers, colon
cancers and stomach cancers (Coolen et al., 2013). Besides miR-9/9*, we identified additional
cancer-associated miRNAs to be differentially expressed in GSCs, including miR-17, miR-21,
miR-221 and miR-222. These miRNAs have previously been shown to be frequently highly ex-
pressed in various types of cancer (Esquela-Kerscher and Slack, 2006, Croce, 2009, Jansson
and Lund, 2012). The identification of miRNAs that are increased in cancer is consistent with the
pre-selection of miRNAs with the highest number of reads in our deep sequencing data. In ad-
dition, the identification of important cancer-related miRNAs within the top-regulated candidates
indicates that our miRNA expression profiling provides a solid basis for further analysis. Our data
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were further confirmed by validation of the top upregulated miRNAs by Northern Blot and anal-
ysis of miR-9/9* expression in a broad spectrum of GBM-derived cell lines. Due to the previous
implication of miR-9/9* into GBM and neurogenesis, we have chosen miR-9/9* for further analysis.
The mechanisms that regulate differential expression of miRNAs in cancer are not known in
most cases. This is also true for miR-9/9*, which can be expressed from three genomic loci (hsa-
mir-9-1, hsa-mir-9-2, hsa-mir-9-3). Which locus or loci are active in GBM and which mechanisms
regulate expression of miR-9/9* is not known. Of note, an initial analysis of genomic GBM data
from the TCGA consortium did not reveal significant genomic amplification of the three miR-9/9*
loci (data not shown). Regarding the regulatory mechanisms that mediate differential miRNA ex-
pression in GSCs versus non-GSCs, transcriptional programs might be probable candidates, as
genetic differences between GSCs and their differentiated progeny are not expected. One study
showed that miR-9 expression is stimulated by MYCN in breast cancer (Ma et al., 2010). It is
therefore tempting to speculate, if MYCN might contribute to miR-9/9* expression in GBM/GSCs
as well. In addition to MYCN, hypoxia has been shown to induce expression of miR-9/9* from mir-
9-1 and mir-9-3 but not mir-9-2 by the hypoxia-associated transcription factor HIF-1α (Shan et al.,
2014). Interestingly, hypoxia plays important roles in GBM and influences GSC activity within its
niche (Seidel et al., 2010, Heddleston et al., 2012). Furthermore, Lin28a regulates neuronal dif-
ferentiation and controls miR-9/9* processing by inducing the degradation of its precursor through
poly-U tailing, mediated by a so far unknown TUTase (Nowak et al., 2014).
Functional analysis of miR-9/9* revealed that miR-9/9* function as oncogenes in GBM. Taking
advantage of the neurosphere-formation assay, we observed severely affected growth of several
GBM-derived cell lines in vitro when miR-9/9* were inhibited. On the other side, neurosphere-
formation increased upon transfection of miR-9/9* mimics. The observed effects might at least
in part be explained by GSC-specific functions of miR-9/9*, as a loss of miR-9/9* resulted in
reduced CD133+ cells and increased differentiation. This is in line with the previously reported
roles of miR-9/9* to exhibit oncogenic function in GBM and other types of cancer and to function as
regulator of differentiation (Coolen et al., 2013). Differentiation upon miR-9/9* inhibition was driven
towards the neuronal lineage, however, we did not investigate whether cells also differentiated
along the oligodendrocytic lineage. Seemingly inconsistent with our observations, miR-9/9* has
been previously implicated as positive regulator of neural differentiation during neurogenesis and
miR-9-2/miR-9-3 double knockouts, which express about 20 to 30 % of the wildtype miR-9/9*
levels, show severe neurodevelopmental defects and die within one week after birth (Shibata
et al., 2011). Despite these findings, other studies suggested that miR-9/9* does not directly
support differentiation but functions to keep cells in a state that is prone to differentiation, but can
also be pushed in the other direction by inhibiting differentiation (Coolen et al., 2013). This reversal
might be regulated by other factors not identified so far. Therefore, whether miR-9/9* supports or
inhibits differentiation seems to be highly context-specific.
Apart from their role in cell differentiation, not much is known on miR-9/9* function. Interestingly,
a study found miR-9 and miR-17 to play important roles in secondary GBM progression (Malzkorn
et al., 2010). This study analyzed miRNAs in secondary GBM compared to their lower-grade
precursor neoplasms. A small set of miRNAs including miR-9 and miR-17 has been found to be
repeatedly increased in GBM relative to the precursor neoplasm, indicating that these miRNAs
are deregulated either during progression to GBM or late within GBM.
Another study has analyzed miRNA expression profiles from 261 TCGA GBM patient samples
(Kim et al., 2011a). Tumors were clustered according to their miRNA expression profiles and
classified using cell lineage marker genes. This revealed neural, oligoneuronal, multipotent, as-
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trocytic and neuromesenchymal classes (Kim et al., 2011a). Interestingly, miR-9/9*, miR-17 and
miR-106b were all found in the oligoneuronal subclass, suggesting that these miRNAs are espe-
cially important for this subclass of GBM. This is an expected finding because of the pronounced
tumor heterogeneity in GBM, represented by different genetic aberrations and gene expression
profiles. Furthermore, tumor heterogeneity on the level of miRNA expression would explain why
miRNA profiles from GBM often differ between studies (see part II section 1.2.2 and 1.3.1). The
oligoneuronal miRNA cluster overlaps well with the proneural mRNA class, which shows slightly
increased survival but resistance to chemotherapy with temozolomide (Phillips et al., 2006, Ver-
haak et al., 2010, Brennan et al., 2013). This is in line with miR-9 and miR-17 being highly
expressed in secondary GBM, which largely cluster into the proneural group (Verhaak et al.,
2010). However, whether miR-9/9*, miR-17 and miR-106b expression correlates with patient sur-
vival and therapy resistance in these subgroups is not known. In addition, we do not know whether
the described subclasses contain different proportions of GSCs. Taken together, these observa-
tions suggest that, in addition to the heterogeneous miRNA expression profiles between tumors,
also GSCs of different tumors might express different miRNAs. It is also conceivable that different
GSC subpopulations within the same tumor express different sets of miRNAs. This has important
implications for possible miRNA-based therapy strategies, as not all tumors would respond to the
same miRNA-targeting therapy.
Identification of miR-9/9* targets and characterization of the novel tumor suppressor
CAMTA1
To better understand miR-9/9* function in GBM and GSCs, we identified miR-9* target mRNAs
in R11. The list of putative targets contained several factors that might be interesting candidates
for further analysis. For example, FoxQ1 is a member of the forkhead transcription factor family
that is involved in differentiation in various cell types (Feuerborn et al., 2011). Another member,
FoxG1, has previously been shown to function as a miR-9 target in mice and to contribute to
the pro-differentiating effects of miR-9/9* during neurogenesis (Shibata et al., 2011). The putative
miR-9/9* target mRNA NEFM encodes for the neurofilament protein medium polypeptide NF-M,
which is exclusively expressed in finally differentiated neurons (Antic et al., 1999). Identification of
this neuronal differentiation marker supports our observation that miR-9/9* expression functions
as a negative regulator of differentiation in GBM. Among the targets, CAMTA1 caught our special
interest and was selected for further characterization. CAMTA1 has been reported to function as
a putative tumor suppressor in neuroblastoma and to be located within 1p36, a region frequently
deleted in various brain tumor types (Barbashina et al., 2005, Ichimura et al., 2007, Weller et al.,
2009, Henrich et al., 2011). Although 1p36 seems to be less frequently deleted in GBM compared
to other gliomas and neuroblastoma, the suppression of CAMTA1 expression by miR-9/9* would
be a possible mechanism to silence this putative tumor suppressor in GBM. Interestingly, we did
not only identify and validate binding sites for miR-9*, but also miR-9 and miR-17, both of which
were upregulated in GSCs. Therefore, these miRNAs might function cooperatively to efficiently
silence CAMTA1.
CAMTA proteins share a series of domains and motifs, including a CG-1 DNA binding motif,
a TIG domain implicated in non-specific DNA-binding and dimerization, ankyrin repeats that can
mediate oligomerization and calmodulin-binding IQ motifs. Mammals contain two CAMTA genes
that encode the highly homologous CAMTA1 and CAMTA2 proteins. CAMTA1 and CAMTA2 ex-
pression partially overlaps in mice: CAMTA2 is mostly expressed in heart and brain and to lower
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levels in liver, kidney and testis. CAMTA1 is expressed at high levels in brain and low levels in heart
and was not detected in any other tissue (Song et al., 2006). We found that CAMTA1 tumor sup-
pressor activity strictly depends on the CG-1 DNA binding domain. This is in line with published
results showing that CAMTA1 protein indeed functions as transcription factor in mammalian cells
and binds DNA via its CG-1 domain (Henrich et al., 2011, Long et al., 2014). Functional character-
ization of the other CAMTA1 domains is lacking. Studies of mouse CAMTA2 showed that CAMTA2
is kept in an inactive state by binding of class II histone deacetylases to CAMTA2 ankyrin repeats
(Song et al., 2006). In addition, CG-1 is not only able to directly bind DNA but can also associate
with the transcriptional coactivator Nkx2-5, supported by the TIG domain. Reported evidence that
mammalian CAMTA1 and CAMTA2 function are regulated by calcium signalling through calmod-
ulin binding is lacking, however, calmodulin binding has been shown for plant and fly CAMTA
proteins (Bouché et al., 2002, Han et al., 2006a).
Due to their high sequence homology, especially within the DNA-binding domain, we looked
for published CAMTA2 regulated genes which could be targets for CAMTA1 as well. CAMTA2
can activate the expression of the natriuretic peptide hormone precursor NPPA in the heart dur-
ing hypertrophic signaling (Song et al., 2006). Interestingly, the processed product of NPPA has
antiproliferative functions in various types of cancer including GBM (Vesely et al., 2005, Vesely
et al., 2007). Strikingly, we have shown that CAMTA1 activates NPPA expression in GBM cells as
well. Moreover, CAMTA1 also stimulates the expression of the NPPA receptor NPR-A. Whether
both NPPA and NPR-A expression indeed mediate CAMTA1 tumor suppressor effects and if their
coactivation enables autocrine signalling remains to be analyzed. Interestingly, the NPPA gene is
located in the 1p36 locus, and it is indeed deleted in a number of gliomas (Ichimura et al., 2007).
To get deeper insights into CAMTA1 regulated genes in GBM, we investigated transcriptome
changes after CAMTA1 overexpression. Although the microarray did not show changes in NPPA
and NPR-A expression, we found further putative CAMTA1-regulated genes. Among those, we
have identified numerous genes that have previously been shown to be up- or downregulated by
CAMTA1 in neuroblastoma (Henrich et al., 2011). This overlap indicates that our dataset provides
a solid basis for further analysis. Of note, CAMTA1 overexpression increases endogenous levels
of neuronal markers like TUBB3, MAP2 and NEFL in neuroblastoma cell lines, which could at
least in part explain the observed effects of miR-9/9* inhibition on differentiation (Henrich et al.,
2011). Among the putative CAMTA1 targets, CASZ1 was the top-downregulated gene. CASZ1
is an highly interesting candidate for further analysis, as it has been shown to function as tumor
suppressor in neuroblastoma and is also located in 1p36 (Liu and Tang, 2011, Virden et al., 2012).
Model and outlook
The identified pathway consisting of miR-9/9*, CAMTA1 and the NPPA/NPR-A prompted us to
propose the following model (Figure 2.4.1). In GSCs, miR-9/9* and miR-17 expression is high
compared to non-GSCs, which results in low CAMTA1 expression in GSCs. Of note, it is likely
that miR-9/9* regulate other target mRNAs as well which might also contribute to the observed
phenotypes. This is also true for the identified putative CAMTA1 targets. CAMTA1 functions as
a transcription factor to induce the expression of NPPA and its receptor. Coexpression of both
NPPA and NPR-A potentially allows autocrine signaling with antiproliferative function. By increas-
ing miR-9/9* levels, GSCs repress CAMTA1 and the anti-proliferative NPPA. In addition miR-9/9*
negatively regulates neuronal differentiation.
One major future perspective is a deeper understanding of miRNA targets in GSCs, including
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Figure 2.4.1. A model for miR-9/9*, CAMTA1 and NPPA/NPR-A function in GBM. A, Schematic representation of
miR-9/9*, CAMTA1, and NPPA/NPR-A expression in GSC and non-GSCs. B, Model of miR-9/9*, CAMTA1 and NPPA/NPR-
A function in GBM. In GSCs, miR-9/9* are elevated and repress CAMTA1 expression by miRNA-mediated gene silenc-
ing. This prevents transcriptional activation of NPPA and NPR-A, which have anti-proliferative function. Whether miR-9/9*
and CAMTA1 have other target genes is not known, but might also contribute to the observed oncogenic effects of miR-9/9*
and tumor suppressor effects of CAMTA1.
the tumor suppressor CAMTA1. One might speculate whether CAMTA1 might function as poten-
tial therapy target, however, as a deeper understanding of CAMTA1 function is still lacking, this
remains to be analyzed. It should be investigated how CAMTA1 regulates its target genes and
whether CAMTA1 is depleted in a broad spectrum of tumors. The generated CAMTA1 knockout
mouse model could provide important insights into these processes. For example, it could be in-
vestigated whether loss of CAMTA1 in p53+/- mice, PTEN+/- mice and other GBM prone mouse
models further increases tumor-formation.
There is extensive scientific effort to develop targeted and patient-specific therapy approaches
as an alternative to conventional radio- and chemotherapy. GSCs have been suggested as impor-
tant driver of GBM growth and novel therapeutic approaches try to target the GSC pool (Stupp
and Hegi, 2007). It would therefore be tempting to see whether GSC-specific miRNAs can be in-
hibited in vivo to reduce GBM growth, as observed in our in vitro studies. This could be tested by
xenograft mouse models that are treated orthotopically with miRNA inhibitors. Our study provided
further evidence that the application of miRNA inhibitor combinations might be effective to reduce
tumor growth. These inhibitor cocktails could be designed patient-specifically to target multiple
GSC-specific miRNAs.
Part III.
Nuclear Import of Argonaute and
TNRC6 proteins
1. Introduction
Argonaute and TNRC6 proteins are the key players in post-transcriptional gene silencing (PTGS)
pathways. Argonaute proteins bind small non-coding RNAs (ncRNAs) and are then guided to
a target messenger RNA (mRNA). Argonaute proteins further associate with TNRC6 proteins,
which recruit deadenylase and decapping complexes. Although these cytoplasmic processes are
reasonably well understood, Argonaute and TNRC6 proteins have also been identified in the
nucleus of mammalian cells. However, which transport routes are used to reach the nucleus are
not characterized so far.
This introduction will give an overview on nuclear functions small RNA-guided gene silencing
components. Then, nuclear transport pathways will be presented and the current knowledge on
nuclear transport of small RNA-mediated gene silencing components.
1.1. Small RNA-mediated gene regulation in the nucleus
Nuclear functions of small RNA-guided gene regulatory proteins have been investigated in diverse
organisms. So far, these nuclear function have only been well characterized in lower organisms
including worms, plants and yeast. I will restrict this section to the nuclear functions in somatic
cells.
1.1.1. Small RNA-guided transcriptional gene regulation
Transcriptional gene regulation by small RNAs has been identified in diverse organisms and has
so far been characterized in S. pombe, plants and worms (Castel and Martienssen, 2013). Cen-
tral principles of small RNA-guided transcriptional regulation are common between organisms:
An Argonaute protein binds via an associated sRNA sequence-specifically to a nascent tran-
script. This tethers the Argonaute protein to specific genomic loci. Argonaute then recruits histone
or DNA methylases that place repressive chromatin marks. This finally leads to transcriptional
gene silencing of the respective loci (TGS). Of importance, apart from this basic principle, differ-
ent kinds of sRNAs, Argonautes and accessory proteins like RNA-dependent RNA polymerases
(RdRP) participate in TGS in different organisms.
Small RNA-guided TGS in S. pombe
S. pombe contains only one Ago protein, referred to as Ago1, which mediates TGS. Furthermore,
S. pombe contains a single Dicer protein (Dcr1) and one RdRP (Rdp1). Ago1, the chromodomain
protein Chp1 and Tas3, which bridges Ago1 and Chp1, form the so-called RNA-induced transcrip-
tional silencing complex (RITS) (Figure 3.1.1, Verdel et al., 2004). RITS is responsible for TGS
and induces heterochromatin-formation around centromeres by methylation of histones (Castel
and Martienssen, 2013). First, a non-coding centromeric transcript (cenRNA) is produced from
centromeric repeat regions. RITS recognizes and binds the nascent cenRNA by base pairing
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(Motamedi et al., 2004). RITS is additionally tethered to chromatin via Chp1, which binds H3K9
methylated histones. The sRNAs that mediate base pairing with the cenRNA are derived from
the cenRNA itself: The RNA-directed RNA polymerase complex (RDRC) containing the RdRP
Rdp1, is recruited by RITS, leading to the synthesis of a long dsRNA from the single-stranded
cenRNA (Colmenares et al., 2007). This dsRNA is then processed by Dcr1 into siRNAs, which
are loaded in a signal amplification loop onto Ago1 (Bühler et al., 2007). RITS also recruits the
Clr4 H3K9 methyltransferase complex (CLRC) to the centromeric chromatin, which leads to H3K9
methylation and heterochromatin-formation (Bayne et al., 2010).
Interestingly, recent work has shown that RITS not only associates with centromeric heterochro-
matin, but also many other loci including retrotransposons and non-coding RNA genes, which
are also under transcriptional control of RITS under specific cellular conditions (Woolcock et al.,
2011). The origin of the priming siRNAs for RITS-cenRNA association is so far unknown.
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Figure 3.1.1. TGS of centromeric chromatin in S. pombe. RNA-induced transcriptional silencing (RITS) complex,
consisting of Ago1, Tas3 and Chp1, binds to nascent transcripts from centromeric chromatin (cenRNA). RITS leads
to transcriptional silencing by placing chromatin marks and recruiting the RNA-dependent RNA polymerase complex
(RDRC). RDRC produces dsRNA, which serves as substrate for siRNA processing by Dcr1. The Clr4 methyltransferase
complex (CLRC) is recruited by RITS and methylates H3K9. Figure taken from Schraivogel and Meister, 2014.
RNA-directed DNA methylation in plants
In A. thaliana, four Dicer-like proteins (DCL1-4) and ten different Argonaute proteins (AGO1-
10) exist. These proteins are involved in various different sRNA-mediated pathways including
siRNA-guided PTGS and TGS by RNA-directed DNA methylation (RdDM) (Bologna and Voinnet,
2014). RdDM transcriptionally represses a subset of transposons and genes by placing repressive
DNA methylation marks and is implicated in various processes including pathogen defense and
stress response (Matzke and Mosher, 2014). Plant RdDM is a highly complex nuclear pathway
that involves DCL3 and AGO4 and eventually AGO6 and AGO9 (Zheng et al., 2007, Havecker
et al., 2010). Furthermore, RdDM requires a specialized transcription machinery and numerous
accessory proteins. As RdDM is not fully understood, it will be depicted here in a very simplified
way (Matzke and Mosher, 2014).
First, the plant-specific RNA polymerase IV produces a long dsRNA, which is processed by
the nuclear protein DCL3 into siRNAs (Daxinger et al., 2009). These siRNAs are also referred to
as heterochromatic (hc-) siRNAs. By a yet unknown mechanism, hc-siRNAs are exported to the
cytoplasm, one strand is loaded onto AGO4, which is then re-imported into the nucleus. In the
nucleus, the AGO4-hc-siRNA complex targets a nascent transcript produced by another plant-
specific RNA polymerase V (Wierzbicki et al., 2008). This targeting then triggers the recruitment
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of DNA methyltransferases to mediate de novo DNA methylation. These repressive chromatin
marks result in transcriptional silencing of Pol V transcribed loci, which are mostly transposons
and other repetitive DNA elements (Wierzbicki et al., 2012).
TGS in C. elegans
When worms are fed with dsRNAs that are complementary to an endogenous gene, not only does
RNAi silence mRNAs post-transcriptionally in the cytoplasm, but also nuclear RNAi mediates TGS
of the respective target locus. This nuclear RNAi pathway in somatic cells of C. elegans promotes
TGS by histone methylation and inhibition of RNA polymerase II (Guang et al., 2008, Guang
et al., 2010). The key players of TGS in somatic cells of C. elegans is the Ago protein NRDE-3,
the RdRP RRF-1 and the Dicer protein DCR-1.
Small RNA-guided TGS in C. elegans is induced by cytoplasmic PTGS. During PTGS, diverse
Ago proteins silence transcripts in the cytoplasm but can also recruit RdRPs like RRF-1 to target
mRNAs. RRF-1 produces long dsRNAs which are processed by DCR-1 into so called secondary
siRNAs (Gent et al., 2010). These secondary siRNAs are subsequently loaded onto the Ago
protein NRDE-3. NRDE-3 is imported into the nucleus where it binds to nascent transcripts of
complementary gene loci (Guang et al., 2008). This association leads to TGS by inhibition of RNA
polymerase II and formation of heterochromatin by histone methylation (Guang et al., 2010). Of
note, in contrast to S. pombe and Arabidopsis, the nuclear processes of this pathway in C. elegans
are far less understood.
What about TGS by small RNAs in mammals?
Argonaute proteins and associated small RNAs have been suggested to mediate TGS in mam-
mals (Morris et al., 2004, Janowski et al., 2006, Kim et al., 2006, Morris et al., 2008, Chu et al.,
2010, Ahlenstiel et al., 2012, Huang et al., 2013). So far, not much is known on this process in
mammalian cells and there is no consensus regarding the underlying mechanisms. Therefore,
TGS by small RNAs in mammals is still controversially discussed.
To mediate TGS, mammalian Argonaute proteins are thought to associate with chromatin (Morris
et al., 2004, Janowski et al., 2006, Schwartz et al., 2008, Matsui et al., 2013). Indeed, chromatin
immunoprecipitation (ChIP) suggested association of Ago1 and Ago2 with chromatin and Ago2
has been identified at sequences including gene promoter regions (Huang and Li, 2014). How Arg-
onaute proteins bind chromatin is not fully understood. So called promoter-associated transcripts
have been suggested to function as putative nuclear target RNAs in this process. Promoter-
associated transcripts can be in sense or antisense orientation relative to gene promoters and
are thought to be tethered to promoters in cis by yet unknown mechanisms (Janowski et al.,
2006). Ago proteins are then expected to associate with these transcripts by not yet character-
ized sRNA populations (Schwartz et al., 2008). These sRNA populations might derive from the
cellular miRNA pool, as for example miR-589 has been suggested to function in transcriptional
regulation (Matsui et al., 2013). How the downstream processes regulate transcription differs be-
tween reports: On the one hand, it has been suggested that Ago-binding leads to degradation
of the promoter-associated transcript (Schwartz et al., 2008, Matsui et al., 2013). Degradation of
the promoter-associated RNA can mediate TGS (Janowski and Corey, 2010). Of note, in addition
to TGS, degradation of the promoter-associated RNA can also mediate transcriptional activation
(Chu et al., 2010). Alternatively, Ago binding might lead to recruitment of DNA methylases that
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methylate CpG islands in gene promoters, which represses transcription initiation (Morris et al.,
2004).
1.2. Diverse nuclear small RNA-guided functions in mammals
Besides transcriptional gene regulation, a diverse spectrum of other small RNA-guided functions
has been suggested to be active in human nuclei. These include silencing of nuclear localized
RNAs, DNA damage repair-associated mechanisms and regulation of alternative splicing.
Silencing of nuclear RNAs
It has been suggested early, that human Ago2 can be active in the nucleus of human somatic
cells. Indeed, it was shown that nuclear localized RNAs like the nuclear RNA 7sk can be effi-
ciently knocked down by transfection of siRNAs (Robb et al., 2005). Subsequently, several reports
showed active nuclear RNAi by targeting other presumably nuclear long non-coding RNAs like
MALAT-1 and NEAT-1 (Nishi et al., 2013, Gagnon et al., 2014). Although this provides strong ev-
idence for active Ago proteins in the nucleus, whether miRNA-mediated PTGS is also active in
human nuclei remains to be demonstrated.
Presuming that miRNA-mediated PTGS is active in the nucleus, nuclear enriched miRNAs
should exist that associate with Ago and TNRC6 proteins. Several studies analyzed miRNA pro-
files from nuclear and cytoplasmic extracts and indeed found nuclear enriched miRNAs (Jeffries
et al., 2011, Gagnon et al., 2014). However, whether the identified profiles indeed overlap be-
tween studies and whether nucleo-cytoplasmic extractions can efficiently separate nuclear and
cytoplasmic RNAs has not been demonstrated. It is also unknown whether these presumably
nuclear enriched miRNAs indeed associate with Ago and TNRC6 proteins in the nucleus. In ad-
dition, studies were so far not able to link the nuclear enriched miRNAs to specific nuclear RNA
targets. One interesting scenario would be that miRNAs could target the 3’-UTRs of precursor-
mRNAs already in the nucleus, however this has to be investigated in future studies.
Small RNA-guided DNA double-strand break repair
It has been suggested that human Dicer, Drosha, Ago proteins and a new class of small RNAs
might be involved in DNA double-strand break (DSB) repair. In cells with artificially generated
DSBs, so-called DSB-induced small RNAs, also referred to as diRNAs, have been identified (Wei
et al., 2012). diRNAs are produced in a Dicer-dependent manner and align to sequences around
DSB sites. Interestingly, DSB repair efficiency decreased upon knockdown of Ago2 and Dicer,
suggesting that diRNAs could associate with Ago2 which somehow supports DSB repair. Which
dsRNAs might function as precursor for diRNA production however remains to be elucidated. Fur-
thermore, it is not clear how Ago2 and diRNAs should support DSB repair. A recent study sug-
gested that diRNAs recruit Ago2 to DSB sites and Ago2 further recruits Rad51, a protein that func-
tions in DSB repair by homologous recombination (Gao et al., 2014). Another study showed similar
results by identification of a small RNA population similar to diRNAs (Francia et al., 2012). In this
study, DSB repair was Drosha- and Dicer-dependent but independent of TNRC6A-C, whereas
Ago dependency has not been investigated.
Although this might provide an highly interesting mechanism, these findings were recently chal-
lenged by a study showing that Dicer knockdown in human cells increases the resistance towards
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DNA-damaging agents (Liu et al., 2015). However, as Dicer seems to be essential for diRNA
production, this is not in line with the suggested small RNA-guided DSB repair mechanism.
Regulation of alternative splicing
The spectrum of nuclear Ago functions has additionally been broadened by several studies inves-
tigating a possible role of Ago1 and Ago2 in alternative splicing (Alló et al., 2009, Liu et al., 2012,
Ameyar-Zazoua et al., 2012). These studies reported that transfected siRNAs targeting exonic
or intronic sequences proximal to splice junctions can regulate alternative splicing. Both Ago1
and Ago2 might be involved in this process. In the current model, Ago1 or Ago2 are targeted to
specific gene loci by a so far not yet identified naturally occurring small RNA population. How
Ago-chromatin interaction might work in this case is also unknown, but might involve an intragenic
antisense transcript that base-pairs with the nascent transcript. Ago1 and Ago2 then function
by placing repressive histone methylation marks, which slow down RNA polymerase II during
transcriptional elongation. In addition, Ago1 and Ago2 might recruit spliceosome complex compo-
nents. Both slowdown of RNA polymerase II and recruitment of the spliceosome then can allow
for different splicing patterns.
The implicated slowdown of RNA polymerase II is a well known mechanism that regulates al-
ternative splicing in vivo (de la Mata et al., 2003). However, the upstream effects and possible
interactions with the spliceosome are not characterized sufficiently. Therefore, whether this mech-
anism indeed functions in vivo is not known.
1.3. Nuclear transport processes
The nuclear envelope (NE) separates nucleoplasm and cytoplasm and is composed of an outer
and an inner nuclear membrane. To allow transport of proteins and RNA between nucleus and cy-
toplasm, nuclear pore complexes (NPC) form partially selective channels that pass through both
nuclear membranes (Wente and Rout, 2010). Small molecules like metabolites and small proteins
can freely diffuse through the NPC. In contrast, proteins and ribonucleoprotein particles (RNPs)
that exceed the exclusion size between 20 to 40 kDa must be actively transported (Görlich and
Kutay, 1999). Nuclear import and export of the vast majority of large cargo proteins is facilitated by
so-called karyopherins or nuclear transport receptors (Görlich and Kutay, 1999). Karyopherins are
subdivided into importins and exportins, depending on the transport direction. In humans, eleven
importins and five exportins have been identified, which recognize unique sets of proteins or RNA,
thus creating multiple transport pathways across the nuclear pore (Chook and Blobel, 2001). To
increase the cargo spectrum of the different karyopherins, they recognize so-called nuclear lo-
calization (NLS) or nuclear export (NES) signals that function as universal adaptor sequences
(Görlich and Kutay, 1999).
Nuclear transport directionality and energy demand is driven by a GTP gradient across the nu-
clear membrane. The proportion of cellular GTP/GDP that drives nucleo-cytoplasmic transport is
associated with the small Ras-related GTPase Ran (Moore and Blobel, 1993). Ran cycles be-
tween a GTP-bound and GDP-bound state and only in its GTP-bound state, Ran is active and
binds karyopherins. Ran’s intrinsic GTPase activity is low and depends on the GTPase activating
protein RanGAP (Bischoff et al., 1994). RanGAP is cytoplasmic and coupled to the NPC, thus
activating GTP hydrolysis when RanGTP enters the cytoplasm. In the nucleus, the Ran guanine
nucleotide exchange factor RCC1 catalyzes the exchange of GDP to GTP (Bischoff and Ponstingl,
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1991). RCC1 is anchored to chromatin and generates high nuclear levels of RanGTP. Therefore,
the asymmetric distribution of RanGAP and RCC1 build up a RanGTP/GDP gradient across the
nuclear envelope. The direction of nuclear transport is determined by RanGTP binding to the
karyopherin: Whereas importins have low affinity to their cargo when bound to RanGTP, exportins
have high affinity to the cargo in their RanGTP-bound state (Görlich and Kutay, 1999). Con-
sequently, importins recruit cargo in the cytoplasm and release cargo in the nucleus, whereas
exportins work the other way around.
How do importins and exportins mediate nuclear import and export? Nuclear import is mediated
by binding of an importin to the NLS sequence of a cargo protein at low RanGTP concentration
in the cytoplasm (Figure 3.1.2 A) (Stewart, 2007). The dimeric complex then translocates through
the NPC. In the nucleus, RanGTP binding to the importin results in dissociation of the importin-
cargo complex. This is mediated by conformational changes within the importin upon RanGTP
binding, that lowers the affinity to the cargo protein. The resulting importin-RanGTP complex is
then recycled back to the cytoplasm. In the cytoplasm, GTP is hydrolyzed, resulting in release
and recycling the importin. Exportins on the other side, have high affinity to the cargo NES when
bound to RanGTP in the nucleus (Figure 3.1.2 B) (Stewart, 2007). The ternary complex composed
of cargo-exportin-RanGTP is transported through the NPC and disassembled in the cytoplasm by
GTP hydrolysis of Ran-bound GTP. The exportin is then recycled back into the nucleus.
Ran
GTP
Exp
Ran
GTP
Ran
GTP
CytA BNuc
Imp
Imp
Imp
CargoCargoCargo
Ran
Ran
GDP
Ran
GDPGTP
Cyt Nuc
Cargo
CargoCargo
Exp Exp Exp
Figure 3.1.2. Principles of nuclear import and export pathways. A, Nuclear import of a cargo protein is mediated by
importins (Imp). In the nucleus, the trimeric transport complex is disassembled by binding of RanGTP. B, Nuclear export
of proteins is mediated by exportins (Exp). RanGTP in the nucleus mediates binding to the cargo, whereas the export
complex is disassembled in the cytoplasm by GTP hydrolysis.
It should be noted, that the RanGTP/GDP gradient does not directly supply energy into the
translocation process through the NPC. Instead, the RanGTP/GDP gradient determines direction-
ality by the described mechanisms, as the direction of cargo flux through the NPC can for example
be reversed by RanGTP/GDP gradient reversion (Nachury and Weis, 1999). Additional direction-
ality seems to occur during the actual NPC passage by a yet unknown mechanism (Pyhtila and
Rexach, 2003). Whether nuclear transport processes need a driving force in addition to Ran-
mediated directionality is controversially discussed. It might be possible that concentration gra-
dients of importins and exportins, RanGTP and RanGTP, the cargo itself and other components
can additionally drive transport in and out of the nucleus. However, it has also been suggested
that the Ran affinity switches alone provide all energy for cargo delivery and release (Wente and
Rout, 2010).
The NPC is a macromolecular assembly of approximately 30 different proteins, termed nucle-
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oporins (Nup). Nups are arranged in a symmetric ring that forms a central channel (Brohawn
et al., 2009). From the ring, filaments extend flexibly into the cytoplasm which carry the Ran-
GAP protein. On the nuclear side, nucleoplasmic filaments form a nuclear basket, which sup-
ports disassembly of the import complexes (Wente and Rout, 2010). How translocation through
the nuclear pore is mediated mechanistically is an unresolved issue (Wente and Rout, 2010,
Grossman et al., 2012). The permeability barrier within the NPC is formed by a subset of Nups
with phenylalanine/glycine-rich repeats (FG-repeats). FG-repeat domains contain up to 50 repeat
units of hydrophobic FG-rich patches, which are separated by hydrophilic spacer sequences. FG-
repeat domains within these Nups are considered to be unfolded and to reach into the central
channel of the NPC. Translocation is then mediated by interactions between FG-repeats and mul-
tiple binding sites on karyopherins (Wente and Rout, 2010).
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Figure 3.1.3. Hallmarking properties of nuclear import pathways. A, Many importins function as dimeric complexes,
while other can mediate transport as single importin. In both cases, nuclear localization signals (NLS) are recognized on
the cargo protein. B, many cargo proteins are imported by redundant import pathways, as for example ribosomal protein
of the large subunit 23 (rpL23). C, Single importins can recognize different NLS sequences, as for example Transportin
1 (Tnpo1), which recognizes the M9 sequence in hnRNPA1 and the beta-like import receptor binding (BIB) domain in
rpL23. D Many proteins shuttle between the cytoplasm by alternating interaction with importins and exportins.
Hallmarking properties of nuclear transport processes are shown in Figure 3.1.3. First, many im-
portins function as heterodimers in which one importin mediates interaction with the cargo protein
NLS, whereas another importin mediates translocation through the NPC. This is for example the
case during classical nuclear transport pathway described in part III section 1.3.1 (Figure 3.1.3
A). Second, many cargo proteins can interact with a broad spectrum of importins, resulting in
multiple redundant import pathways. This has for example been shown for most histones and
ribosomal proteins, like rpL23, which can be imported by four different importins (Figure 3.1.3
B, Jäkel and Görlich, 1998). Third, many importins can recognize variable NLS sequences, like
for example Tnpo1. Tnpo1 interacts with the M9 sequence of hnRNPA1 but also with the BIB
domain in rpL23 (Figure 3.1.3 C, Pollard et al., 1996, Jäkel and Görlich, 1998). Last but not
least, many cargo proteins are alternately imported and exported, a process also referred to
as nucleo-cytoplasmic shuttling. Depending on the respective transport rates during nuclear im-
port and export, shuttling proteins are predominantly nuclear or cytoplasmic (Gama-Carvalho and
Carmo-Fonseca, 2001). One well-studied example is heterogeneous nuclear ribonucleoprotein
A1 (hnRNPA1), an mRNA binding protein and important splicing regulator. hnRNPA1 is mainly
nuclear, but constantly shuttles out of the nucleus bound to precursor mRNAs and is imported
back after dissociation from the mature mRNA (Piñol-Roma and Dreyfuss, 1992).
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1.3.1. Classical nuclear import by Importin alpha/beta
The vast majority of eukaryotic proteins are imported into the nucleus by a well characterized
nuclear import pathway mediated by Importin-alpha (Impα) and Importin-beta (Impβ) (Görlich
et al., 1995, Radu et al., 1995, Moroianu et al., 1996). Impα functions as an adapaptor karyopherin
by binding to a cargo NLS, whereas Impβ binds Impα and interacts with the NPC (Figure 3.1.3
A).
The classical NLS that is recognized by Impα is enriched in basic residues, mostly lysine (K)
and arginine (R). These basic sequences can be arranged in different ways: Monopartite NLS se-
quences are single short clusters, like the SV40 large T antigen NLS with the sequence PKKKRKV
for example. Bipartite NLS sequences, like KR[PAATKKAGQA]KKKK within nucleoplasmin, are
composed of two basic clusters spaced by approximately 10 less conserved amino acids. In-
terestingly, NLS sequences seem to be largely independent of their localization within the protein
and can experimentally be transferred to a heterologous protein or within the same protein without
loosing function (the same is true for NES sequences, which will be described below).
Unlike other karyopherins, Impα is represented by six family proteins in humans, which are
Impα1, Impα3, Impα4, Impα5, Impα6 and Impα7 (Malik et al., 1997). Each Impα family member
can bind both types of classical NLS sequences, however with partially different affinities. Indeed,
cargo proteins have been identified that bind to all Impα subtypes, or bind a specific subset of
Impαs or are highly specific for a single Impα (Köhler et al., 1999).
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Figure 3.1.4. Structural properties of Impα/Impβ bound to a classical nuclear localization sequence. A, Complex
of Impα (green), Impβ (blue) and nucleoplasmin with its classical NLS (yellow) is shown. B, Structure of Impα bound to
the classical NLS of nucleoplasmin (yellow). Individual ARM repeats consist of three alpha-helices organized in a helical
structure. C, Structural view of Impβ that wraps around the Importin-beta binding domain (IBB) of Impα (green). HEAT
repeats are composed of pairs of antiparallel alpha-helices. Figure A has been taken from PDB structural views of biology
section and includes PDB entries 1qgk, 1ee5 and 1k5j. Structures in B and C have been published in Marfori et al., 2012
(PDB entry 3UL1) and Cingolani et al., 1999 (PDB entry 1QGK).
The structure of Impα/Impβ with nucleoplasmin, as exemplary cargo protein for classical import
is shown in Figure 3.1.4. Impα is composed of a core domain with 10 Armadillo (ARM) repeats
and an N-terminal importin-beta binding domain (IBB) (Fontes et al., 2000, Figure 3.1.4 B). The
ARM repeats form two NLS binding sites whereas the IBB domain functions as Impβ docking
site (Conti et al., 1998, Cingolani et al., 1999). Without bound Impβ, the IBB functions as NLS
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for Impα itself and outcompetes binding of cargo-derived NLS sequences. Therefore, the IBB
has an autoinhibitory function that blocks cargo binding without Impβ and releases cargo upon
Ran-mediated Impβ dissociation (Kobe, 1999, Fanara et al., 2000). Impβ is composed of 19
HEAT repeats (Figure 3.1.4 C). These HEAT repeats wrap around the Impα IBB and are therefore
responsible for Impα binding (Cingolani et al., 1999). On the opposite surface, the HEAT repeats
provide multiple binding sites for interaction with the FG-repeats of the NPC.
How Impβ mediates translocation through the NPC is not yet known in detail. After translocation
through the NPC, the trimeric cargo-Impα-Impβ complex remains attached to the NPC. Finally,
binding of RanGTP leads to extensive conformational changes in Impβ that result in cargo release
and dissociation from the NPC (Bayliss et al., 2000). Impβ returns to the cytoplasm bound to
RanGTP without the need for export factors. Impα instead is exported by specialized exportin
termed Cas (Kutay et al., 1997).
1.3.2. Non-classical import pathways
It has been estimated for yeast, that around half of the nuclear proteins contain a classical NLS
and are imported via Impα/Impβ. The remaining proteins must therefore be imported by other
means via non-classical nuclear import.
The best characterized non-classical pathways is mediated by Impβ and Transportin 1 (Tnpo1,
Imp2, KPNB2). Impβ can function independently of Impα by directly interacting with the cargo pro-
tein, as in the case of rpL23 and many other proteins (Chook and Süel, 2011). Furthermore, Impβ
can also use other adaptor proteins besides Impα, as for example Imp7 or even non-karyopherin
adaptors like Snurportin (Huber et al., 1998). Tnpo1 uses NLS sequences of which some share
common characteristics that defined a new class of NLS sequences, termed PY-NLS. However,
PY-NLS sequences are highly diverse and are not predictable as it is the case for classical NLS
sequences (Lee et al., 2006a). Well characterized targets of Tnpo1 are c-Jun, hnRNPA1 and
several RNA-binding proteins including HuR (Chook and Süel, 2011).
Much less is known of the specific functions of other importins including Imp4, Imp5, Imp7,
Imp8, Imp9, Imp11 and Imp12 (reviewed in Görlich and Kutay, 1999, Chook and Süel, 2011). Al-
though some of those importins have numerous known targets, NLS sequences are not uniform
and consequently not predictable. Another unconventional nuclear transport pathway is mediated
by karyopherins that transport cargo in both directions. These importins/exportins include Imp13
and Exp4. Of note, the cargos that are exported are different from the imported cargos and in
addition, are not obviously functionally related (Mingot et al., 2001).
Interestingly, recent studies identified specific double-stranded RNA binding domains (dsRBD)
as unconventional NLS sequences. These dsRBDs not only mediate RNA-protein interaction,
but can also serve as protein-protein interaction domains for importin binding for example. The
RNA-editing enzyme ADAR1 contains three dsRBDs, of which one mediates nuclear import
via Tnpo1. RNA binding and Tnpo1 interaction seems to be mutually exclusive (Barraud et al.,
2014). Furthermore, the dsRBD of human Dicer has been suggested to function as NLS. How-
ever, how importins are bound is not characterized so far (Doyle et al., 2013). The dsRBD of
fission yeast Dicer (Dcr1) seems to be involved in nuclear localization of Dcr1 as well (Barraud
et al., 2011).
The vast majority of large molecules are imported in an importin-dependent manner. However,
some proteins can mediate their own import by direct interaction with the NPC, a process also
referred to as karyopherin-independent transport (Colwell et al., 2010, Sharma et al., 2012). A well
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studied example is β-Catenin, which is structurally very similar to Impβ and indeed, β-Catenin’s
ARM repeats mediate its translocation through the NPC in in vitro nuclear import assays (Sharma
et al., 2012). Other studies even propose that a broad spectrum of related HEAT repeat proteins
or even proteins that simply contain extended hydrophobic surfaces or amphiphilic alpha helices
might be capable of karyopherin-independent import (Naim et al., 2009, Kumeta et al., 2012,
Yoshimura et al., 2014).
1.3.3. Nuclear export of proteins
Several exportins have been identified in human cells. These include Crm1 (Exp1), Cas (Exp2),
Exp-t (Exp3), Exp5, Exp6 and Exp7. These exportins mediate transport of proteins, tRNAs and
pre-miRNAs (Köhler and Hurt, 2007). Nuclear export of mRNAs is mediated by another non-
karyopherin system, for which I want to refer to reviews Köhler and Hurt, 2007 and Carmody
and Wente, 2009. The classical protein export mechanism by Crm1 will be described here in
short. Other alternative nuclear protein export pathways include piggyback mechanisms with
mRNA and the export of large nuclear particles by nuclear nuclear envelope budding (Parton
et al., 2014, Hatch and Hetzer, 2014).
Like the other exportins and the majority of importins, Crm1 is a HEAT repeat containing pro-
tein. Crm1 is a highly versatile nuclear transport receptor that recognizes a broad spectrum of
structurally unrelated proteins. The simplest Crm1-dependent NES, also termed classical NES
or leucine rich NES, is a short peptide of four spaced hydrophobic residues which are mostly
lysines (L) (Fukuda et al., 1997). Prototypical representatives are the PKI NES (LALKLAGLDI)
and the MAPKK NES (LQKKLEELELD). Leucine rich NES sequences bind the outer convex sur-
face of Crm1, whereas RanGTP binds to the inner concave surface (Dong et al., 2009). It has
been shown that RanGTP and NES binding are cooperative, i.e. Crm1 only binds to the cargo
in its RanGTP-bound state and NES binding further strengthens the RanGTP binding (Monecke
et al., 2013). Although the classical leucine-rich NES seems to be present in the vast majority
of Crm1 substrates and consequently on most exported proteins, other export signatures are
known. One example is a complete structured domain in the case of Snurportin (Paraskeva et al.,
1999, Monecke et al., 2009).
1.4. Nuclear transport of small RNA-silencing proteins
To fulfill their possible nuclear functions, Argonaute proteins and other small RNA-guided gene si-
lencing pathway components have to reach the nucleus (Schraivogel and Meister, 2014). Although
the underlying nuclear transport pathways could shed light on the interesting nuclear functions,
they still remain largely elusive. Furthermore, nuclear transport might have critical implications
for nuclear and cytoplasmic small RNA-guided functions as it could provide a simple but effec-
tive mechanism to regulate protein activity. Therefore, I will summarize the current knowledge of
nuclear transport processes of small RNA-guided gene silencing components. In addition, it will
be discussed how their nuclear localization is regulated and how nuclear transport might regulate
their function.
78 PART III. NUCLEAR IMPORT OF ARGONAUTE AND TNRC6 PROTEINS
Nuclear import of Argonaute proteins is often regulated by small RNA-binding
It is believed, that small RNAs are loaded onto Argonaute proteins in the cytoplasm, indepen-
dent of nuclear or cytoplasmic small RNA-function (Guang et al., 2008, Ohrt et al., 2008, Noto
et al., 2010, Olivieri et al., 2010, Ye et al., 2012, Gagnon et al., 2014). Interestingly, it has been
shown that many Argonaute proteins that function in the nucleus are only imported when they
are loaded with small RNAs. This was the case for the Ago clade members A. thaliana AGO4, C.
elegans NRDE-3 and Tetrahymena thermophila Twi1p and Twi12p (Guang et al., 2008, Noto et al.,
2010, Couvillion et al., 2012, Ye et al., 2012). Furthermore, the same observations were made
for the Piwi clade proteins Mouse Miwi2 and Drosophila Piwi (Reuter et al., 2009, Saito et al.,
2009, Olivieri et al., 2010). The underlying mechanism has been characterized in more detail for
C. elegans NRDE-3 (Figure 3.1.5) and Arabidopsis AGO4. NRDE-3 contains a bipartite classical
NLS and associates with secondary siRNAs that are generated in the cytoplasm. Without bound
siRNA, the NLS is not accessible, however, upon small RNA loading, the NLS is exposed and
loaded NRDE-3 gets imported (Guang et al., 2008). Arabidopsis AGO4 import is regulated in a
similar way but additionally, the correct removal of the passenger strand has been shown to be
prerequisite for activation of the NLS (Ye et al., 2012). Therefore, nuclear transport seems to func-
tion as quality control step that allows only correctly assembled small RNA-Argonaute complexes
to be imported.
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Figure 3.1.5. Nuclear import of C. elegans Argonaute protein NRDE-3 requires small RNA binding. In the cyto-
plasm, secondary siRNAs are produced that guide NRDE-3 to complementary nascent transcripts in the nucleus. NRDE-
3 nuclear import is mediated by a nuclear localization signal (NLS) and so far unknown importins (Imp). Without bound
siRNA, nuclear import is inhibited by masking the NLS sequence, however, after binding the secondary siRNA, the NLS
gets accessible resulting in nuclear import. Figure adapted from Schraivogel and Meister, 2014.
Nucleo-cytoplasmic shuttling of small RNA-guided gene silencing components
A restricted set of gene silencing components including human TNRC6A, TNRC6B, Dicer and
S. pombe Dicer (Dcr1) have been identified to be nucleo-cytoplasmic shuttling proteins (Till et al.,
2007, Emmerth et al., 2010, Doyle et al., 2013, Nishi et al., 2013). Whereas nothing is known on
the functional significance of shuttling of the human gene silencing factors, recent studies sug-
gest a model for S. pombe Dcr1 shuttling (Figure 3.1.6, Emmerth et al., 2010). Dcr1 is mainly nu-
clear and is anchored to centromeric chromatin which is localized at the inner nuclear membrane
around nuclear pores. Together with centromeric chromatin, heat-shock response genes are also
located at the nuclear periphery. Nuclear Dcr1 silences these heat-shock response genes by func-
tioning in small RNA-guided transcriptional gene silencing processes (part I section 1.1). After
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heat shock, Dcr1 is released from chromatin and exported to the cytoplasm. The effect of this pro-
cess is the expression of heat-shock response genes (Woolcock et al., 2012). The mechanisms
that prevent Dcr1 export under steady-state conditions are not yet understood, but might depend
on nuclear export signals that are only exposed upon heat shock (Woolcock et al., 2012).
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Figure 3.1.6. S. pombe Dcr1 is a nucleo-cytoplasmic shuttling protein and shuttling is activated by heat shock.
Dicer 1 (Dcr1) shuttles between the cytoplasm (Cyt) and nucleus (Nuc) but is mainly nuclear under steady-state con-
ditions. Import is mediated by an unknown importin (Imp), export by an also unknown exportin (Exp). Nuclear Dcr1 is
anchored at centromeric chromatin, which is localized to the inner nuclear membrane. Heat-shock response genes are
also localized at the nuclear periphery and are silenced by Dcr1. Upon heat-shock, Dcr1 is released from these regions and
is subsequently exported, whereas heat-shock response genes can now be expressed. Figure adapted from Schraivogel
and Meister, 2014.
Nuclear transport mechanisms
So far, nuclear import receptors that guide Argonaute and other gene silencing pathway compo-
nents to the nucleus are largely unknown. Many proteins like Arabidopsis AGO4, DCL1, DCL4,
Drosophila Piwi, C. elegans NRDE-3 and human TNRC6A-C contain classical NLS sequences,
which would indicate import via the classical Impα/Impβ pathway (Schauer et al., 2002, Hiraguri
et al., 2005, Guang et al., 2008, Ye et al., 2012, Nishi et al., 2013). Indeed, this transport pathway
and the recognized NLS consensus sequences are conserved among species. However, direct
evidence for classical import of these components is completely lacking and therefore, the import
receptors remain to be identified.
For several other gene silencing components, however, specific importins have been suggested
to mediate nuclear import. Human Dicer contains a dsRBD at its C-terminus that can function as
NLS, at least when expressed as an isolated domain (Doyle et al., 2013). Interestingly, the three
importins Impβ, Imp7 and Imp8 function redundantly in Dicer nuclear import. However, whether
this non-canonical NLS is also used in the full-length context remains elusive. In the case of
human Ago2, knockdown of Imp8 seems to reduce the nuclear Ago2 pool, however, whether
Imp8 is directly involved in nuclear Ago2 transport is not known (Weinmann et al., 2009, Wei
et al., 2014). Instead, Imp8 has shown to be implicated in cytoplasmic Ago2 functions (Weinmann
et al., 2009). Last but not least, the S. pombe RNA-dependent RNA polymerase Rdp1, that is
involved in small RNA-mediated transcriptional gene silencing in the nucleus, has been shown to
be imported by Sal3, the S. pombe homolog of human Imp5 (Park et al., 2012).
2. Aims of part III
The cytoplasmic functions of Argonaute (Ago) and TNRC6 proteins are well understood. How-
ever, both protein families have also been identified in the nucleus of mammalian cells. Whereas
the nuclear functions of TNRC6 proteins are unknown, diverse functions have been attributed
to nuclear Ago including transcriptional gene regulation, regulation of mRNA splicing and DNA
repair.
To fulfill their nuclear functions, Ago and TNRC6 proteins must reach the nucleus. Therefore,
the aim of this thesis is to analyze nuclear transport pathways of both protein families. We will
use nuclear transport assays to directly show nuclear transport of Ago and TNRC6 proteins and
to further characterize these transport pathways. We will then apply diverse biochemical, cell
biological and functional assays to identify import receptors that mediate nuclear transport of Ago
and TNRC6 proteins.
Nuclear transport processes can be regulated by diverse mechanisms and they provide an
effective way to regulate nuclear and cytoplasmic protein function. Therefore, we want to inves-
tigate how nuclear transport of Ago and TNRC6 proteins is regulated. Furthermore, we want to
investigate how nuclear transport influences nuclear and cytoplasmic function of Ago and TNRC6
proteins.
Our findings should provide important insights into nuclear transport processes of Ago and
TNRC6 proteins. These processes are important for the understanding of Ago and TNRC6 pro-
tein function, especially those in the nucleus. Further more, they might provide novel but so far
uncharacterized steps in miRNA-guided gene regulatory pathways.
Taken together, the specific aims in part II of this work include:
1. Identification of nuclear transport processes of Ago and TNRC6 proteins.
2. Investigation of the underlying nuclear import and export mechanisms.
3. Characterization of how nuclear transport of Ago and TNRC6 is regulated.
4. Identification of the functional significance of nuclear Ago2 and TNRC6 transport.
3. Results
3.1. Nucleo-cytoplasmic distribution of human Ago2
Here, we analyze nuclear transport pathways of Ago and TNRC6 proteins and how these pro-
cesses are regulated. To investigate these questions, the nucleo-cytoplasmic distribution of Ago
proteins will be investigated first.
In immunofluorescence (IF) stainings, the vast majority of Ago2 is located in the cytoplasm
(Jakymiw et al., 2005, Liu et al., 2005b, Sen and Blau, 2005, Leung et al., 2006, Rüdel et al.,
2008). To get comprehensive insights into Ago2 localization in a broad spectrum of cells, we
stained endogenous Ago2 in 26 cell lines (Figure 3.3.1 and Appendix Figure A3). As antibody
against Ago2, we used a previously reported monoclonal antibody (Rüdel et al., 2008). For quan-
titative information on nuclear and cytoplasmic Ago2 signals, we measured signals from cytoplas-
mic and nuclear regions and calculated a nucleo-cytoplasmic ratio from the mean signal intensities
(for technical details, see Materials and Methods section 5.3). The mean nucleo-cytoplasmic ra-
tio over all 26 cell lines was 0.55 ± 0.12, i.e. the mean signal in the cytoplasm was about twice
as intense as the nuclear signal normalized over all cell lines. Interestingly, we identified a cell
line from human pulmonary artery smooth muscle cells (HPASMC) and the melanoma cell line
Sk-Mel-28 to have exceptionally high nucleo-cytoplasmic ratios (Figure 3.3.1 A and B). The cell
lines HEK 293T and HeLa, that were subsequently used during this study, contained rather low
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Figure 3.3.1. Ago2 localization in different human cell lines from various tissue origins A, Ago2 was stained in
HeLa, HEK 293T and Sk-Mel-28, three exemplary cell lines from overall 26 cell lines that were tested for Ago2 localization
(Figure is continued as Appendix Figure A3). DAPI was used to stain nuclei. B, Tabular summary of Ago2 signal quan-
tifications from the 26 different human cell lines. To calculate nucleus-to-cytoplasm ratio, Ago2 signal was quantified from
nuclear and cytoplasmic regions. Scale bars in A represent 20 µm. Data in B are shown as mean ± SEM.
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nuclear Ago2 levels. No correlation with specific tissue-origins was observed. Additionally, we did
not observe correlation with passage number and plating density in HeLa and HEK 293T as well
as differentiation in primary keratinocytes (data not shown).
Although specificity of the used anti-Ago2 antibody has been shown before (Rüdel et al., 2008),
we again verified the obtained Ago2 IF signal (Figure 3.3.3 A, D and E). We performed Ago2
knockdowns in HeLa cells, followed by the comparison of anti-Ago2 antibody signals in IF and
Western Blot. For knockdown of Ago2, we used so called siPools, which are mixtures of multiple
siRNAs against the same target mRNA, which increases specificity of the knockdown (Hannus
et al., 2014). Although we observed a clear signal decrease in IF and Western Blot, the knock-
down efficiency with the used Ago2 siPools was low with about 50 % remaining protein. However,
upon Ago2 knockdown we measured almost identical Ago2 signal reductions in the total cell
lysates used for Western as well as in cytoplasmic and nuclear regions quantified from IFs. The
Western signal for Ago2 was further validated with a polyclonal anti-Ago2 antibody and again, we
measured a very similar signal reduction. Therefore, we conclude that we detect Ago2 in both the
nuclear and cytoplasmic compartments with high specificity in IF and Western experiments.
3.2. Ago2 is imported into the nucleus and shuttles between
nucleus and cytoplasm
3.2.1. Heterokaryon assays provide direct evidence for Ago2 nuclear
import
To solidify that Ago2 is indeed found in the nucleus, we wanted to investigate whether Ago2 is
imported into the nucleus. We therefore applied a modified heterokaryon assay. In the classical
heterokaryon assay, mouse NIH 3T3 cells are fused with human HeLa cells and the redistribution
*
0.0
0.2
0.4
0.6
0.8
1.0
1.2
A
go
2 
si
gn
al
 n
or
m
al
iz
ed
 
to
 H
eL
a 
nu
cl
eu
s
H
eL
a
3T
3
before 
fusion
after 
fusion
H
eL
a
3T
3
DA
N N
C
import
classical assay modified assay
N N
C
shuttling
C
[3T3]
[HeLa]
DAPI Ago2
H
eL
a
N
IH
 3
T3
af
te
r f
us
io
n
quantification
[3T3]
[HeLa]
B DAPIHA-Tag
FH
-
hn
R
N
PA
1
FH
-
hn
R
N
P
C
20 µm
Figure 3.3.2. Ago2 is imported into the nucleus of human cells. A, Schematic diagram showing classical and
modified heterokaryon assay as described in the main text. B, HeLa cells transfected with FH-hnRNPA1 and FH-hnRNPC
were fused to mouse NIH 3T3 cells. Proteins were observed to appear in the mouse nucleus after fusion. Nuclei from
3T3 can be distinguished by the intense speckled DAPI staining. C, HeLa was fused to 3T3 and endogenous Ago2 was
detected with monoclonal anti-Ago2 antibody. Microscopy shows Ago2 staining in unfused HeLa cells and no signal in
unfused 3T3 cells. After fusion, Ago2 can be detected in heterokaryon cytoplasm and both human and mouse nuclei. D,
Diagram shows quantification of Ago2 signal HeLa and 3T3 nuclei before and after fusion with data normalized to human
nucleus. N, nucleus; C, cytoplasm; FH, Flag/HA tag. Scale bars in B and C represent 20 µm. Data in D are shown as
mean plus SEM. *P < 0,05.
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of a human nuclear protein into the mouse nucleus is observed. As Ago2 is mainly cytoplasmic,
we modified the assay readout and investigated the redistribution of cytoplasmic Ago2 into the
mouse nucleus (Figure 3.3.2 A). To validate functionality of our assay, we performed classical het-
erokaryon assay with the shuttling protein hnRNPA1 as positive control and the non-shuttling pro-
tein hnRNPC as negative control (Figure 3.3.2 B). Indeed, we observed hnRNPA1 in the mouse
nucleus after 4 hours, whereas hnRNPC remained in the human nucleus. Of note, for classical
and modified heterokaryon assays, the cells were treated with cycloheximide to prevent synthesis
of new protein in the cytoplasm, which would falsify the readout of the assay. Strikingly, when
endogenous Ago2 was analyzed, we found that human Ago2 levels increased slightly but clearly
measurable over background signal in the mouse nucleus (Figure 3.3.2 B). The increase of Ago2
in the mouse nucleus corresponded to the Ago2 levels that have been measured in the human
nucleus. Therefore, Ago2 is transported from the cytoplasm into the mouse nucleus.
3.2.2. Ago2 is a nucleo-cytoplasmic shuttling protein
Based on the above mentioned results, we conclude that Ago2 is mainly cytoplasmic but can be
imported into the nucleus. Next we tested whether Ago2 can shuttle between the nucleus and
cytoplasm and applied two different transport assays.
First, we analyzed endogenous Ago2 localization upon inhibition of Crm1-mediated nuclear
export by Leptomycin B (LMB). LMB is a metabolite of Streptomyces and has been found as
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Figure 3.3.3. Ago2 shuttles between the nucleus and cytoplasm. A, Endogenous Ago2 signal was detected in HeLa
cells treated with Leptomycin B or control treated. Cells were transfected with control or Ago2 siPool. B and C, Signal
quantification and calculation of nucleus-to-cytoplasm ratio in untreated or Leptomycin B treated HeLa (B) and Sk-Mel-28
(C) cells. D, Ago2 protein was analyzed upon knockdown of Ago2 or transfection of a control siPool with two different
antibodies. Signal quantification of knockdown versus control was normalized to αTubulin. E, Ago2 signal was quantified
from nucleus and cytoplasm in untreated or Leptomycin B treated cells upon knockdown of Ago2 or transfection of a
control siPool. Signals were normalized to control siPool. siP, siPool; LMB, Leptomycin B. Scale bars in A represent 10
µm. Data in B to E are shown as mean plus SEM. *P < 0,05; ***P < 0,0005.
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potent nuclear export inhibitor that covalently binds Crm1 within its NES-binding site (Nishi et al.,
1994, Fornerod et al., 1997, Kudo et al., 1999, Sun et al., 2013). Of note, LMB seems to be highly
specific for Crm1, as biotinylated LMB specifically pulls down a single protein from HeLa cell
lysate and the cytotoxic effect of LMB can be completely reversed with a LMB-insensitive Crm1
mutant (Nishi et al., 1994, Kudo et al., 1999). Nucleo-cytoplasmic shuttling proteins which are
exported from the nucleus in a Crm1-dependent manner, accumulate in the nucleus upon LMB
treatment. We treated HeLa cells with LMB and detected endogenous Ago2 in the nucleus and
cytoplasm (Figure 3.3.3 A and B). Strikingly, we observed a clear increase of Ago2 in the nucleus,
as shown by a higher nucleo-cytoplasmic ratio upon treatment with LMB. Again, Ago2 signal
seems to be specific, as knockdown of Ago2 leads to partial signal loss in both the nucleus and
cytoplasm (Figure 3.3.3 A, D and E). To validate this finding, we tested another independent cell
line Sk-Mel-28 and indeed, we again detected an increase in nuclear Ago2 upon LMB treatment
(Figure 3.3.3 C). In both cell lines HeLa and Sk-Mel-28, the nucleo-cytoplasmic Ago2 signal ratio
almost doubled and in Sk-Mel-28, the signal intensity after LMB treatment was stronger in the
nucleus compared to the cytoplasm. As LMB affected Ago2 export from the nucleus, we conclude
that Ago2 nuclear export is probably mediated by Crm1, the classical nuclear export factor that is
used by the vast majority of proteins.
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Figure 3.3.4. Classical heterokaryon assay with a nuclear trapped Ago2 fusion confirms Ago2 shuttling activity.
A, HeLa cells stably transfected with FH-NLS-Ago2 with or without Leptomycin B treatment were used for heterokaryon
assay. Ago2 was detected by anti-HA IF. B, FH-NLS-Ago2 was quantified from nucleus and cytoplasm before fusion with
3T3. C, Quantification of Ago2 signal from HeLa and 3T3 nuclei before and after fusion of untreated or Leptomycin B
treated cells. FH, Flag/HA tag; NLS, SV40 nuclear localization sequence; LMB, Leptomycin B. Scale bars in A represent
10 µm. Data are shown as mean plus SEM. *P < 0.05; ***P < 0.0005.
To further solidify the observed nucleo-cytoplasmic shuttling activity of Ago2, we performed
heterokaryon assays. As the readout from the classical heterokaryon assay depends on strictly
nuclear proteins, we fused Ago2 to the strong SV40 nuclear localization sequence (NLS). This
resulted in nuclear trapped Flag/HA-tagged NLS-Ago2 that can be detected in IF with an anti-HA
antibody. To achieve a uniform NLS-Ago2 expression, we generated a stable monoclonal HeLa
cell line. We then investigated whether the generated cell line contains residual NLS-Ago2 in
the cytoplasm, as this might lead to unspecific observations regarding nucleo-cytoplasmic shut-
tling. We quantified anti-HA signal from the NLS-Ago2 cell line and compared it to background
signal from an untransfected HeLa cell line. We observed a very weak NLS-Ago2 signal in the cy-
toplasm which could, at least in part, mimic the readout from the heterokaryon assay. When these
cells were fused with NIH 3T3 cells, NLS-Ago2 signal clearly increased in the mouse nucleus. To
show that this is indeed NLS-Ago2 that shuttles from the human to the mouse nucleus, we treated
heterokaryons with LMB to prevent nuclear export from the human nucleus. Strikingly, significantly
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less nuclear NLS-Ago2 was found in the mouse nucleus after LMB treatment, demonstrating that
NLS-Ago2 indeed shuttled from the human nucleus to the mouse nucleus.
Taken together, we have shown that human Ago2 is mainly cytoplasmic but can also be found
in the nucleus. Ago2 can be imported into the nucleus and is a nucleo-cytoplasmic shuttling pro-
tein. Nuclear export of Ago2 seems to depend on Crm1.
3.3. Nuclear transport of Ago2
3.3.1. A functional assay suggests redundant import routes for Ago2
Importins mediate nuclear import of a wide spectrum of proteins by recognition of nuclear local-
ization sequences on the cargo protein and interaction with the nuclear pore complex. To identify
importins that mediate nuclear transport of Ago2, we designed an siRNA library against each hu-
man importin (Imp) identified so far. We did not generate siRNAs against the Impα family of import
factors, as it is thought that Impα function strictly depends on Impβ (see part III section 1.3). For
all other importins, except for Imp4, the siRNA library contained two independent siRNAs des-
ignated as si1 and si2. The siRNA library was validated by quantitative real-time PCR to detect
importin mRNA levels after knockdown (Figure 3.3.5 C). Except for si1/2 Imp3, si1/2 Imp9 and si2
Tnpo1, all siRNAs showed knockdown efficiencies of around 10 % remaining mRNA levels and
therefore provide a solid basis for further analysis.
The importin siRNA library was then screened by anti-Ago2 IF upon importin knockdown. If
a single importin is needed for Ago2 import, knockdown should lead to a decrease in nuclear
Ago2. Therefore, HeLa cells were transfected with the Importin siRNA library and two days and
three days post-transfection, Ago2 localization was analyzed (data not shown). However, we did
not observe any decrease in nuclear Ago2 when single Importins where knocked down. To our
surprise, also the knockdown of Imp8, which has been previously reported to slightly decrease the
nuclear Ago2 pool, did not show effects in our analysis (Weinmann et al., 2009). Taken together,
these data indicate that single importin knockdown does not significantly change the nuclear Ago2
pool.
As the performed loss-of-function analysis with direct readout of Ago2 localization did not prove
informative, we tested the requirement for import receptors by another independent method. As
the steady-state pool of Ago2 is low in the used cell system, we established an assay with a func-
tional readout for nuclear Ago2 activity. It has been shown that nuclear localized RNAs like the
7sk RNA can be knocked down by RNAi (Robb et al., 2005). In addition, siRNA loading seems to
be a cytoplasmic process (Ohrt et al., 2008, Gagnon et al., 2014). Therefore, if importin knock-
down affects Ago2 import, less 7sk siRNA loaded Ago2 should be present in the nucleus and
knockdown efficiency of 7sk should consequently be affected (Figure 3.3.5 A). To validate this
system, we depleted Ago1-4 and analyzed 7sk knockdown efficiency (Figure 3.3.5 B). 7sk levels
were determined by Northern Blot and normalized to U6 RNA. As expected, 7sk knockdown ef-
ficiency was clearly reduced only after depletion of Ago2. This demonstrates that the measured
effects are Ago2-dependent and the assay is suitable for the analysis of Ago2 import routes. Of
note, similar to the observed knockdown efficiency of Ago2 siPools, the used Ago2 siRNAs in
this experiment did not allow complete Ago2 knockdown (data not shown). However, we were still
able to see clear elevation of 7sk snRNA levels upon 7sk siRNA transfection. Subsequently, we
knocked down Impβ, Imp3-5, Imp7-9, Imp11-13 and Tnpo1 and measured 7sk knockdown effi-
ciency as described (Figure 3.3.5 D). However, none of the tested knockdown conditions resulted
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in a significant change in 7sk knockdown efficiency. Of note, we measured slight effects with one
of two siRNAs for Imp5, however si2 Imp5 did not show the same effects although it reduced
Imp5 mRNA level more efficiently than si1 Imp5. Taken together, we conclude that knockdown of
single import receptors is not sufficient to prevent nuclear Ago2 transport. This is in line with the
results from Ago2 IF experiments. It is therefore conceivable that several import receptors function
redundantly in transporting Ago2 to the nucleus.
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Figure 3.3.5. A functional assay suggests redundant importins for Ago2 nuclear import. A, Schematic representa-
tion of the experimental procedure for the 7sk assay to measure nuclear Ago2 activity upon Importin knockdown. Nuclear
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3.3.2. Ago2 is probably not imported via the classical
Impα/Impβ-dependent pathway
Many human proteins are imported via the classical Impα/Impβ-dependent nuclear transport
pathway. This import mechanism includes binding of Impα to a short monopartite or bipartite
stretch of largely basic amino acids (Görlich and Kutay, 1999). Since it is possible to predict these
classical nuclear localization signals (NLS), we used in silico linear motif prediction to search for
a classical NLS sequences in mammalian Ago proteins. In addition, as nuclear export of Ago2
seems to be Crm1-dependent, we also looked for classical nuclear export sequences (NES). We
found an NLS within the Ago PAZ domain and an NES within the Piwi domain (Figure 3.3.6
A). Both sequences including the critical basic and hydrophobic residues were conserved among
human and mouse Ago1-4.
Using the recently published Ago2 structure in complex with miR-20a, we observed that both
sequence stretches are located on the surface of Ago2 and should therefore be accessible for
karyopherin binding (Figure 3.3.6 B). Regarding the NLS, structural analysis revealed that miRNA-
binding might conceal the NLS. Therefore, we did site-directed mutagenesis of critical residues
within the predicted NLS and NES in Ago2 wildtype and Y529E mutant background (Figure 3.3.6
C and E). Ago2 Y529E mutant does not bind miRNAs anymore, as shown previously (Rüdel
et al., 2008). Localization of the generated mutants revealed that mutagenesis of the NLS did not
reduce the nuclear Ago2 pool and mutagenesis of the NES did not increase the nuclear Ago2
pool (Figure 3.3.6 C and E). To solidify our results, we fused the predicted Ago2 NLS and NES
to eGFP and investigated localization of the generated eGFP fusions (Figure 3.3.6 D and F). Of
note, eGFP can passively diffuse into the nucleus due to its limited size, therefore eGFP alone
is located in both the nucleus and cytoplasm. While the strong SV40 NLS resulted in a clear ac-
cumulation of eGFP in the nucleus, the predicted Ago2 NLS had no effect. Similarly, the strong
MAPKK NES resulted in exclusively cytoplasmic eGFP, whereas the predicted Ago2 NES had not
effect. Therefore we conclude that the predicted NLS and NES are probably not functional. In addi-
tion this hints towards an Impα/Impβ-independent transport pathway for Ago proteins. Regarding
the nuclear export pathway, we suggest an additional NES that is not predictable in Ago2.
Although these data suggest that classical NLS sequences are not present in Ago2, the ob-
tained data do not finally prove independency of Impα/Impβ. However, this observation is further
supported by the finding that Impβ knockdown did not decrease the nuclear pool of endogenous
Ago2 (see section 3.3.1). As the nuclear Ago2 pool is low under steady state-conditions, the
expected effects might be below the detection limit of Ago2 IF quantification. We therefore inves-
tigated whether the nuclear import of Ago2 is affected by Impβ knockdown under conditions of
increased nuclear Ago2 localization, as observed upon LMB treatment (Figure 3.3.7). However,
even after LMB addition, Impβ knockdown did not affect nuclear accumulation of Ago2.
Therefore, we conclude that nuclear import of Ago2 is most likely not mediated by classical
Impα/Impβ-dependent transport pathway. Furthermore, because Impβ knockdown did not affect
Ago2 localization, nuclear import of Ago2 also seems to be independent of non-classical Impβ-
mediated pathways.
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Figure 3.3.6. In silico predicted classical NLS and NES sequences in Ago2 are not functional. A, Linear motif pre-
diction identified classical NLS and NES within conserved regions of human and mouse Ago1-4 PAZ and PIWI domain. B,
The predicted NLS and NES lie on the surface of human Ago2 and were mutated within the critical residues. Human Ago2
is shown in light gray, miR-20a is shown in dark gray. C and E, NLS and NES were mutated in Ago2 wildtype and 529E
background and used for microscopic analysis. Schematic representation of the generated mutations and the resulting
predominant localization in C. Corresponding IF pictures are not shown in E. D and F, Ago2 NLS and NES were fused
to eGFP and localization of the generated fusions was investigated. SV40 NLS and MAPKK NES served as controls for
nuclear and cytoplasmic localization, respectively. Scale bars in E and F represent 20 µm.
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3.3.3. Biochemical analyses did not show Ago2-associated import factors
As our loss-of-function analyses by knockdown of import factors did not identify single importins
that might contribute to Ago2 import, we performed biochemical analyses to identify import factors
that associate with Ago2. We cloned human importins de novo from HeLa cDNA, including Impβ,
Imp3, Imp11, Imp13 and Tnpo1. Imp4 and Imp8 expression constructs were available (Weinmann
et al., 2009). Cloning of Imp5, Imp7 and Imp12 was not successful. These constructs were then
used for co-immunoprecipitation with Ago2 with importins as bait, Ago2 as bait as well as with
overexpressed and endogenous Ago2 (data not shown). However, none of the tested importins
did efficiently coimmunoprecipitate with Ago2. PABPC was used as positive control and has been
found in Ago2-immunoprecipitations (Fabian et al., 2009), indicating successful immunoprecipita-
tions.
In order to investigate Ago2-importin interaction in another independent system, we collabo-
rated with Oliver Gruss (ZMBH, Heidelberg, Germany) to perform Ago2-pulldowns from Xenopus
oocyte extracts. Homology between human and Xenopus importins is high and almost identi-
cal sets of importins exist in both organisms. In addition, Xenopus oocytes express comparably
high amounts of import factors. As importin-cargo interaction is negatively regulated by RanGTP,
we additionally depleted RanGTP from the extracts. Supplementing RanGTP back to this system
should then allow to identify Ran-dependent Ago2 interactors. We first expressed HA-tagged Ago2
(HA-Ago2) in insect cells and obtained highly pure Ago2 protein (Figure 3.3.8 A to C). Oocyte
extract with or without RanGTP was incubated with HA-Ago2, Ago2 interacting proteins were
isolated by anti-HA antibody and pulled down proteins were identified by mass spectrometry. As
we enriched numerous known RNA-dependent and -independent Ago2 interaction partners, we
conclude that the pulldown was successful. However, we did not identify any import factors that
significantly increased in the Ran-free sample.
Taken together, we did not identify Ago2 interacting importins biochemically in different sys-
tems. However, Ago2 is a mainly cytoplasmic protein and only a subpopulation of Ago2 seems
to be imported as shown by nuclear transport assays. Therefore, Ago2-importin interaction might
only occur in a small Ago2 subpopulation. Furthermore, cargo-importin interaction is transient
and only occurs during import, which might complicate biochemical identification. Therefore fur-
ther analyses are needed to investigate Ago2 import in more detail.
90 PART III. NUCLEAR IMPORT OF ARGONAUTE AND TNRC6 PROTEINS
A DB
C
B2Fractions B1 C1 C2 C3 C4 C5 C6 C7
170
130
100
70
55
40
35
25
Expression in SF-21
Lysis
Ni-IMAC
TEV cleavage
HiPrep desalting
Ni-IMAC
Superdex 200
W S PS S S
4 5 61 2 3
4 5 61 2 3 10 117 8 9
72h
100 kDa
0h
anti-HA
anti-Ago2
24h 48h
100 kDa
pooled fractions
Ago2
Symbol
Cullin 9
Ago2
DHX9
MGC80941
Dicer
MGC82638
PABP-A
ePABP-B
IMP3A
IMP3B
TNRC6A
TNRC6B
EPABP
ILF3B
SF3B1
Dicer
Sympk
ILF3B
ILF3A
TOP2A
HADHA
ZFR
SYNCRIP
Hsc70
YBX2A
POLR3A
ATD3A
YBX2B
POLR3A
eIF4-T
VTG A2
ATD3B
SF3B3
Fxr1
MOV10
PRKRA
hnRNPB
Ago1
DDX5-like
Fxr1
LSM14AA
SUGP2
Ago3
ILF2
Stau1
Anapc7
MYEF2
PABP-A
DDX5
ELV1A
FAM120A
hnRNPR
Lsm14AB
POLR3A
SLC25A
FMRP-B
Stau1
12
0
11
0
0
0
7
2
2
5
5
0
0
2
0
0
0
0
0
0
0
4
0
0
16
1
0
1
0
0
0
0
2
0
0
0
1
0
4
0
0
0
0
4
0
0
0
0
0
0
0
0
0
0
0
1
0
0
23
1
22
0
0
0
10
1
1
11
12
0
1
1
0
0
0
0
0
0
0
6
0
0
21
4
0
4
3
0
0
0
5
0
3
2
5
0
7
0
3
0
0
7
0
0
0
0
0
0
0
0
0
0
0
5
0
0
63
63
60
42
42
31
33
31
29
28
28
30
29
27
25
21
24
23
23
22
28
22
21
23
20
22
16
19
19
16
17
14
17
16
17
14
12
14
14
15
14
14
13
13
9
15
12
13
13
13
9
9
11
12
10
15
12
13
67
65
63
46
45
38
34
32
33
34
33
31
31
28
29
32
28
29
27
25
19
21
22
19
21
18
22
16
16
18
16
19
15
16
13
14
17
13
12
11
12
12
12
11
15
9
11
10
10
9
13
13
11
10
12
7
9
8
72
26
70
48
52
26
62
63
60
56
54
26
29
51
47
34
20
36
36
28
23
44
32
44
52
66
22
37
54
25
28
16
37
22
28
15
58
34
16
29
28
38
18
16
66
21
42
25
26
25
54
19
29
31
35
26
35
21
130
128
123
88
87
69
67
63
62
62
61
61
60
55
54
53
52
52
50
47
47
43
43
42
41
40
38
35
35
34
33
33
32
32
30
29
29
27
26
26
26
26
25
24
24
24
23
23
23
22
22
22
22
22
22
22
21
21
1.06
1.03
1.05
1.10
1.07
1.23
1.03
1.03
1.14
1.21
1.18
1.03
1.07
1.04
1.16
1.52
1.17
1.26
1.17
1.14
0.68
0.95
1.05
0.83
1.05
0.82
1.38
0.84
0.84
1.13
0.94
1.36
0.88
1.00
0.76
1.07
1.42
0.93
0.86
0.73
0.86
0.86
0.92
0.85
1.67
0.60
0.92
0.77
0.77
0.69
1.44
1.44
1.00
0.83
1.20
0.47
0.75
0.62
3.71
Ran-GTP - + - +
FH-Ago2 - - + +
Co
ve
rag
e
Measured peptides To
tal
 pe
pti
de
s
Ra
n-G
TP
de
pe
nd
en
cy
En
ric
hm
en
t
in 
pu
lld
ow
n
128.00
3.73
∞
∞
∞
3.94
21.00
20.67
3.88
3.59
∞
60.00
18.33
∞
∞
∞
∞
∞
∞
∞
4.30
∞
∞
1.11
8.00
∞
7.00
11.67
∞
∞
∞
4.57
∞
10.00
14.50
4.83
∞
2.36
∞
8.67
∞
∞
2.18
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
3.67
∞
∞
2.0
1.0
0.5
50
1
Figure 3.3.8. Identification of Ran-dependent Ago2 interactors did not reveal Ago2-associated import factors. A,
Purification strategy of human HA-tagged Ago2 from SF-21 insect cells. B, Identity of the expressed protein was deter-
mined by Western Blot from lyzed insect cells with anti-HA and anti-Ago2. Shown are four time points (0, 24, 48 and 72 h)
with soluble (S), whole-cell (W) and insoluble/pelleted (P) protein fractions. C, After gelfiltration, purity of the elution frac-
tions was assessed by Coomassie staining. Marked are fractions that were used for pulldown experiments. D, Pulldowns
of FH-Ago2 with anti-HA antibody from Ran-depleted oocyte extracts that were supplemented with GTP-loaded Ran or
not. The left heat map shows the IP versus control ratio of measured peptides independent of Ran-addition (enrichment in
pulldown). The heat map on the right compares enrichment ratios with and without addition of Ran, i.e. green color would
show proteins that are less abundant in the Ago2-pulldowns upon addition of Ran (Ran-GTP dependency). Of note, Ago2
peptides were annotated to both Xenopus tropicalis and Xenopus laevis; therefore, Ago2 is listed twice in the table. Color
code shows enrichment in pulldown compared to input sample and relative enrichment in RanGTP samples. ∞, infinite
value.
3.4. TNRC6 proteins are nucleo-cytoplasmic shuttling
proteins
TNRC6 proteins interact with Ago proteins during miRNA-mediated post-transcriptional gene si-
lencing. It has been previously shown that TNRC6A and TNRC6B can localize in the nucleus
upon inhibition of Crm1-dependent export by LMB (Till et al., 2007, Nishi et al., 2013). Therefore,
at least TNRC6A and TNRC6B seem to shuttle between the nucleus and cytoplasm. Further-
more, TNRC6A contains functional classical NLS and NES sequences (Nishi et al., 2013). To
get further insights into TNRC6 nuclear transport processes, we initially investigated whether all
three human TNRC6 proteins shuttle. We expressed Flag/HA-tagged TNRC6A-C and treated
cells with LMB for inhibition of Crm1-dependent nuclear export (Figure 3.3.9 A and B). Under
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steady state-conditions, overexpressed TNRC6A-C localizes in cytoplasmic foci which probably
resemble P-bodies (Kulkarni et al., 2010). When cells were treated with LMB, however, TNRC6A-
C exclusively localized in the nucleus indicating that all three human TNRC6 proteins constantly
shuttle between the nucleus and cytoplasm. Similar to the observed cytoplasmic foci, TNRC6A-C
localized in distinct foci in the nucleus upon LMB treatment. This was in agreement with previous
observations, observing similar nuclear foci for nucleus-trapped TNRC6A and TNRC6B (Till et al.,
2007, Nishi et al., 2013).
As overexpression of proteins can lead to unspecific effects, we generated a monoclonal anti-
body against TNRC6B in cooperation with Elisabeth Kremmer (Helmholtz Center, Munich, Ger-
many). To show that the antibody is specific for TNRC6B, we transfected siPools against TNRC6B
(Figure 3.3.9 C and E). The generated antibody specifically detected TNRC6B in Western Blot and
IF experiments, as shown by complete signal loss upon TNRC6B knockdown (Figure 3.3.9 C and
E). We then performed LMB treatment as described above but detected endogenous TNRC6B
(Figure 3.3.9 C to E). Strikingly, TNRC6B accumulated in the nucleus upon LMB treatment, show-
ing shuttling activity and Crm1-dependent export. Of note, the cytoplasmic pool of TNRC6B as
well as the nuclear accumulated pool did not generate such discrete foci as observed for the over-
expressed protein. In addition, we did not observe a quantitative shift of the complete cytoplasmic
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Figure 3.3.9. Human TNRC6A-C are nucleo-cytoplasmic shuttling proteins. A and B, HeLa cells were transfected
with FH-TNRC6A, FH-TNRC6B or FH-TNRC6C and treated with Leptomycin B or not. TNRC6 proteins were detected
with anti-HA antibody. Diagram in B shows the percentage of cells with cytoplasmic foci, nuclear foci or cells with foci in
both compartments (intermediate). C and D, Endogenous TNRC6B was detected with monoclonal antibody in control or
TNRC6B siPool transfected cells. TNRC6B signal intensity was determined and nucleus-to-cytoplasm ratio was calculated
and shown in D. E, Western Blot of TNRC6A/B/C siPool transfected cells and detection of TNRC6B, Ago2 and αTubulin
as loading control. FH, Flag/HA; LMB, Leptomycin B; siP, siPool. Scale bars in A and C represent 20 µm. Data are
represented as mean plus SEM. ***P < 0.0005.
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TNRC6B pool to the nucleus as it was the case with overexpressed TNRC6B.
Taken together, all three human TNRC6 proteins shuttle between the nucleus and cytoplasm
and their export route seems to be Crm1-dependent.
As nuclear trapped TNRC6A-C formed P-body like structures after overexpression, we investi-
gated whether the observed nuclear foci resemble cytoplasmic P-bodies. This might provide in-
formation on possible nuclear TNRC6 functions. In addition, we were interested whether nuclear
TNRC6 colocalizes with known nuclear compartments. We therefore performed colocalization ex-
periments by confocal microscopy with nuclear trapped TNRC6A. As LMB treatment might affect
localization of a broad spectrum of proteins, we specifically shifted TNRC6A into the nucleus by
using a nuclear-trapped TNRC6A mutant, which contains mutations within the NES (Nishi et al.,
2013). As expected, the mutant was exclusively nuclear and formed the expected nuclear foci
(Figure 3.3.10 and Appendix Figure A4). We next tested colocalization with Ago2 (Figure 3.3.10
A). Ago2 partially colocalized with the nuclear TNRC6A foci, however non-colocalizing Ago2 and
TNRC6A was also present, indicating that nuclear TNRC6A and Ago2 can interact but are also
present as independent pools. We then investigated colocalization with other P-body components
including YB-1, CNOT7 and Lsm4 (Appendix Figure A4 E). However, none of the mention fac-
tors were present in these foci, indicating that the nuclear TNRC6 foci are different compared to
cytoplasmic P-bodies. Similarly, we did not find an overlap with diverse nuclear compartments
including PML bodies, nuclear speckles, Cajal bodies, paraspeckles and heat shock granules
(Appendix Figure A4 C). As antibodies were available, we also tested possible colocalization with
DNA double-strand breaks, the exosome, RNA-polymerases and the ubiquitin-proteasome sys-
tem, but did not find any overlap (Appendix Figure A4 D and E).
From these data, we conclude that the nuclear trapped TNRC6 proteins form foci in the nu-
cleus, which lack typical P-body markers but can still interact with Ago proteins. Future studies
will therefore bee needed, to investigate the significance and possible function of these nuclear
TNRC6 pool.
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Figure 3.3.10. Nuclear trapped TNRC6A colocalizes with Ago2. A Colocalization of endogenous Ago2 with nuclear
trapped TNRC6A NES mutant (NESmut). B, Tabular summary of the performed colocalization analyses as shown in
Appendix Figure A4. Scale bars in A represent 20 µm.
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3.5. Nuclear import of TNRC6 proteins is mediated by Impα
and Impβ
3.5.1. Nuclear import of TNRC6 proteins requires Impβ
To elucidate the nuclear import pathway of TNRC6 proteins, we investigated which importins are
needed for nuclear import of TNRC6 proteins by loss-of-function analysis. As a test system, we
used the nuclear trapped TNRC6A NES mutant in a stably transfected inducible HEK 293T cell
line (Figure 3.3.11). We screened this cell line with the previously established importin siRNA
library. Two days after siRNA transfection, TNRC6A NES mutant expression was induced and
24 hours later, TNRC6A NES mutant was localized via its eGFP tag. Strikingly, we observed
a strong decrease in nuclear localized TNRC6A NES mutant upon transfection of two indepen-
dent Impβ siRNAs. However, transfection of siRNAs against any other human Importin did not
affect TNRC6A NES mutant localization (Figure 3.3.11, data shown for a representative subset of
siRNAs). Therefore, we conclude that TNRC6A import requires Impβ but is independent of other
importins.
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Figure 3.3.11. Nuclear Import of TNRC6 proteins is facilitated by Impβ. A, HEK 293T cells with inducible nuclear
trapped myc-GFP-TNRC6A NES mut were transfected with the Importin siRNA library. TNRC6A NES mut was localized
by detection of GFP fluorescence. B, Diagram showing the percentage of cells with cytoplasmic or nuclear GFP foci and
cells with foci in both compartments (intermediate). Scale bars in A represent 10 µm.
To further verify this strict Impβ dependency, we analyzed localization of endogenous TNRC6B
after Impβ knockdown (Figure 3.3.11). As the nuclear TNRC6B pool was very low under steady-
state conditions, we additionally treated cells with LMB to investigate whether shuttling is Impβ-
dependent. As expected from our previous results, endogenous TNRC6B accumulates in the
nucleus upon LMB treatment. Strikingly, when Impβ was depleted by RNAi, nuclear accumulation
of TNRC6B was not observable upon LMB treatment. This shows that Impβ knockdown prevents
nuclear import of endogenous TNRC6B. These data were reproduced using a second indepen-
dent Impβ siRNA (data not shown).
Taken together, we conclude that TNRC6 proteins are imported by an Impβ-dependent pathway
into the nucleus. In addition, as we did not observe effects of Impβ on Ago2 nuclear import,
we suggest that both TNRC6 and Ago proteins follow different import routes and are imported
independently.
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Figure 3.3.12. Impβ is needed for nuclear import of TNRC6B but not Ago2. A and B, Endogenous TNRC6B was
detected in untreated or Leptomycin B treated cells upon knockdown of Impβ or transfection of a control siRNA. Diagram
in B shows quantification of TNRC6B signal shown as nucleus-to-cytoplasm ratio. LMB, Leptomycin B. Scale bars in A
and C represent 20 µm. Data are represented as mean plus SEM. *P < 0.05; n.s., not significant.
3.5.2. TNRC6 proteins interact with Impα and Impβ
During classical import, Impα binds an NLS of a cargo protein and recruits Impβ, which facilitates
translocation through the nuclear pore complex. In contrast, non-classical Impβ-dependent import
can be mediated by direct interaction of Impβ with the cargo protein (Jäkel and Görlich, 1998,
Görlich and Kutay, 1999). To test interactions between Impα, Impβ and TNRC6 proteins, we
performed in vitro binding assays by pulldown of in vitro transcribed and translated TNRC6A with
GST-tagged importins (Figure 3.3.13).
We first tested interactions for classical import with Impα and Impβ. Since Impβ affects Impα’s
binding affinity to cargo proteins and vice versa (Fanara et al., 2000, Kobe, 1999), binding of both
proteins was analyzed simultaneously (Figure 3.3.13 A). GST-Impα family members (Impα1, α3,
α4, α5, α7) were immobilized and incubated with His-Impβ and radiolabeled TNRC6A. Strikingly,
we found robust binding of TNRC6A for most Impα family members in the presence of Impβ. To
validate specificity of the interaction, we performed binding experiments with TNRC6A containing
mutations in the recently suggested NLS (Figure 3.3.13 B, Nishi et al., 2013). Indeed, binding
of Impα/Impβ to this mutant appeared to be weakened compared to wildtype control, indicating
that Impα/Impβ uses this NLS for binding. To validate that Impα binds TNRC6A directly and
independently of Impβ, we performed pulldowns with GST-Impα and radiolabeled TNRC6A alone
(Figure 3.3.13 C). We still observed binding of Impα to TNRC6A, albeit the amount of pulled down
TNRC6A was different between the tested Impα subtypes compared to the reactions with His-
Impβ. However, because our pulldowns were not quantitative, interpretations regarding affinities
and direct comparison of different binding assays is not possible so far.
We next analyzed the non-classical import scenario by direct binding of Impβ to TNRC6A. We
also identified robust binding of GST-Impβ alone to radiolabeled TNRC6A (Figure 3.3.13 A to
C, lane 7). This binding seems to be independent of the reported NLS sequence in TNRC6A,
because we did not observe an obvious decrease of GST-Impβ pulled down TNRC6A NLS mut
(Figure 3.3.13 A to C). As our experiments suggest that at least Impβ can bind TNRC6A directly
but independently of its previously identified NLS, we further validated the functionality of the
reported NLS. We performed LMB treatments with TNRC6A NLS mutant and presuming that the
identified NLS is sufficient for TNRC6A import, TNRC6A NLS mutant should remain cytoplasmic
(Figure 3.3.14). While wildtype TNRC6A was trapped in the nucleus upon LMB treatment, the
NLS mutated variant remained only partially cytoplasmic. Therefore, the reported NLS seems to
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Figure 3.3.13. TNRC6A-C interact with Impα and Impβ. A, In vitro transcribed and translated TNRC6A was incu-
bated with recombinant GST alone (lane 1), GST-tagged Impα-family members and Impβ-His (lane 2 to 6) or Impβ-GST
alone (lane 7) followed by GST-pulldown. TNRC6A was detected by autoradiography, recombinant proteins by Coomassie
staining. B, Same experiment as described in A but with TNRC6A NLS mutant. Wildtype TNRC6A with Impα7 was loaded
as control in lane 8. Inputs are shown in lane 9 and 10. C, Same experiment as described in A but without addition of
Impβ-His. D and E, Same experiment as described in A with In vitro transcribed and translated TNRC6B (D) and TNRC6C
(E). NLS, nuclear localization sequence.
affect nuclear import of TNRC6A but does not fully abolish its import. This indicates that a so far
unidentified second NLS might exist in TNRC6A.
To get insights into importin binding of TNRC6B, we performed binding experiments with Impα
and Impβ (Figure 3.3.13 D and E). Of note, both TNRC6B and TNRC6C were not conserved in
the NLS that is present and functional within TNRC6A. Similarly to TNRC6A, Impβ alone or in
combination with Impα variants bound TNRC6B and TNRC6C. However, the amount of pulled
down TNRC6B and TNRC6C were seemingly lower, but this has to be investigated further in
quantitative experiments.
Taken together, our binding experiments suggest two different import routes for TNRC6 pro-
teins. First, TNRC6 is imported via the classical Impα/Impβ pathway by directly binding Impα. Sec-
ond, we suggest a second non-classical import route by direct binding to Impβ via a so far un-
known second NLS.
3.5.3. miRNA-mediated gene silencing is affected by Impβ
We have established that nuclear import of TNRC6 proteins requires Impβ. In addition, TNRC6
proteins can shuttle between the nucleus and the cytoplasm. During translocation through the
nucleus, TNRC6 proteins should not be available for miRNA-mediated post-transcriptional gene
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Figure 3.3.14. LMB treatments with a TNRC6A NLS mutant suggest the existence of a second NLS in TNRC6A.
A, HeLa cells were transfected with myc-GFP-TNRC6A wildtype, NLS mut or NES mut. Cells were then treatment with
Leptomycin B or control treatment. B, Diagram shows percentage of cells with cytoplasmic or nuclear GFP foci or foci in
both compartments (intermediate). Scale bars in A represent 10 µm.
silencing, a process that seems to take place in the cytoplasm. To test this hypothesis, we
analyzed the efficiency of miRNA-mediated post-transcriptional gene silencing on an artificial
miRNA reporter. This reporter contains firefly luciferase with Hmga2 3’-UTR, which harbors mul-
tiple miRNA binding sites including sites for the miRNA let-7. Therefore, firefly is under post-
transcriptional control by the Hmga2 3’-UTR. Cells were transfected with siRNAs against Impβ
and the Hmga2 3’-UTR luciferase reporter plasmid (Figure 3.3.15). As control, we transfected
inhibitors against let-7a, and as expected, inhibition of let-7a led to a strong derepression of the
reporter (Figure 3.3.15). Interestingly, depletion of Impβ resulted in an elevated silencing activity,
suggesting that retention of TNRC6 proteins in the cytoplasm positively affects gene silencing by
miRNAs. Therefore, the transition of TNRC6 proteins through the nuclear pore seems to directly
influence cytoplasmic gene silencing by miRNAs.
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Figure 3.3.15. Knockdown of Impβ increases miRNA-mediated gene silencing. HeLa cells were transfected with
Impβ siRNA or control siRNA and a Hmga2 3’-UTR reported or an empty reporter. As positive control, miRNA inhibitors
against let-7a or control inhibitors were transfected. Firefly is under control of the Hmga2 3’-UTR. Firefly activity was
normalized to renilla luciferase and control siRNA or control inhibitor. Data are shown as mean plus SEM. *P < 0.05; **P
< 0.005; n.s., not significant.
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3.6. Cytoplasmic Ago and TNRC6 levels influence nuclear
localization
3.6.1. Cytoplasmic retention mechanisms of Argonaute and TNRC6
Both Ago and TNRC6 proteins can shuttle through the nucleus by presumably independent
pathways. In addition, both proteins can interact with each other in the cytoplasm and the nu-
cleus. Thus, we investigated whether both proteins can influence each others import. To do so,
we coexpressed Ago2 and TNRC6A as wildtype proteins and different mutants (Figure 3.3.16). As
expected, both wildtype proteins were found to colocalize in the cytoplasm. Strikingly, expression
of the normally nuclear-trapped TNRC6A NES mutant with wildtype Ago2 resulted in an exclu-
sively cytoplasmic TNRC6A NES mutant. This suggests that high levels of Ago2 retain TNRC6A
in the cytoplasm. This cytoplasmic retention seems to depend on small RNA binding of Ago2 since
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Figure 3.3.16. Cytoplasmic retention of TNRC6 and Ago2. A, Coexpression of myc-GFP-TNRC6A wildtype, NES
mut or ∆GW NES and FH-Ago2 wildtype, Y529E, PAZ9 or empty plasmid (FH). TNRC6A and its mutants were detected
by GFP signal, Ago2 and its mutants with anti-HA antibody staining. B, Percentage of cells with cytoplasmic or nuclear
GFP foci or foci in both compartments (intermediate). Ago2 PAZ9 and myc-GFP-TNRC6A ∆GW NES are shown in the
diagrams only. Scale bars in A represent 20 µm.
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Ago2 Y529E, which cannot bind miRNAs, does not retain TNRC6A in the cytoplasm. This was also
observed for another miRNA binding deficient Ago2 mutant referred to as Ago2 PAZ9 (data not
shown, Liu et al., 2005b). As negative control, we analyzed cytoplasmic retention with a TNRC6
protein that contains a deleted Ago2 binding motif together with the mutated NES (TNRC6A ∆GW
NESmut, Figure 3.3.16 B). As expected, this Ago2-binding deficient mutant still accumulates in
the nucleus indicating that indeed binding of Ago2 mediates nuclear retention. Of note, the nu-
clear localization of TNRC6A ∆GW NESmut further supports the finding, that both proteins are
imported independently.
To support the identified nuclear retention mechanism, we investigated localization of the en-
dogenous proteins upon knockdown of the respective interaction partner. Knockdown of single
TNRC6 proteins did not significantly increase nuclear Ago2 levels. However, when TNRC6A-C
were knocked down simultaneously, nuclear Ago2 levels increased significantly (Figure 3.3.17).
Therefore, also TNRC6 can influence the nuclear localization of Ago2. Because the observed
effects were only visible upon knockdown of all three TNRC6 proteins but not after separate
knockdown, this finding indicates redundant functions of TNRC6 proteins in this retention mech-
anism. Surprisingly, upon knockdown of Ago1-4 we did not observe a significant increase of nu-
clear TNRC6B (data not shown). So far we can only speculate that the observed reduction of
Ago protein to about 50% remaining protein might not be sufficient to observe the expected ef-
fects. However this has to be analyzed further in future studies.
Taken together, we observed that TNRC6 and Ago proteins influence each others import by a
cytoplasmic retention mechanism. This mechanism depends on the interaction of both proteins in
the cytoplasm and is regulated by miRNA-binding.
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Figure 3.3.17. Decreased levels of TNRC6A-C increase nuclear Ago2 pool. A, HeLa cells were transfected with
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3.6.2. Ago2 prevents binding of TNRC6A-importin interaction
Since the reported NLS in TNRC6A is close to the Ago2-binding domain, we asked whether
importin and Ago2 binding to TNRC6 might be mutually exclusive (Figure 3.3.18 A). This could
mechanistically explain the observed cytoplasmic retention mechanism. To test this hypothesis,
GST-Impβ alone or GST-Impα with His-Impβ was immobilized and incubated with radiolabeled
3. RESULTS 99
TNRC6A (Figure 3.3.18 B and C). In addition, recombinant HA-Ago2 was added to the reactions
or not. Strikingly, when HA-Ago2 was present in the reactions, both the direct binding GST-Impβ
as well as GST-Impα/His-Impβ binding to TNRC6A was completely blocked by Ago2. Therefore,
Ago2 seems to preferentially bind TNRC6A and can block accessibility of the importin binding
sites. To exclude binding of recombinant Ago2 to Impα and Impβ in these assays, we performed
direct Ago2 binding experiments (Figure 3.3.18 A). As expected, HA-Ago2 bound specifically
to a TNRC6B peptide containing the Ago binding motif (TNRC6B 599-683, Pfaff et al., 2013),
however binding to Impα and Impβ was not observed. This indicates that Ago2 blocks Impα and
Impβ binding to TNRC6A via direct interaction with TNRC6A. In addition, this further supports the
finding that Ago2 is not imported via Impα and Impβ.
Taken together, we have identified a mechanism of mutually exclusive binding of Impα/Impβ
and Ago2 to TNRC6A. TNRC6A seems to preferentially bind Ago2 and bound Ago2 can mask
accessibility of the identified classical NLS and the not yet identified second NLS. Consequently,
Impα and Impβ cannot mediate import TNRC6 any more (Figure 3.3.16 A). However, when Ago2
is not present, the NLS sequences are accessible and can mediate nuclear import of TNRC6 via
Impβ- and Impα/Impβ-dependent pathways.
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Figure 3.3.18. Ago2 affects TNRC6A NLS accessibility. A, Schematic representation of the proposed mechanism
by which Ago2 blocks accessibility of TNRC6A NLS for Impα and Impβ. B, In vitro transcribed and translated TNRC6A
was incubated with recombinant GST (lane 1 and 2) or Impβ-GST (lane 3 and 4). Recombinant HA-Ago2 was added
when indicated (even lanes). After GST-pulldown, TNRC6A was detected by autoradiography, recombinant proteins by
Coomassie staining. C, GST-tagged Impα-family members and Impβ-His (lane 3 to 12) were mixed with In vitro transcribed
and translated TNRC6A. Recombinant HA-Ago2 was added when indicated (even lanes). D, TNRC6B 599-683 (lane 2),
Impα3-GST and Impβ-His (lane 3), Impα3-GST (lane 4), Impβ-His (lane 5) and recombinant GST (lane 6) were incubated
with recombinant HA-Ago2. HA-Ago2 was detected in pulldowns by anti-HA antibody Western.
4. Discussion of Part III
Mammalian Ago proteins are key players in miRNA-mediated gene silencing processes in the
cytoplasm. However, Ago proteins have also been implicated in various nuclear functions ranging
from transcriptional regulation to DNA double-strand break repair and alternative splicing. Al-
though still conversely discussed, those nuclear Ago functions might play important roles beyond
cytoplasmic miRNA-mediated regulation. Furthermore, other gene silencing factors like TNRC6
proteins can localize to the nucleus as well, however, their nuclear functions have not been elu-
cidated yet. Nuclear import is a prerequisite for nuclear functions and might provide an important
regulatory mechanism that could affect cytoplasmic as well as nuclear Ago and TNRC6 func-
tions. As nuclear import of Ago and TNRC6 proteins is almost totally uncharacterized so far, we
wanted to identify nuclear import pathways of Ago and TNRC6 proteins and to unravel mecha-
nisms that regulate nuclear import.
Nuclear localization and transport of Ago2
To provide a solid basis for the analysis of nuclear transport pathways, we show that human Ago2
is indeed found in the nucleus and that we specifically detect Ago2 by immunofluorescent stain-
ings. Nuclear localization of Ago proteins has been observed in numerous publications before by
immunofluorescence or nucleo-cytoplasmic extractions (Meister et al., 2004b, Robb et al., 2005,
Rüdel et al., 2008, Ohrt et al., 2008, Weinmann et al., 2009, Chu et al., 2010, Benhamed et al.,
2012, Gagnon et al., 2014). Quantitative analysis of the obtained immunofluorescence data fur-
ther suggested that only a minor portion of Ago2 is present in the nucleus in most human cell
lines investigated. Although we only identified minor proportions of Ago2 in the nucleus, condi-
tions might exist which accompany increased nuclear Ago2 localization. For example, it has been
reported that Ago2 proteins are found in the nucleus upon senescence induction (Benhamed
et al., 2012).
To show nuclear transport processes of Ago proteins in vivo, we directly measured nuclear
import of Argonaute proteins in heterokaryon assays. We show that Ago2 travels into the nucleus
in this system and therefore provide the first direct insight into nuclear Ago2 import.
Because Ago2 is imported into the nucleus but is mainly cytoplasmic under steady-state condi-
tions, we investigated whether Ago2 can shuttle between the nucleus and cytoplasm. Using Lep-
tomycin B (LMB) treatment, we show that nuclear Ago2 increases when Crm1-mediated export
is inhibited. Importantly, however, we did not observe a complete shift of Ago2 into the nucleus,
indicating that only a part of the cellular Ago pool shuttles between the nucleus and cytoplasm. Al-
though LMB is thought to specifically inhibit Crm1-mediated export, it is also conceivable, that Ago
proteins use additional export routes, which have not been analyzed in this study. One example
would be nuclear export bound to mRNAs, a mechanism that should be investigated in future
studies. Furthermore, direct interaction of Ago2 with Crm1 should be analyzed followed by identi-
fication of the necessary nuclear export signal in Ago2.
We were further able to validate these observations with heterokaryon assays using overex-
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pressed and tagged Ago proteins. Similar as observed for LMB treatment, Ago2 shuttled through
the nucleus in this assays when fused to a classical NLS. Of note, although we measured shut-
tling of Flag/HA-NLS-Ago2 in this assay, we did not observe shuttling of Flag/HA-Ago2 upon LMB
treatment, a result which has not been shown. However, we do not know whether overexpression
or the N-terminal tag might affect shuttling of Flag/HA-Ago2. Furthermore, we suggest that resid-
ual shuttling activity is retained in both Flag/HA-NLS-Ago2 and Flag/HA-Ago2, however, we only
observed shuttling with the more sensitive heterokaryon assay.
The observed shuttling activity of Ago2 and its nuclear localization presumes active nuclear
transport pathways, because Ago2 can not passively diffuse through the nuclear pore due to its
size. The nuclear transport receptor Importin 8 (Imp8) has recently been implicated in the cyto-
plasmic function of miRNAs and was reported to eventually contribute to nuclear localization of
mature miRNAs and Ago2 (Weinmann et al., 2009, Wei et al., 2014). However, by targeting the
nuclear RNA 7sk, we find that knockdown of Imp8 did not affect nuclear RNA interference (RNAi)
by Ago2-mediated cleavage of the nuclear target. We also did not observe a decrease of the
nuclear Ago2 pool upon Imp8 knockdown. In addition to Imp8, none of the other tested import
receptors changed nuclear RNAi efficiency and Ago2 localization. Using different biochemical as-
says, we further tried to directly identify Ago2-bound import receptors. Both in human cell extracts
and Xenopus oocyte extracts, Ago2 did not coprecipitate with detectable importins. However, be-
cause only a minor pool of Ago2 seems to be imported into the nucleus, only a small proportion
of Ago2 might transiently interact with importins, which might complicate biochemical identifica-
tion. We therefore suggest that importins function redundantly and several import receptors can
mediate nuclear import of Ago2. Such redundant import pathways have been found for several
proteins before including the miRNA-biogenesis factor Dicer, which can be imported by redundant
action of Impβ, Imp7 and Imp8 (Doyle et al., 2013).
In addition to the tested import pathways, future analysis should analyze importin-independent
transport by direct interaction with the nuclear pore. One might speculate, that Ago interacts with
the phenylalanine residues of the FG-repeat meshwork in the nuclear pore in a similar way it
binds tryptophan residues of TNRC6 proteins. Indeed, the tryptophan binding pockets mainly
function by hydrophobic interactions rather than specific stacking interactions and have affinity
to phenol (Schirle and MacRae, 2012). In addition, most phenylalanines within the FG-repeats
are 10 to 20 amino acids apart, which is in the range of the distance needed to bind into both
tryptophan binding pockets of Ago2 (Wente and Rout, 2010, Pfaff et al., 2013). Of note, this
binding scenario would also provide an explanation how TNRC6 could mediate the observed
cytoplasmic retention of Ago proteins, as both TNRC6 and the NPC FG-repeats would use the
same binding mechanism.
Nuclear localization and transport of TNRC6 proteins
Similar to Ago proteins, TNRC6 proteins localize predominantly to the cytoplasm as shown before
by nucleo-cytoplasmic fractionations and immunofluorescent analysis of overexpressed TNRC6A-
C (Meister et al., 2005, Jakymiw et al., 2005, Liu et al., 2005a, Lazzaretti et al., 2009, Gagnon
et al., 2014).
Here, we clearly show that all three human TNRC6 proteins shuttle between the nucleus and
cytoplasm and are trapped in the nucleus when Crm1-mediated export is inhibited by LMB. This
has been observed for TNRC6A and TNRC6B before and a classical nuclear export signal (NES)
for TNRC6A has been identified (Till et al., 2007, Nishi et al., 2013). To get insights into the in-
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tracellular localization of endogenous TNRC6 and to validate the observed shuttling activity, we
generated an antibody that detects TNRC6B in Western Blot and immunofluorescent stainings
with high specificity. We show that endogenous TNRC6B is mainly cytoplasmic with similarly low
nucleo-cytoplasmic ratios as observed for endogenous Ago2. Furthermore, endogenous TNRC6B
partially accumulated in the nucleus upon LMB treatment and therefore, at least a part of endoge-
nous TNRC6 proteins shuttles between the nucleus and cytoplasm.
We then took advantage of the nuclear localization of a TNRC6A nuclear export sequence
(NES) mutant and found that Impβ is needed for nuclear import of TNRC6A. Furthermore, none of
the other tested import receptors affected nuclear localization of TNRC6A, indicating that TNRC6
import is strictly Impβ-dependent. Impβ did not affect nuclear Ago2 localization and function,
indicating that both protein families are imported via different transport routes and are not co-
imported. To further characterize the Impβ-dependent nuclear transport routes of TNRC6 pro-
teins, we used biochemical assays to directly show importin-TNRC6 binding. During classical
nuclear import, Impα binds an NLS on the cargo protein and associates with Impβ, which facil-
itates transport through the nuclear pore complex (Görlich et al., 1995). Alternatively, Impβ can
directly contact cargo proteins and mediate non-classical import (Jäkel and Görlich, 1998). We
find that Impα binds a previously identified NLS on TNRC6A and that Impβ participates in this
interaction. In addition, Impβ can contact TNRC6A-independently of Impα, presumably via a
so far unknown second NLS. Although the in vitro binding data should be further validated by
co-immunoprecipitations, we suggest that Impβ facilitates transport of TNRC6 proteins into the
nucleus via a classical Impα-dependent route and by direct interaction with TNRC6.
Interestingly, we and others found that overexpressed human TNRC6 proteins can form distinct
foci in the nucleus. We analyzed these structures further and found that they neither resemble
cytoplasmic P-bodies nor known nuclear structures. Furthermore, none of the other proteins in-
vestigated here were present in the nuclear TNRC6 foci. Only a sub-pool of nuclear Ago2 can be
found in these structures. Therefore, we speculate that TNRC6 proteins can form these foci inde-
pendent of any other cytoplasmic P-body component. This might be mediated by functioning as a
scaffold protein which forms a meshwork by numerous interactions of the GW repeats in the large
unstructured N-termini. Similar mechanisms might be responsible for the formation of RNA gran-
ules and also the better characterized FG-repeat meshwork of the nuclear pore complex (Frey and
Görlich, 2007, Wente and Rout, 2010, Han et al., 2012, Kato et al., 2012). Therefore, these nu-
clear foci might provide an interesting system to investigate P-body and RNA granule formation in
vivo and to better understand the function of TNRC6 proteins in general. Of note, the comparison
of endogenous Ago2 and TNRC6 stainings showed very similar granular patterns of the cytoplas-
mic signals. Because we only observed microscopically visible P-bodies upon overexpression of
P-body components, we speculate that the observed granular pattern might represent submicro-
scopical P-bodies and that this granularity has functional implications for miRNA-mediated gene
silencing. Therefore, future studies are needed to investigate this staining pattern with higher
resolution.
Cytoplasmic retention of Ago and TNRC6 proteins
We have shown that Ago and TNRC6 proteins are imported via different import routes. In addition,
localization and quantification of the endogenous proteins revealed similar nucleo-cytoplasmic
distributions of Ago and TNRC6 and both protein families partially accumulated in the nucleus
upon LMB treatment. Therefore, we speculated whether Ago and TNRC6 proteins might influ-
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ence each others nuclear transport pathways. We coexpressed Ago and TNRC6 proteins and
different mutants thereof. Interestingly, when overexpressing Ago2, even the normally nuclear lo-
calized TNRC6A NES mutant remains in the cytoplasm. This suggested that Ago proteins can
prevent nuclear import of TNRC6 proteins. In the cytoplasm, Ago2 and the TNRC6A NES mutant
clearly colocalized, indicating that interaction of both proteins might affect nuclear transport. Inter-
estingly, a miRNA-binding deficient Ago2 mutant was not able to retain TNRC6 in the cytoplasm,
indicating that Ago and TNRC6 only stably interact when miRNAs are bound to Ago2. We further
show that a loss of TNRC6 proteins results in an increased nuclear Ago2 pool, indicating that also
TNRC6 proteins can prevent nuclear import of Ago proteins. In contrast to the proposed cytoplas-
mic retention mechanism, we found that Ago-binding deficient TNRC6 mutants are still mainly
cytoplasmic (data not shown). This observation, however, might be explained by interaction with
Ago1, 3 and 4 as it is not known whether Ago2-binding deficient TNRC6 mutants can still interact
with the other Ago proteins (Baillat and Shiekhattar, 2009, Nishi et al., 2013, Pfaff et al., 2013). Al-
ternatively, we suggest that not all Ago-free TNRC6 is immediately imported into the nucleus and
that so far unknown regulatory processes exist to regulate TNRC6 or Ago import. One attractive
possibility would be post-translational modifications, which have been shown to regulate NLS and
NES function in diverse proteins (Nardozzi et al., 2010).
Using biochemical assays, we further identified a mechanism by which Ago2 can regulate nu-
clear import of TNRC6 proteins. We found that Ago2-TNRC6 binding blocks the accessibility of the
previously identified NLS and therefore prevents binding of Impα/Impβ. Furthermore, direct bind-
ing of Impβ was also prevented in the presence of Ago2, indicating that both proposed nuclear
transport mechanisms are regulated by Ago2 binding. How Ago2 blocks the NLS is not known
so far, however the small distance between the Ago2 binding-site and the NLS might result in a
sterical block of the NLS. In future studies, it will be interesting to see how Ago1, Ago3 and Ago4
might influence TNRC6-importin binding.
A model for nuclear transport of Ago and TNRC6 proteins
Our study provided first insights into nuclear import processes of Ago and TNRC6 proteins and
show that both protein families are nucleo-cytoplasmic shuttling proteins. In addition we identified
Impβ-dependent import pathways of TNRC6 proteins and provide evidence for redundant trans-
port pathways of Ago proteins. Finally, we uncovered a cytoplasmic retention mechanism by which
both protein families can regulate each others import.
Figure 3.4.1 presents the proposed model for nucleo-cytoplasmic transport of Ago and TNRC6
proteins. In the cytoplasm, Ago and TNRC6 proteins function in miRNA-mediated post-transcrip-
tional gene silencing. Free Argonaute and TNRC6 proteins instead can shuttle between the
nucleus and cytoplasm. TNRC6 protein shuttling is mediated by import via classical Impα/β-
dependent transport and non-classical Impβ-dependent transport. Ago protein shuttling probably
depends on several redundant import receptors. Both TNRC6 and Ago proteins can be exported
again by the same Crm1-dependent export route. In the nucleus, Ago and TNRC6 proteins can
interact and colocalize, but are also present in independent pools.
The proposed cytoplasmic retention mechanism suggests that Ago and TNRC6 proteins might
travel through the nucleus in case they are not needed for miRNA-mediated gene silencing in the
cytoplasm. Furthermore, it is tempting to speculate that nuclear import contributes to balanced
cytoplasmic Ago and TNRC6 levels, which might be important for miRNA-mediated gene silenc-
ing in the cytoplasm. This hypothesis also includes, that rather than being imported for separate
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Figure 3.4.1. A model for nuclear transport of Argonaute and TNRC6 proteins. In the cytoplasm, Argonaute and
TNRC6 proteins interact during post-transcriptional gene silencing. Free Argonaute and TNRC6 proteins instead can shut-
tle between the nucleus and cytoplasm which balances cytoplasmic levels. Nuclear import of TNRC6 proteins is mediated
by classical Impα/β pathway (A) as well as non-classical import via Impβ (B). Nuclear import of Argonaute proteins instead
is non-classical, Impβ-independent and probably mediated by several redundant importins. Nuclear export of both Arg-
onaute and TNRC6 proteins is mediated by Crm1. In the nucleus, Ago2 and TNRC6 can interact and colocalize, however,
functions of these nuclear structures are not known.
nuclear functions, Ago and TNRC6 proteins might travel to the nucleus for storage. Upon increas-
ing need of cytoplasmic gene silencing components, Ago and TNRC6 proteins can be exported
again. Therefore, nuclear transport and localization of Ago and TNRC6 proteins might be a sim-
ple economic mechanism to balance cytoplasmic gene silencing components. In addition, the
proposed cytoplasmic balancing model would explain why TNRC6 and Ago proteins shuttle and
provides an alternative to the so far elusive functions of Ago and TNRC6 proteins in mammalian
nuclei.
Part IV.
Materials and Methods
1. Materials
1.1. Chemicals and Enzymes
Unless states otherwise, chemicals were purchased from Applichem (Darmstadt, Germany), Merck
(Darmstadt, Germany), Roth (Karlsruhe, Germany) and Sigma Aldrich (Munich, Germany). All en-
zymes for cloning, DNA modification and RNA modification were purchased from Thermo Fisher
Scientific (Waltham, USA) or New England Biolabs (Ipswich, USA). DNA oligonucleotides were
ordered from Metabion (Martinsried, Germany). RNA oligonucleotides were synthesized by in-
house synthesis service at Max-Planck-Institute of Biochemistry (Martinsried, Germany) or or-
dered at Biomers (Ulm, Germany).
1.2. Instruments
Instruments are described in chapter 2 to chapter 7 in the context of the respective application.
All other instruments like centrifuges are listed here.
Polymax 2040 Heidolph (Schwabach, Germany)
Vortexer REAX top Heidolph (Schwabach, Germany)
Screen Eraser-K Bio-Rad (Hercules, USA)
Trans-Blot SD Bio-Rad (Hercules, USA)
PowerPac HC Power Supply Bio-Rad (Hercules, USA)
2720 Thermal Cycler Applied Biosystems (Foster City, USA)
GeneAmp PCR System 9700 Applied Biosystems (Foster City, USA)
Mastercycler gradient Eppendorf (Hamburg, Germany)
Thermomixer compact Eppendorf (Hamburg, Germany)
Thermostat 5320 Eppendorf (Hamburg, Germany)
Centrifuge 5415D Eppendorf (Hamburg, Germany)
Hybridization oven T 5042 Heraeus (Hanau, Germany)
Incubator Model B6200 Heraeus (Hanau, Germany)
Agilent 2100 Bioanalyzer Agilent Technologies (Böblingen, Germany)
IKA MS3 Agilent Technologies (Böblingen, Germany)
Biofuge pico Thermo Scientific (Rockford, USA)
Cytoperm Thermo Scientific (Rockford, USA)
Fresco 17 Thermo Scientific (Rockford, USA)
HeraCell 240i CO2 Incubator Thermo Scientific (Rockford, USA)
Megafuge 40R Thermo Scientific (Rockford, USA)
HeraSafe KS Thermo Scientific (Rockford, USA)
Branson Sonifier 450 Heinemann (Schwäbisch Gmünd, Germany)
Film Processor CP 1000 AGFA (Mortsel, Belgium)
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Geiger Counter LB123 EG&G Berthold (Bad Wildbad, Germany)
Power Supply EV233 Consort (Turnhout , Belgium)
Microscope Diavert Leica (Wetzlar, Germany)
Milli-Q PLUS Millipore (Billerica, USA)
Ultraspec 3300 pro Amersham Biosciences (Little Chalfont, UK)
Avanti J-20 XP Centrifuge Beckman Coulter (Krefeld, Germany)
Quantum ST4 PeqLab (Erlangen, Germany)
1.3. Buffers and Solutions
Phosphate buffered saline (PBS)
130 mM NaCl
774 mM Na2HPO4
226 mM NaH2PO4
Tris/Borate/EDTA buffer (TBE)
89 mM Tris pH 8,3
89 mM Boric acid
2,5 mM EDTA
Tris buffered saline (TBS)
10 mM Tris pH 7,5
150 mM NaCl
Western Blot blocking buffer
2 % milk powder
0,01 % Tween-20
add TBS
Western Blot wash buffer
2 % milk powder
0,01 % Tween-20
add TBS
Laemmli protein sample buffer
300 mM Tris pH 6,8
50 % Glycerol
10 % SDS
0,01 % Bromophenol blue
Proteinase K buffer
300 mM NaCl
200 mM Tris pH 7,5
25 mM EDTA
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2 % SDS
2 x RNA loading dye
99,9 % Formamide
0,05 % Xylene cyanol
0,05 % Bromphenol blue
Colloidal Coomassie solution
8,3 % H3PO4
8,3 % (NH4)2SO4
20 % Methanol
1 g/L Coomassie Brilliant Blue G250
20 x SSC for Northern Blot
3 M NaCl
0,3 M NaCitrate pH 7,0
50 x Denhardt’s Solution for Northern Blot
1 % Albumin Fraction V
1 % Polyvinylpyrrolidon K30
1 % Ficoll 400
Hybridization solution for Northern Blot
50 ml 20x SSC
4 ml 1 M Na2HPO4 pH 7.2
140 ml 10 % SDS
4 ml 50X Denhardt’s Solution
ad. 200 ml H2O
Wash Solution I for Northern Blot
5 x 20 x SSC
1 % (w/v) SDS
Wash Solution II for Northern Blot
1 x 20 x SSC
1 % (w/v) SDS
EDC crosslinking solution
2 ml H2O
61,25 µl Methylimidazol
75 µl 1 M HCl
188,25 mg 1-Ethyl-3(3-Dimethylaminopropyl)carbodiimide hydrochloride (EDC)
ad. 6 ml H2O
Elution buffer for RNA cloning
300 mM NaCl
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2 mM EDTA
Firefly buffer for Luciferase assay
470 mM D-Luciferine (PJK GmbH, Kleinblitterdorf, Germany)
530 mM ATP (PJK GmbH, Kleinblitterdorf, Germany)
270 mM Coenzyme A (PJK GmbH, Kleinblitterdorf, Germany)
20 mM Tricine
5,34 mM MgSO4 • 7 H2O
0,1 mM EDTA
33,3 mM DTT
Renilla buffer for Luciferase assay
2.2 mM EDTA
220 mM K2PO4 pH 5,1
0,44 mg/ml BSA
1,1 M NaCl
1,3 mM NaN3
1,43 mM Coelenterazine (PJK GmbH, Kleinblitterdorf, Germany)
2 x HEPES for Calcium phosphate transfection
274 mM NaCl
54,6 mM Hepes
1,5 mM Na2HPO4
10 % SDS-PAGE separation gel
10 % Acrylamide-Bis 37,5:1 30 % (w/v) (Serva, Heidelberg, Germany)
400 mM Tris-HCl pH 8,8
0,1 % SDS
0,1 % APS
0,05 % TEMED
5 % SDS-PAGE stacking gel
5 % Acrylamide-Bis 37,5:1 30 % (w/v) (Serva, Heidelberg, Germany)
75 mM Tris-HCl pH 6.8
0,1 % SDS
0,1 % APS
0,05 % TEMED
2 x siRNA annealing buffer
60 mM HEPES pH 7,4
4 mM MgAc
200 mM KAc
SDS running buffer
200 mM Glycine
25 mM Tris pH 7,5
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25 mM SDS
Towbin buffer
38,6 mM Glycine
48 mM Tris
0,0037 % (w/v) SDS
20 % Methanol
Nuclear lysis buffer
1 % SDS
10 mM EDTA
50 mM Tris pH 8,0
0,1 % Sodium deoxycholate
2 mM AEBSF
5 U/ml DNaseI
IP lysis buffer
150 mM KCl
25 mM Tris pH 7,5
2 mM EDTA
1 mM NaF
0,5 % NP-40
0,5 % DTT
0,5 % 4-(2-Aminoethyl)benzenesulfonyl fluoride (AEBSF)
IP wash buffer
300 mM NaCl
50 mM Tris pH 7,5
1 mM NaF
0,01 % NP-40
5 mM MgCl2
FACS buffer
1 % BSA
0,1 % NaN3
add PBS
PBS-A for IF
0,2 g KCl
0,2 g KH2PO4
8 g NaCl
2,2 g Na2HPO4 • H2O
ad. 1 l H2O, adjust to pH 7,4
Fixation solution for IF
4 % paraformaldehyde (PFA)
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add PBS-A
Stopping solution for IF
100 mM Glycine
add PBS-A
Permeabilization solution for IF
0,1 % Triton-X-100
add PBS-A
Wash solution for IF
5 % bovine serum albumin (BSA)
0,01 % Triton-X-100
add PBS-A
PEG solution for Heterokaryon Assay
50 % (w/v) polyethylene glycol (PEG) 1500 (Sigma Aldrich, Munich, Germany)
add PBS-A
DMEM/CHX solution for Heterokaryon Assay
1 % (v/v) fetal bovine serum (FBS)
1x penicillin/streptomycin mixture
75 µg/ml cycloheximide (CHX) (Sigma Aldrich, Munich, Germany)
Buffer A for Ago2 purification
50 mM HEPES pH 7,5
1 M NaCl
0,1 % NP-40
10 mM imidazole
5 % glycerol
1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF)
5 U/ml Benzonase
Buffer B for Ago2 purification
50 mM HEPES pH 7,5
300 mM NaCl
200 mM imidazole
1 mM DTT
Desalting buffer for Ago2 purification
50 mM HEPES pH 7,5
1 M NaCl
10 mM Imidazole
Gelfiltration buffer for Ago2 purification
20 mM HEPES pH 7,5
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200 mM KCl
2 mM EDTA
1 mM DTT
5 % glycerol
Elution buffer for Importin purification
50 mM Tris-HCl pH 8,0
10 mM reduced glutathione
Dialysis buffer for Importin purification
50 mM HEPES-KOH pH 7,5
200 mM NaCl
5 % glycerol)
Buffer A for Ran purification
20 mM Tris pH 8,0
300 mM NaCl
10 mM Imidazole
1 mM AEBSF
5 U/ml Benzonase
5 µg/ml Lysozyme
Buffer B for Ran purification
20 mM Tris pH 8,0
300 mM NaCl
250 mM Imidazole
1 mM AEBSF
Dialysis buffer for Ran purification
25 mM Tris pH 7,5
150 mM NaCl
1,5 mM MgCl2
0,25 % NP-40
1 mM AEBSF
10 % Glycerol
GST pulldown buffer for GST pulldowns
20 mM HEPES pH 7,5
100 mM KOAC
0,5 mM EGTA
5 mM MgOAc
250 mM sucrose
Coupling buffer for antibody purification
0,1 M NaHCO3 pH 8,3
0,5 M NaCl
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Wash buffer low pH for antibody purification
0,1 M NaAc pH 3-4
0,5 M NaCl
Wash buffer high pH for antibody purification
0,1 M Tris pH 8-9
0,5 M NaCl
Elution buffer for antibody purification
100 mM glycine pH 2,3
Roeder A
10 mM HEPES pH 7,9
10 mM KCl
1,5 mM MgCl2
0,5 mM DTT
1 mM AEBSF
Roeder B
300 mM HEPES pH 7,9
1,4 M KCl
30 mM MgCl2
0,5 mM DTT
1 mM AEBSF
Roeder C
20 mM HEPES pH 7,9
420 mM KCl
1,5 mM MgCl2
0,2 mM EDTA
5 % glycerol
0,5 mM DTT
1 mM AEBSF
Roeder D
20 mM HEPES pH 7,9
100 mM KCl
1,5 mM MgCl2
0,2 mM EDTA
5 % glycerol
0,5 mM DTT
1 mM AEBSF
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1.4. DNA and RNA oligonucleotides
1.4.1. DNA oligonucleotides for molecular cloning
DNA oligonucleotides used for molecular cloning are listed in Table 1.1.
Table 1.1. List of DNA oligonucleotides for molecular cloning. Restriction enzyme substrate sequences are shown
in bold.
Primer name Sequence 5’→3’
CAMTA1 UTR SacI fwd ATACGAGCTCAGACATACAGCAGCATCCCTTAGCAATGTG
CAMTA1 UTR NaeI rev ATACGCCGGCGGAAATTTTCTTCATTTTTAATTTACAGCAG
CAMTA pIRES EcoRV fwd ATACGATATCATGTGGCGCGCGGAGGGGAAATG
CAMTA pIRES NotI rev ATATGCGGCCGCTCAAGTTCCTTGGCCTTTTTCAATTCTTTCACTC
CAMTAdN pIRES RV fwd ATACGATATCATGGGCAAGCCTTGCGGCCCCATCCTCTG
CAMTAdC pIRES rev ATATGCGGCCGCTCATTCATGATCAGACAGAGTGAGCTGAGC
CAMTAdN VP5 NotI fwd TACTGCGGCCGCATGGGCAAGCCTTGCGGCCCCATCCTCTG
CAMTAdC VP5 Bam rev ATATGGATCCATCATTCATGATCAGACAGAGTGAGCTGAGC
CAMTA1 VP5 NotI fwd TACTGCGGCCGCATGTGGCGCGCGGAGGGGAAATG
CAMTA1 VP5 BamHI rev ATATGGATCCATCAAGTTCCTTGGCCTTTTTCAATTCTTTCACTC
CAMTA1 SalI rev2 TACTGTCGACTCACATTGCTAAGGGATGCTGCTGTATGTCTTCAAG
CAMTA1 f1 BamHI fwd ATATGGATCCACAGGGGGGTACGGGAGCCACTCG
CAMTA1 f2 BamHI fwd ATATGGATCCCCCGGGGAGCGGAGCTTCAGCTTTAC
CAMTA1 f1/2 NotI rev ATATGCGGCCGCCTATTACAGCATGCCTAGGGTGCCCTGG
pFseI TNRC6A fwd AGAGGGCCGGCCATGAGAGAATTGGAAGCTAAAG
pAscI TNRC6A rev AGAGGGCGCGCCTTACATGGACTCTCCACCC
pFseI NLS Ago2 fwd2 GAGAGGCCGGCCCCAAAAAAGAAGAGAAAGGTAGCTGGTATCATGTACTCGGGAGCCGGC
pFseI Ago2 fwd AGAGGGCCGGCCATGTACTCGGGAGCCGGC
pAscI Ago2 rev AGAGGGCGCGCCTCAAGCAAAGTACATGGTGCG
phnRNPA1 NotI fwd AGAGGCGGCCGCATGTCTAAGTCAGAGTCTCCTAAAGAGC
phnRNPA1 BamHI rev AGAGGGATCCATTAAAATCTTCTGCCACTGCC
phnRNPC NotI fwd AGAGGCGGCCGCATGGCCAGCAACGTTACC
phnRNPC BamHI rev AGAGGGATCCATTAAGAGTCATCCTCGCCATT
pBam TEVHA fwd AGAGGGATCCATACCCTTATGACGTGCCCGATTACGCTCTCGAGATGTACTCGGGAGCCGGC
pAgo2 NotI rev AGAGGCGGCCGCTTATCAAGCAAAGTACATGGTGCG
pTNRC6A SacI fwd GAGAGAGCTCATGGATGCTGATTCTGCCTCC
pTNRC6A XhoI rev GAGACTCGAGTTACATGGACTCTCCACCCC
pTNRC6B BamHI fwd GAGAGGATCCATGAGAGAGAAGGAGCAAGAAAG
pTNRC6B NotI rev GAGAGCGGCCGCTCAGATTGAATCCGACCCTCC
pTNRC6C SacI fwd GAGAGAGCTCATGGCTACAGGGAGTGCCC
pTNRC6C XhoI rev GAGACTCGAGCTACAGGGACTCCCCGCT
pRan FseI fwd AGAGGGCCGGCCATGGCTGCGCAGGGA
pRan AscI rev AGAGGGCGCGCCTCACAGGTCATCATCCTCATC
pmycGFPTNRC6A fwd AGAGGGATCCATGGAACAAAAACTCATCTCAGA
pmycGFPTNRC6A rev AGAGCTCGAGTTACATGGACTCTCCACCC
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Detailed information on molecular cloning strategy for each generated construct is given in sub-
section 2.1.3.
1.4.2. DNA oligonucleotides for quantitative real-time PCR
DNA oligonucleotides used for quantitative real-time PCR are listed in Table 1.2. All primers were
designed against the human protein and to be exon-intron spanning.
Table 1.2. List of DNA oligonucleotides for quantitative real-time PCR. All primers are designed to detect the human
mRNA.
Amplicon Accession Primer name Sequence 5’→3’
pRT GAPDH fwd TGGTATCGTGGAAGGACTCATGAC
GAPDH NM_001256799
pRT GAPDH rev ATGCCAGTGAGCTTCCCGTTCAGC
pRT Actin fwd GGACTTCGAGCAAGAGATGG
β-Actin NM_001101
pRT Actin rev AGGAAGGAAGGCTGGAAGAG
Ile tRNA fwd GGTACTTATATGACAGTGC
Ile tRNA
Ile tRNA rev TGCTCCAGGTGAGGATCGAAC
CAMTA1 RT fwd ATCCTTATCCAGAGCAAATTCC
CAMTA1 NM_015215
CAMTA1 RT rev AGTTTCTGTTGTACAATCACAG
pRT NPPA fwd CAGGATGGACAGGATTGGA
NPPA NM_006172
pRT NPPA rev TCTTCAGTACCGGAAGCTGTT
pRT NPPB fwd CTTTCCTGGGAGGTCGTTC
NPPB NM_002521
pRT NPPB rev AGGGATGTCTGCTCCACCT
pRT NPPC fwd CTTGTCGCCCTTCTTCTGAC
NPPC NM_024409
pRT NPPC rev CTGCTCACGCTGCTCTCC
pRT NPR-A fwd TCGAAACCACCAAACTCCTC
NPR-A NM_000906
pRT NPR-A rev AGTGGTGGGACTGAAGATGC
pRT NPR-B fwd GGGGTTCTCGGTACGTGAT
NPR-B NM_003995
pRT NPR-B rev TACCTGGATGTCTTTGGGGA
pRT NPR-C fwd CATCGTGGAATCCTTCAACA
NPR-C NM_000908
pRT NPR-C rev GCATACTCGTCCCTCCAGAC
pRT 7sk fwd CCTGCTAGAACCTCCAAACAAG
7sk
pRT 7sk rev GCCTCATTTGGATGTGTCTG
qRT Impb1 fwd CAGCAGAACAAGGACGGCCCC
Impβb NM_002265
qRT Impb1 rev TGCTGCTTTGCAGGGGTTCCA
qRT Imp3 fwd CAAGGCCTTCTTATCCGACA
Imp3 NM_013433
qRT Imp3 rev GAGTGGGTGGTCAAGGAGTC
qRT Imp4 fwd TGTTGTCAGCCAGAATGAGG
Imp4 NM_024658
qRT Imp4 rev GAGGACTTGGAGGAGTGGGT
qRT Imp5 fwd2 GGAGATCAGCAAAGCTTTGGT
Imp5 NM_002271
qRT Imp5 rev2 AAAGGGACCATCAGTTTGACA
qRT Imp7 fwd ATGTCGGAACAGCTGGATTTACCTG
Imp7 NM_006391
qRT Imp7 rev CCCCTGGTGCTGTTTCTCGATCA
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Table 1.2. List of DNA oligonucleotides for quantitative real-time PCR, continued.
Amplicon Accession Primer name Sequence 5’→3’
qRT Imp8 fwd AGCCGAGAACGAGCTCAACCA
Imp8 NM_006390
qRT Imp8 rev CGATCTGGCCAGTATTGTGTCACCA
qRT Imp9 fwd GGCATCCGCACCCGCTCTAAG
Imp9 NM_018085
qRT Imp9 rev CCTGGCGAGCGGCATTAGCC
qRT Imp11 fwd TCCTGTTTCAGGATCTTCCG
Imp11 NM_016338
qRT Imp11 rev CTTTCAGCTTTGGCTTTGCT
qRT Imp12 fwd TTGGGGAGCTGCAGCGTTC
Imp12 NM_012470
qRT Imp12 rev CATGAGAGTCTGTGGGGAGCTCA
qRT Imp13 fwd TCGACAGCAGTGTGGAGGCCA
Imp13 NM_014652
qRT Imp13 rev TTCTGCACTGCCTGCCGCAG
qRT TRPO1 fwd GGTTCTCTGGATGGTGGTGT
TRPO1 NM_002270
qRT TRPO1 rev GTCTGGGATGGTGTGGGA
hsa-miR-9 TCTTTGGTTATCTAGCTGTATG
hsa-miR-9* ATAAAGCTAGATAACCGAAAG
hsa-miR-34a TGGCAGTGTCTTAGCTGGTTG
forward primer
U6 snRNA GATGACACGCAAATTCGTGAAG
reverse primer URT AACGAGACGACGACAGACTTT
1.4.3. DNA oligonucleotides for Northern Blot
DNA oligonucleotides used as probes for Northern Blot are listed in Table 1.3. Probes were
designed to correspond the exact antisense sequence for the miRNA strand of interest.
Table 1.3. List of DNA oligonucleotides used as Northern Probes.
Oligo name Sequence 5’→3’
hsa-miR-9 TCATACAGCTAGATAACCAAAGA
hsa-miR-9* ACTTTCGGTTGTCTAGCTTTAT
hsa-miR-17-5p CTACCTGCTCTGTAAGCACTTTG
hsa-miR-106b ATCTGCACTGTCAGCACTTTA
human U6 GAATTTGCGTGTCATCCTTGCGCAGGGGCCATGCTAA
human Ile-tRNA TGCTCCAGGTGAGGATCGAAC
human 7sk snRNA ACTCGTATACCCTTGACCGAAGA
1.4.4. DNA oligonucleotides for mouse genotyping
DNA oligonucleotides for genotyping of CAMTA1fl/fl (Long et al., 2014) and Nes-cre/ERT2+/0 as
well as the derived mouse strains are shown in Table 1.4.
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Table 1.4. List of DNA oligonucleotides used for mouse genotyping.
Oligo name Sequence 5’→3’ Reference
A1CKOsLA Seq TGGTGGAGAGGGTCATCTCAGAAATCTC Long et al., 2014
A1CKOASeq-6 CTCACACCTGATTCTGGCTGTGTAATG Long et al., 2014
A1CKOfP-1 CTGGAAGAGCAGCTAGTGCTCTTAATTGC Long et al., 2014
oIMR1084 cre fwd CTAGGCCACAGAATTGAAAGATCT jaxmice.jax.org
oIMR1085 cre rev GTAGGTGGAAATTCTAGCATCATCC jaxmice.jax.org
1.4.5. RNA oligonucleotides
1.4.6. siRNAs and siPools
RNA oligonucleotides that were used as siRNAs are listed in Table 1.5.
Table 1.5. List of siRNAs. Sense (s) and antisense (as) sequences are shown seperately.
siRNA name Sense sequence 5’→3’ Antisense sequence 5’→3’
CAMTA1 si1 CUACCGAAGUUAUAAGAAAUdT UUUCUUAUAACUUCGGUAGUdT
CAMTA1 si2 GAAUCAAGCAGGAGAAUUUUdT AAAUUCUCCUGCUUGAUUCGdT
si2 Impb1 GGAAAGAAGAGCCUAGUAAUdT UUACUAGGCUCUUCUUUCCUdT
si1 Impb1 CUGAAUGAGCUAAGGGAAAUdT UUUCCCUUAGCUCAUUCAGUdT
si1 Imp3 GGGCAGAGAUGCAGCCUUAUdT UAAGGCUGCAUCUCUGCCCUdT
si2 Imp3 GGGAUGAAGUACUCGGAAAUdT UUUCCGAGUACUUCAUCCCUdT
si1 Imp4 UGCGAUACGCAUACGUAUUUdT AAUACGUAUGCGUAUCGCAUdT
si1 Imp5 GAGAAAUGCACGAGGCAAUUdT AUUGCCUCGUGCAUUUCUCUdT
si2 Imp5 GUGCAAAAUCCUUGGAAAAUdT UUUUCCAAGGAUUUUGCACUdT
si1 Imp7 GGAAAGAGGUACUGCAAAAUdT UUUUGCAGUACCUCUUUCCUdT
si2 Imp7 GGAAGAAGAUGAUGCUGAAUdT UUCAGCAUCAUCUUCUUCCUdT
si2 Imp8 ACAAUAGUGUGGAUGAAUAUdT UAUUCAUCCACACUAUUGUUdT
si3 Imp8 UGAGCUCAAUCUAAGAAAUUdT AUUUCUUAGAUUGAGCUCAUdT
si1 Imp9 CCUAAUGGGUUGAGAGAAUUdT AUUCUCUCAACCCAUUAGGUdT
si2 Imp9 CCACAGAUUUCCAGAAUGAUdT UCAUUCUGGAAAUCUGUGGUdT
si1 Imp11 GGAAGAUGGUUUAGAAUUAUdT UAAUUCUAAACCAUCUUCCUdT
si2 Imp11 GAUAAUGUGUGUAGAGAUAUdT UAUCUCUACACACAUUAUCUdT
si1 Imp12 ACGUGAAGAUUUAGACAAAUdT UUUGUCUAAAUCUUCACGUUdT
si2 Imp12 GCACAGAAAUUAUAGAAGAUdT UCUUCUAUAAUUUCUGUGCUdT
si1 Imp13 CCCUUCUGAUGAGGAAUAUUdT AUAUUCCUCAUCAGAAGGGUdT
si2 Imp13 GGGAAAGGUGGUACAGGAAUdT UUCCUGUACCACCUUUCCCUdT
si1 Tnpo1 GUAUAGAGAUGCAGCCUUAUdT UAAGGCUGCAUCUCUAUACUdT
si2 Tnpo1 GCCACAGGUAUUCAUUUAUUdT AUAAAUGAAUACCUGUGGCUdT
si1 control UUGUCUUGCAUUCGACUAAUdT UUAGUCGAAUGCAAGACAAUdT
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Table 1.5. List of siRNAs, continued.
siRNA name Sense sequence 5’→3’ Antisense sequence 5’→3’
si2 control UCGAAGUAUUCCGCGUACGUdT CGUACGCGGAAUACUUCGAUdT
As controls, si1 and si2 controls were used. si2 control is directed against firefly luciferase. All
siRNAs were designed with Dharmacon siRNA Design Center and Whitehead siRNA selection
tool which are publicly available online.
siPools were designed by and ordered at siTool Biotech (Martinsried, Germany). Following
siTools were used during this study: siP TNRC6A, siP TNRC6C, siP TNRC6C, siP Ago1, siP
Ago2, siP Ago3, siP Ago4, siP Neg.
1.4.7. miRNA inhibitors
RNA oligonucleotides that were used for miRNA inhibition experiments were synthesized as 2’-O-
methylated RNAs and are listed in Table 1.6.
Table 1.6. List of 2’-O-methylated miRNA inhibitors.
Inhibitor name Sequence 5’→3’
hsa-miR-9 antisense UCAUACAGCUAGAUAACCAAAGAT
hsa-miR-9* antisense ACUUUCGGUUAUCUAGCUUUAT
hsa-miR-17-5p antisense ACUACCUGCACUGUAAGCACUUUGT
hsa-miR-106b antisense AUCUGCACUGUCAGCACUUUAT
hsa-miR-122 antisense ACAAACACCAUUGUCACACUCCAT
hsa-miR-301 antisense GCUUUGACAAUACUAUUGCACUGT
hsa-miR-330 antisense GCCUAAGACACAGGCCCAGAGAT
1.4.8. miRNA mimics
RNA oligonucleotides that were used as miRNA mimics are listed in Table 1.7.
Table 1.7. List of miRNA mimics.
Oligo name Sequence 5’→3’
hsa-miR-9/9* mimic sense UCUUUGGUUAUCUAGCUGUAUGAT
hsa-miR-9/9* mimic antisense AUAAAGCUAGAUAACCGAAAGUT
hsa-miR-122 mimic sense UGGAGUGUGACAAUGGUGUUUGT
hsa-miR-122 mimic antisense AACGCCAUUAUCACACUAAAUAT
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1.5. Plasmids
Following plasmids were available in advance of this work or purchased:
pMIR-RL Modified commercially available pMIR-REPORT (Thermo Scientific, Rockford, USA) in
which Renilla reniformis luciferase under control of SV40 promoter has been inserted for
dual luciferase assay. Modifications have been reported in Beitzinger et al., 2007.
pIRESneo Mammalian expression vector with CMV promoter and ECMV internal ribosome entry
side for Cap-independent translation (Takara Bio, Otsu, Japan).
pIRES-Flag/HA Modified pIRESneo, which allows expression of N-terminal Flag/HA-tagged fu-
sion proteins. Modifications have been reported in Meister et al., 2004b.
pIRES-Flag/HA-FA pIRES-Flag/HA with modified multiple cloning that contains FseI and AscI
sites for molecular cloning.
pCS2-myc(6) Published in Meister et al., 2004b.
pCS2-myc(6)-FAME Modified pCS2 plasmid, which encodes N-terminal 6 x myc-Tag and addi-
tional FseI/AscI restriction sites for cloning. Modifications reported in Weinmann et al., 2009.
pIRES-Flag/HA-eYFP Plasmid expressing N-terminally Flag/HA-tagged eYFP from Meister et al.,
2004b.
pGEX-6P-1 Expression of N-terminal GST tagged fusion protein in bacteria (GE Healthcare, Lit-
tle Chalfont, UK).
pET28a Commercially available from Novagen/Merck (Darmstadt, Germany).
pIRES-Flag/HA-TNRC6B 599-683-eYFP Plasmid containing TNRC6B fragment aa 599-683 of
full length TNRC6B. Fragment is expessed as N-terminally Flag/HA-tagged and C-terminally
eYFP-tagged fusion protein. Kindly provided by Judith Hauptmann.
pIRES-Flag/HA-TNRC6B 599-683 mut-eYFP Plasmid containing TNRC6B fragment aa 599-683
of full length TNRC6B. Kindly provided provided by Judith Hauptmann.
pIRES-Flag/HA-eYFP Plasmid containing eYFP. Cloning has been reported in Meister et al.,
2004b.
pcDNA5-FRT/TO Commercially available from Life Technologies (Carlsbad, USA).
pOG44 Commercially available from Life Technologies (Carlsbad, USA).
VP5-Ago1, Ago2, Ago3, Ago4 Published in Meister et al., 2005.
pCS2-myc(6)-Ago1, Ago2, Ago3, Ago4 Published in Meister et al., 2005.
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pCS2-myc(6)-Ago2 529E Contains Ago2 with Y529E mutation, which interrupts miRNA binding.
Published in Rüdel et al., 2011.
pIRES-Flag/HA-TNRC6B Contains 1724 aa TNRC6B ORF. Published in Pfaff et al., 2013.
pIRES-Flag/HA-TNRC6C Contains 1691 aa TNRC6C ORF. Cloned by Janina Pfaff, unpublished
construct.
pIRES-Flag/HA-TNRC6B W623A Contains 1724 aa TNRC6B ORF with W623A mutation which
prevents binding to Ago2 in vitro. Published in Pfaff et al., 2013.
pcDNA3.1-myc-GFP-TNRC6A, NLS mut, NES mut, δGW, δGW NES mut Contains 1709 aa TNRC6A
ORF and mutant ORFs. 1709 aa TNRC6A variant doesn’t contain the 254 aa N-terminal
part of the longest annotated version of TNRC6A (1963 aa) including the Q-rich domain.
Published in Nishi et al., 2013.
pCS2-myc(6)-TNRC6A Contains TNRC6A ORF, however it is not clear which variant of TNRC6A
(sequencing never worked, but myc-tagged protein with size and distribution of 1709 TNRC6A
version is expressed).
pCS2-myc(6)-TNRC6B Contains 1724 nt TNRC6B ORF. Published in Pfaff et al., 2013.
pCS2-myc(6)-TNRC6C Contains 1691 nt TNRC6C ORF. Cloned by Janina Pfaff, unpublished
construct.
pFastBac-HTa-3TEV-Ago2 Cloned by Lasse Weinmann to express 3 TEV sites between N-
terminal His-tag and Ago2, unpublished construct.
pET28a-Ago1, Ago2, Ago3, Ago4 Published in Weinmann et al., 2009.
1.6. Antibodies
Antibodies used for Western Blot, Immunoprecipitations and FACS analysis are listed in Table 1.8.
Table 1.8. Antibodies used for Western Blot, immunoprecipitations and FACS. Dilutions were shown for Western
Blot applications. monocl, monoclonal antibody; polycl, polyclonal antibody; HS, hybridoma supernatand; pf, purified.
Antibody Properties/Source Dilution
rat-anti-Ago1 monocl, HS, clone 4B8, Beitzinger et al., 2007 1:10
rat-anti-Ago2 monocl, HS, clone 11A9, Rüdel et al., 2008 1:20
rat-anti-Ago3 monocl, HS, clone 5A3, Weinmann et al., 2009 1:20
rat-anti-TNRC6B monocl, HS, clone 6G3, this work 1:10
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Table 1.8. Antibodies used for Western Blot, immunoprecipitations and FACS, continued.
Antibody Properties/Source Dilution
rat-anti-TNRC6ABC monocl, HS, clone 7A9, this work 1:10
mouse-anti-HA monocl, clone 16B12, Covance (Princeton, USA) 1:1000
rabbit-anti-c-Myc polycl, C3956, Sigma Aldrich (Munich, Germany) 1:1000
mouse-anti-αTubulin monocl, clone DM1A, Sigma Aldrich (Munich, Germany) 1:10000
rabbit-anti-Lamin A/C polycl, H-110, Santa Cruz Biotechnology (Dallas, USA) 1:1000
mouse-anti-Tuj1 monocl, MMS-435p, Covance (Princeton, USA) 1:1000
mouse-anti-βActin monocl, clone AC15, Abcam (Cambridge, UK) 1:10000
rabbit-anti-GFAP monocl, clone 6F2, Dako (Eching, Germany) 1:2000
rabbit-anti-CAMTA1 polycl, rabbit#1886, Schraivogel et al., 2011 1:200
rabbit-anti-CAMTA1 polycl, rabbit#1901, this work 1:200
goat-anti-rabbit-HRP secondary antibody, Sigma Aldrich (Munich, Germany) 1:5000
goat-anti-mouse-HRP secondary antibody, Sigma Aldrich (Munich, Germany) 1:5000
goat-anti-rabbit 680 secondary antibody, Li-Cor Biosciences (Lincoln, USA) 1:10000
goat-anti-mouse 680 secondary antibody, Li-Cor Biosciences (Lincoln, USA) 1:10000
goat-anti-rat 680 secondary antibody, Li-Cor Biosciences (Lincoln, USA) 1:10000
goat-anti-rabbit 800 secondary antibody, Li-Cor Biosciences (Lincoln, USA) 1:10000
goat-anti-mouse 800 secondary antibody, Li-Cor Biosciences (Lincoln, USA) 1:10000
goat-anti-rat 800 secondary antibody, Li-Cor Biosciences (Lincoln, USA) 1:10000
anti-CD133/2-PE FACS antibody, clone 293C3, Miltenyi (B. Gladbach, Germany)
Antibody production and purification will be described in section 3.2.
Antibodies that were used for Immunofluorescence stainings are listed in Table 1.9
Table 1.9. Antibodies used for Immunofluorescence stainings. monocl, monoclonal antibody; polycl, polyclonal
antibody; HS, hybridoma supernatand; pf, purified.
Antibody Properties/Source Dilution
rat-anti-Ago1 monocl, HS, clone 4B8, Beitzinger et al., 2007 1:10
rat-anti-Ago2 monocl, HS, clone 11A9, Rüdel et al., 2008 1:10
rat-anti-Ago2 monocl, pf, clone 11A9, Rüdel et al., 2008 1:1000
rabbit-anti-Ago2 polycl, HS, clone 1526, this work 1:100
rabbit-anti-Ago2 polycl, pf, clone 1526, this work 1:1000
mouse-anti-Ago2 polycl, 2E12-1C9, Abnova (Danvers, USA) 1:200
rabbit-anti-Ago2 polycl, C34C6, Cell Signalling (Danvers, USA) 1:200
rat-anti-Ago3 monocl, HS, clone 5A3, Weinmann et al., 2009 1:10
rat-anti-TNRC6B monocl, HS, clone 6G3, this work 1:10
rat-anti-TNRC6ABC monocl, HS, clone 7A9, this work 1:10
mouse-anti-HA monocl, clone 16B12, Covance (Princeton, USA) 1:400
rabbit-anti-c-Myc polycl, C3956, Sigma Aldrich (Munich, Germany) 1:400
chicken-anti-Lsm4 polycl, GW22314F, Sigma Aldrich (Munich, Germany) 1:500
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Table 1.9. Antibodies used for Immunofluorescence stainings, continued.
Antibody Properties/Source Dilution
rabbit-anti-YB1 polycl, ab12148, Abcam (Cambridge, UK) 1:400
mouse-anti-RPA194 monocl, C-1, Santa Cruz Biotechnology (Danvers, USA) 1:250
mouse-anti-RBP1 CTD monocl, clone 8WG16, provided by Dirk Eick 1:10
rabbit-anti-Coilin polycl, H-300, Santa Cruz Biotechnology (Dallas, USA) 1:50
mouse-anti-SC35 monocl, ab11862, Abcam (Cambridge, UK) 1:500
mouse-anti-p54nrb monocl, clone 3, BD Biosciences (Franklin Lakes, USA) 1:200
mouse-anti-PML polycl, H-238, Santa Cruz Biotechnology (Dallas, USA) 1:100
rabbit-anti-HSF1 monocl, D3L8I, Cell Signalling (Danvers, USA) 1:400
rabbit-anti-CBP80 polycl, ab42389, Abcam (Cambridge, UK) 1:100
rabbit-anti-CNOT7 provided by Laura Corbo, Chapat et al., 2013 1:100
rabbit-anti-SKIV2L2 polycl, Novus Biologicals (Littleton, USA) 1:100
rabbit-anti-Xrn2 provided by David Bentley, Brannan et al., 2012 1:400
mouse-anti-Ubiquitin monocl, clone 6C1, Sigma Aldrich (Munich, Germany) 1:500
mouse-anti-Proteasome monocl, MCP231, Enzo Lifesciences (Farmingdale, USA) 1:100
mouse-anti-γH2AX polycl, clone JBW301, Millipore (Darmstadt, Germany) 1:100
rabbit-anti-53BP1 polycl, Novus Biologicals (Littleton, USA) 1:100
rabbit-anti-HSF1 polycl,#4356, Cell Signalling (Danvers, USA) 1:500
goat-anti-mouse 488 secondary antibody, Life Technologies (Carlsbad, USA) 1:500
goat-anti-rat 488 secondary antibody, Life Technologies (Carlsbad, USA) 1:500
goat-anti-rabbit 488 secondary antibody, Life Technologies (Carlsbad, USA) 1:500
goat-anti-chicken 488 secondary antibody, Life Technologies (Carlsbad, USA) 1:500
goat-anti-mouse 555 secondary antibody, Life Technologies (Carlsbad, USA) 1:500
goat-anti-rat 555 secondary antibody, Life Technologies (Carlsbad, USA) 1:500
goat-anti-rabbit 555 secondary antibody, Life Technologies (Carlsbad, USA) 1:500
goat-anti-chicken 555 secondary antibody, Life Technologies (Carlsbad, USA) 1:500
anti-CD133/2-PE clone 293C3, Miltenyi (B. Gladbach, Germany)
1.7. Bacterial Strains and Media
Following Escherichia coli strain was used for cloning:
XL1-blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac[F’proAB lacIqZ∆M15 Tn10 (Tetr)]
Following E. coli strain was used for expression of CAMTA1 fragments:
BL21 B F- dcm+ Hte ompT hsdS(rB- mB-) gal endA Hte
Liquid and solid media for cultivation of E. coli were composed as follows:
Lysogeny broth (LB) medium
5 g yeast extract
10 g Tryptone
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10 g/l NaCl
ad. 1 l H2O
LB-Agar
1 l LB medium
16,4 g Agar
Ampicillin (50 µg/ml) or Kanamycin (30 µg/ml) were added to LB medium for Mini and Midi prepa-
rations of plasmid DNA. Isopropylthio-β-galactoside (IPTG) for induction of recombinant protein
expression from trp/lac hybrid promoter in pGEX was prepared as 0,1 M solution and added to
growing cells to 0,1 mM final concentration.
1.8. Mammalian Cell lines and Media
1.8.1. Glioblastoma cell lines
Human glioblastoma cell lines that have been used during this work are listed below. Generation of
cell lines has been described in Beier et al., 2007. All cell lines are derived from primary tumors of
grade IV Glioblastoma multiforme. Type I cancer stem cell (CSC) lines are CD133-positive, show
neurosphere growth, express proneural signature genes and are similar to fetal neural stem cell
lines. Type II CSC lines are CD133-negative, show semi-adherent growth, express mesenchymal
signature genes and are similar to adult neural stem cell lines. Classification of CSC lines has
been done in Lottaz et al., 2010 and in Beier et al., 2012, mesenchymal-proneural classification
was done in these studies according to signatures from Phillips et al., 2006. Interestingly, GBM
derived cell lines are genetically stable during long-term cultivation in stem cell medium (Lee et al.,
2006b), what can be confirmed for R28 and R11 by regular microarray analysis (Christoph Beier,
personal communication).
R8 human primary astrocytic GBM, Type II CSC, adherent growth pattern, established and de-
scribed in Lottaz et al., 2010
R11 human primary astrocytic GBM, Type I CSC, neurosphere-like growth, established and de-
scribed in Lottaz et al., 2010
R20 human primary GBM, origin not investigated, Schraivogel et al., 2011
R28 human primary astrocytic GBM, Type I CSC, neurosphere-like growth, established and de-
scribed in Lottaz et al., 2010
R28-luc R28 cell line stably transduced with a lentiviral vector expressing firefly luciferase under
control of the constitutive spleen focus forming virus LTR promoter. Cell line was generated
by Martina Anton (TU Munich, Institute of Experimental Oncology and Therapy Research,
Munich, Germany) for Schraivogel et al., 2011. Detailed experimental procedures are pre-
sented in section 4.4.3.
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R40 human primary GBM, origin not investigated, Schraivogel et al., 2011
R44 human primary GBM, origin not investigated, Type I CSC, neurosphere-like growth, estab-
lished and described in Lottaz et al., 2010
R52 human primary GBM, origin not investigated, Schraivogel et al., 2011
R54 human primary GBM, origin not investigated, Type I CSC, neurosphere-like growth, estab-
lished and described in Lottaz et al., 2010
Additional human and murine glioblastoma cell lines that were used for this work:
LN-229 human glioblastoma cell line with adherent growth. Cells exhibit mutated TP53 (C98T)
and homozygous deletions in p16 and p14ARF tumor suppressor genes. PTEN status is
wildtype.
SMA-560 murine glioma cell line which grows as adherent monolayer under standard growth
conditions or as sphere culture in neural stem cell medium. Spontaneous murine anaplas-
tic astrocytoma (SMA) 560 arose in a VM/Dk mouse strain followed by serial transplanta-
tions back into VM/Dk mice with stable tumorigenicity (Serano et al., 1980). SMA-560 have
low S-100 expression, high expression of GFAP and glutamine synthetase and exhibit a
CD133-positive subpopulation with cancer stem cell like properties (Oh et al., 2014; Ghaz-
aleh Tabatabai, personal communication).
T89G human Glioblastoma Multiforme derived cell line with adherent growth.
U87MG human Glioblastoma Multiforme derived cell line with adherent growth.
1.8.2. Mammalian and murine cell lines
Human pulmonary artery smooth muscle cells (HPASMC) and endothelial cells (HPAEC) were
purchased from Lonza (Basel, Switzerland). Primary keratinocytes were isolated as described in
Kretz et al., 2013. Flp-In T-REx 293 cell line was purchased from Life Technologies (Carlsbad,
USA).
All other cell lines are listed at ATCC: HeLa, HeLa S3 HEK 293T, NIH 3T3, U-2 OS, HCT116,
Hep G2, HuH-7, A549, H1299, MCF7, T-47D, NCCIT, MRC-5, DU 145, GM5756, Ntera2 and
Sk-Mel-28, Arpe-19, DLD-1, LNCaP.
1.8.3. Cell culture media
Following cell culture media were used for cells listed in sections 1.8.1 and 1.8.2.
Standard cell culture medium
Dulbecco’s Modified Eagle Medium (DMEM) (Sigma Aldrich, Munich, Germany)
10 % FBS (Sigma Aldrich, Munich, Germany)
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1 % penicillin/streptomycin (Sigma Aldrich, Munich, Germany)
Tet-free DMEM Zeo/Blast medium
DMEM
10 % Tetracycline-free FBS (Clontech, Saint-Germain-en-Laye, France)
1 % penicillin/streptomycin
100 µg/ml Zeocin (Life Technologies, Carlsbad, USA)
15 µg/ml Blasticidin (Applichem, Darmstadt, Germany)
Tet-free DMEM HygB/Blast medium
DMEM
10 % Tetracycline-free FBS
1 % penicillin/streptomycin
200 µg/ml Hygromycin B (Life Technologies, Carlsbad, USA)
15 µg/ml Blasticidin
DMEM-F12 complete medium
DMEM Nutrient Mixture F-12 (DMEM-F12) (PAN, Aidenbach, Germany)
10 % FBS
1 % penicillin/streptomycin
RPMI complete medium
RPMI-1640 (Sigma Aldrich, Munich, Germany)
10 % FBS
1 % penicillin/streptomycin
Neural stem cell medium complete
DMEM-F12
20 ng/ml epidermal growth factor (EGF) (R&D Systems, Minneapolis, USA)
20 ng/ml fibroblast growth factor (FGF) (R&D Systems, Minneapolis, USA)
20 ng/ml leukaemia inhibitory factor (LIF) (Millipore, Billerica, USA)
2 % B27 supplement (Life Technologies, Carlsbad, USA)
1 % penicillin/streptomycin
1 % MEM vitamins solution (Life Technologies, Carlsbad, USA)
Neural stem cell medium incomplete
DMEM-F12
1 % penicillin/streptomycin
1 % MEM vitamins solution
SmBM complete
Smooth muscle basal medium (SmBM) (Lonza, Basel, Switzerland)
10 % FBS (Lonza, Basel, Switzerland)
1 % SingleQuots Kit (Lonza, Basel, Switzerland)
EBM-2 complete
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Endothelial basal medium 2 (EBM-2) (Lonza, Basel, Switzerland)
10 % FBS (Lonza, Basel, Switzerland)
1 % SingleQuots Kit
Keratinozyte medium
50 % KSF-M (Gibco)
40 % Medium 154 for keratinozytes (Gibco)
10 % EGF
1 x bovine pituitary extract
Minimum essential medium eagle Joklik Modification (Joklik’s)
11,02 g/l Joklik’s dry powder (Sigma Aldrich, Munich, Germany)
0,29 g/l L-glutamine
1 % penicillin/streptomycin
1 % non-essential amino acids
2 g/l NaHCO3
Joklik’s medium
Joklik’s
5 % FBS
SingleQuots Kit contains human epidermal growth factor (hEGF), hydrocortisone, human recom-
binant fibroblast growth factor-Beta (hFGF-β), vascular endothelial growth factor (VEGF), insulin-
like growth factor (R3-IGF-1), ascorbic acid, heparin, FBS, and gentamicin/amphotericin-B (GA).
The prepared stem cell medium contains human epidermal growth factor (EGF) and fibroblast
growth factor (FGF), which have multiple effects by mainly preventing differentiation and apoptosis
and accelerating cell growth (Pollard et al., 2009). B27 supplement includes a range of hormones,
anti-oxidants and retinal acetate, transferrin, insulin, putrescine, progesterone and sodium sele-
nate as formulated in Bottenstein and Sato, 1979 and Bottenstein and Sato, 1979 and was shown
to support long-term survival of CNS derived non-neoplastic and GBM derived primary cell lines.
B27 serum-free supplement was shown to increase survival of long-term cultivated primary GBM
derived cell lines (Pollard et al., 2009).
All cell culture plates, dishes and wells were purchased from Sarstedt (Nümbrecht, Germany).
2. Molecular Biological Methods
2.1. DNA cloning
2.1.1. General DNA cloning
Polymerase chain reaction (PCR) was performed with Phusion High-Fidelity DNA Polymerase
(Thermo Scientific, Rockford, USA) according to the manufacturer’s instructions. PCR fragments
were purified by agarose gel electrophoresis according to Sambrook et al., 1989. Purification
of PCR fragment from Agarose gels has been done using NucleoSpin Gel and PCR Clean-Up
Kit (Macherey-Nagel, Düren, Germany). Fragments were then digested with restriction enzymes,
purified again using NucleoSpin Gel and PCR Clean-Up Kit and used for ligation. Ligations were
done for 2 h at RT or o/n at 16 ◦C.
Preparation and transformation of chemically competent E. coli has been described in Inoue
et al., 1990. DNA isolation from E. coli was done by alcaline lysis according to Sambrook et al.,
1989. Plasmids were then controlled by analytical digest with multi-cutting restriction enzyme.
Positive cloned were re-purified with NucleoBond Xtra PC20 gravity columns (Macherey-Nagel,
Düren, Germany) and sent to sequencing. Sequencing has been done at GATC Biotech (Kon-
stanz, Germany) or Macrogen (Amsterdam, Netherlands). DNA concentration and quality was
determined using NanoDrop 1000 Spectrophotometer (Thermo Scientific, Rockford, USA). Midi
preparations have been done using NucleoBond Xtra Midi Kit (Macherey-Nagel, Düren, Ger-
many). For nucleofection experiments, plasmids were prepared using EndoFree Plasmid Midi
Kit (Qiagen, Hilden, Germany).
2.1.2. Site-directed mutagenesis
For site directed mutagenesis QuikChange II site-directed mutagenesis Kit (Agilent Technologies,
Santa Clara, USA) was used according to the manufacturer’s instructions. Mutagenesis was
controlled by sequencing of the complete 3’-UTR.
2.1.3. Cloning strategies for plasmids produced in this work
Following plasmids were cloned during this work. Primers are listed in Table 1.1.
pMIR-RL-CAMTA1 The 3’-UTR of CAMTA1 mRNA was PCR amplified from R28 genomic DNA
using primers CAMTA1 UTR SacI fwd and CAMTA1 UTR NaeI rev and cloned via SacI and
NaeI into pMIR-RL.
pMIR-RL-CAMTA1 miR-9 mut For analysis of miR-9 binding sites, all sites predicted with Tar-
getScan 5.0 and all seed matches conserved in mammals were mutated by site-directed
mutagenesis from CAAA to GTTT.
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pMIR-RL-CAMTA1 miR-9* mut For analysis of miR-9* binding sites, all sites predicted with Tar-
getScan 5.0 and all seed matches conserved in mammals were mutated by site-directed
mutagenesis from CTTT to GAAA.
pIRES-CAMTA1 CAMTA1 cDNA was amplified from Marathon whole human brain cDNA library
(BD Biosciences, Franklin Lakes, USA). CAMTA1 ORF was reamplified using primers CAMTA
pIRES EcoRV fwd and CAMTA pIRES NotI rev and cloned via EcoRV and NotI into pIRES-
neo. All CAMTA1 clones from Marathon whole human brain cDNA library contained an
additional exon of 21 nt in size (AGCTGACATGGATAGCCTTGA) compared to the RefSeq
sequence NM_015215. The additional nucleotides are inserted after nt 4687 of NM_015215
and encode for seven additional amino acids which localize to the predicted Calmodulin
binding domain. Therefore, the used CAMTA1 construct encoded for a 1680 aa protein in-
stead of the RefSeq 1673 aa protein.
pIRES-CAMTA1 ∆N N-terminally deleted CAMTA1 truncation lacking amino acids 1-188 (nt 1-
564) which contain the predicted DNA binding domain. Fragment was PCR amplified from
pIRES-CAMTA1 using primers CAMTAdN pIRES RV fwd and CAMTA pIRES NotI rev and
cloned via EcoRV and NotI into pIRES-FH.
pIRES-CAMTA1 ∆C C-terminally deleted CAMTA1 truncation lacking the last 161 aa of full length
1680 aa CAMTA1. This results in deletion of the predicted IQ domain and Calmodulin
binding domain. Fragment was PCR amplified from pIRES-CAMTA1 using primers CAMTA
pIRES EcoRV fwd and CAMTAdC pIRES rev and cloned via EcoRV and NotI into pIRES-FH.
pIRES-Flag/HA-CAMTA1 CAMTA1 was amplified with primer CAMTA1 VP5 NotI fwd and CAMTA1
VP5 BamHI rev from pIRES-CAMTA1 and cloned via NotI and BamHI into pIRES-Flag/HA.
pIRES-Flag/HA-CAMTA1 ∆N N-terminally deleted CAMTA1 fragment was amplified with primer
CAMTAdN VP5 NotI fwd and CAMTA1 VP5 BamHI rev from pIRES-CAMTA1 and cloned
via NotI and BamHI into pIRES-Flag/HA.
pIRES-Flag/HA-CAMTA1 ∆C C-terminally deleted CAMTA1 fragment was amplified with primer
CAMTA1 VP5 NotI fwd and CAMTAdC VP5 Bam rev from pIRES-CAMTA1 and cloned via
NotI and BamHI into pIRES-Flag/HA.
pGEX-6P-1-CAMTA1 f1 Expression of N-terminal GST tagged 86 kDa CAMTA1 fragment con-
taining aa 294-864 used for immunization of rabbits. Fragment was amplified from pIRES-
CAMTA1 using primers CAMTA1 f1 BamHI fwd and CAMTA1 f1/2 NotI rev and cloned via
into pGEX-6p-1.
pGEX-6P-1-CAMTA1 f2 Expression of N-terminal GST tagged 63 kDa CAMTA1 fragment con-
taining aa 516-864 used for immunization of rabbits. Fragment was amplified from pIRES-
CAMTA1 using primers CAMTA1 f2 BamHI fwd and CAMTA1 f1/2 NotI rev and cloned via
into pGEX-6p-1.
pIRES-Flag/HA-TNRC6A The 1709 aa TNRC6A ORF from pcDNA3.1-myc-GFP-TNRC6A was
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amplified with primer pFseI TNRC6A fwd and pAscI TNRC6A rev and inserted into pIRES-
Flag/HA-FA via FseI/AscI.
pIRES-Flag/HA-SV40NLS-Ago2 and Ago2 529E Contains Ago2 with N-terminally fused SV40
large T-antigen NLS. Ago2 or its mutant was amplified from pIRES-Flag/HA-Ago2 and pIRES-
Flag/HA-Ago2 529E using primer pFseI NLS Ago2 fwd2 and pAscI Ago2 rev and cloned via
FseI/AscI into pIRES-Flag/HA-FA.
pIRES-Flag/HA-Ago1 NLS mut and NES mut Mutants of predicted Ago1 NLS and NES were
generated by site directed mutagenesis. Ago1 putative NLS was mutated from MKRKYRV to
MQQQYQV. Ago1 putative NES was mutated from EDLSYMVRELLIQ to EDVSYMVREVVIQ.
pIRES-Flag/HA-Ago2 NLS mut and NES mut Mutants of predicted Ago2 NLS and NES were
generated by site directed mutagenesis. Ago2 NLS was mutated from MKRKYRV to MQRKYRV
and MKQKYRV. Ago2 putative NES was mutated from DLAAMVRELLIQ to DVAAMVREVVIQ.
pIRES-Flag/HA-Ago3 NLS mut Mutants of predicted Ago3 NLS were generated by site directed
mutagenesis. Ago3 NLS was mutated from MRRKYRV to MQQQYQV.
pIRES-Flag/HA-Ago4 NLS mut Mutants of predicted Ago4 NLS were generated by site directed
mutagenesis. Ago4 NLS was mutated from MKRKYRV to MQQQYQV.
pIRES-Flag/HA-Ago2 529E NLS mut and NES mut Generation of combined Ago2 529E and
putative NLS/NES mutations was done by ligation of ligating FseI/SphI digested PCR from
pIRES-Flag/HA-Ago2 NLS/NES mut and SphI/AscI digested PCR from pIRES-Flag/HA-
Ago2 529E into pIRES-Flag/HA-FA. PCR was done with pFseI Ago2 fwd and pAscI Ago2
rev.
pIRES-Flag/HA-hnRNPA1 hnRNPA1 ORF was amplified from HeLa cDNA with primer phnRNPA1
NotI fwd and phnRNPA1 BamHI rev and cloned via NotI/BamHI into pIRES-Flag/HA.
pIRES-Flag/HA-hnRNPC hnRNPC ORF was amplified from HeLa cDNA with primer phnRNPC
NotI fwd and phnRNPC BamHI rev and cloned via NotI/BamHI into pIRES-Flag/HA.
pFastBac-HTa-HA-Ago2 pFastBac-HTa-HA-Ago2 was cloned from pFastBac-HTa-3TEV-Ago2
(Lasse Weinmann, unpublished construct) by replacing 2 of the 3 TEV sites with HA-tag. Re-
placement was done by amplification of Ago2 from pIRES-Flag/HA-Ago2 with primer pBam
TEVHA fwd and pAgo2 NotI rev and cloning via BamHI/NotI into pFastBac-HTa-3TEV-Ago2.
pET28a-TNRC6A, NLS mut, NES mut, NLS/NES mut, δGW, δGW NES mut TNRC6A or mutants
ORFs were amplified from pcDNA3.1-myc-GFP-TNRC6A or mutant plasmids using primer
pTNRC6A SacI fwd and pTNRC6A XhoI rev and cloned via SacI/XhoI into pET28a.
pET28a-TNRC6B, W623A TNRC6B or mutant ORFs were amplified from VP5-TNRC6B and mu-
tant plasmid using primer pTNRC6B BamHI fwd and pTNRC6B NotI rev and cloned via
BamHI/NotI into pET28a.
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pET28a-TNRC6C TNRC6C ORF was amplified from VP5-TNRC6C using primer pTNRC6C SacI
fwd and pTNRC6C XhoI rev and cloned via SacI/XhoI into pET28a.
pET28a-Ran, Ran Q69L, Ran T24N Ran and Ran mutant ORFs were amplified using primer
pRan FseI fwd and pRan AscI rev from pCS2-Ran and Ran mutant plasmids.
pcDNA5-FRT/TO-myc-GFP-TNRC6A, NES mut, δGW NES mut myc-GFP-TNRC6A and mutant
ORFs were amplified from pcDNA3.1-myc-GFP-TNRC6A or mutant plasmids using primer
pmycGFPTNRC6A fwd and pmycGFPTNRC6A rev and cloned via BamHI/XhoI into pcDNA5-
FRT/TO.
2.2. Working with RNA
2.2.1. RNA extraction
RNA extraction from cells for quantitative real-time PCR (qPCR) and microarray experiments has
been done with NucleoSpin RNA Kit (Macherey-Nagel, Düren, Germany) following the manufac-
turer’s protocol. RNA was resuspended and stored in H2O.
RNA extraction from cells for small RNA detection by Northern Blot and small RNA cloning has
been done with TRIzol reagent (Life Technologies, Carlsbad, USA) essentially as described in the
manufacturer’s protocol. RNA precipitation from aqueous phase from samples with low amount of
input material was supported by adding RNA grade glycogen (Life Technologies, Carlsbad, USA).
After precipitation, pellet was washed with 80 % EtOH and finally resuspended in H2O.
For extraction of RNA from mouse organs, male or female animals of the mouse strain C57BL/6
were used. Tissue was prepared, snap frozen in liquid nitrogen and pulverized in a mortar with a
pestle. Crushed tissue was lyzed immediately using TRIzol reagent (Life Technologies, Carlsbad,
USA), mixed rigorously and incubated for 10 min at RT. Further steps for RNA isolation with TRIzol
were done as described above.
RNA extraction from Ago2-immunoprecipitations and R11 cells for miR-9* target identification
have been done as follows: R11 cells were lyzed with IP lysis buffer and immunoprecipitation was
done as described in section 3.1. Immunoprecipitation samples and corresponding samples of
input material were proteinase K digested, followed by Roti-Phenol/Chloroform/Isoamyl alcohol
extraction (Carl Roth, Karlsruhe, Germany), and precipitation of RNA in 80 % EtOH at -20 ◦C.
RNA was pelleted, air dried and treated with DNaseI for 45 min at 37 ◦C, followed by thermal
inactivation of DNaseI.
RNA concentration and quality for qPCR from cells and mouse tissues was determined using
NanoDrop 1000 Spectrophotometer (Thermo Scientific, Rockford, USA). RNA quality for Northern
Blot was additionally checked by nucleic acid staining of gels before Northern Blot in TBE sup-
plemented with 5 µl/100ml ethidium bromide. RNA for microarray analysis was analyzed using
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, USA).
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2.2.2. Polyacrylamide urea gel electrophoresis of RNA
SequaGel UreaGel system (National Diagnostics, Atlanta, USA) was used to prepare polyacry-
lamide urea gels for electrophoresis of RNA. For small RNA detection, 12 % gels were prepared
by mixing 29 ml concentrate, 25 ml diluent and 6 ml buffer with 24 µl tetramethylethylenediamine
(TEMED) and 480 µl 10 % ammonium persulfate (APS). For 7sk and U6 detection after Importin
knockdown, 6 % gels were prepared by mixing 14,4 ml concentrate, 39,6 ml diluent and 6 ml buffer
with 24 µl TEMED and 480 µl 10 % APS. After polymerization for at least 1 h, gels were pre-run
at 250 V for 20 min in TBE buffer prior to loading of RNA. Gel pockets were rinsed directly before
loading to remove excess urea. 5 to 20 µg RNA were mixed with 2x RNA sample buffer, heated
for 2-3 min at 98 ◦C and loaded. Gels were run at 250 V until bromphenol blue band reaches a
distance of 7 to 8 cm from pocket bottom. In 12 % denaturating polyacrylamide gels, bromophenol
blue migrates at a size corresponding to about 10 nt ssRNA and xylene cyanol at about 70 nt. In
6 % gels, bromophenol blue migrates at about 26 nt and xylene cyanol at about 106 nt. No fur-
ther marker for RNA length determination was used. Disassembled gels were ethidium bromide
stained and used for Northern Blot as described in section 2.2.3.
2.2.3. Northern Blotting, probe labelling and RNA detection
Northern Blot was essentially performed as described in Pall and Hamilton, 2008. After disas-
sembling polyacrylamide urea gels, RNA was blotted semi-dry onto a Hybond-N membrane (GE
Healthcare, Little Chalfont, UK). For detection of miRNAs with 7sk or U6 as loading control, blot
was done at 20 V for 30 min using H2O as transfer buffer. RNA was subsequently chemically
crosslinked using EDC crosslinking solution for minimum 1 h to maximum 1,5 h at 50 ◦C. Mem-
brane was shortly rinsed in water and pre-hybridized with hybridization solution. For detection of
7sk with U6 as loading control, blot was done at 20 V for 45 min. RNA was subsequently UV cross
linked by exposing membrane from both sides for 30 sec each to high UV intensity from Quantum
gel documentation system (Peqlab, Erlangen, Germany) and an additional chemical cross link
done as described above.
Probe labeling was done using 20 pmol DNA oligonucleotide (listed in Table 1.3) with 20 µCi of
γ32P-ATP (Hartmann Analytics, Braunschweig, Germany) in a 20 µl T4 PNK reaction according
to the manufacturer’s protocol (Life Technologies, Carlsbad, USA). Reaction was incubated for
30 min at 37 ◦C. The reaction was directly added onto a Illustra MicroSpin G-25 columns (GE
Healthcare, Little Chalfont, UK) and flow through was mixed with 30 µl 30 mM EDTA to stop PNK
reaction. Radioactivity of the labeled oligo was determined.
The radioactively labeled probe was added to the pre-hybridized membrane and incubated o/n
at 50 ◦C on rating wheel with about 50 ml hybridization solution. From U6 probe, only a fifth
of one labeling reaction was used per membrane, all other reactions were used completely for
one hybridization reaction. The membrane was washed twice with wash solution I and once with
wash solution II for Northern Blot, incubating each wash step for 15 min on a turning wheel at
50 ◦C. Liquid was discarded and membrane was wrapped in saran for exposure. Signals were
detected either by exposure to a Imaging Screen-K (Kodak, Rochester, USA) and read out with
Personal Molecular Imager System (Bio-Rad, Hercules, USA) or exposure to BioMax MS films
(Kodak, Rochester, USA) using an intensifying screen (GE Healthcare, Little Chalfont, UK) and
subsequent film development. Signal quantifications were done using Personal Molecular Imager
System.
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For repeated hybridization of different probes on the same blot membrane, the current probe
was stripped off the membrane. H2O was boiled, membrane was added to water to be completely
covered and 10 % SDS was added to a final concentration of 0,1 %. After 30 min incubation at RT
on a rocker, membrane was wrapped in saran end exposed to check efficiency of probe removal.
Procedure was repeated if stripping was not effective.
2.3. cDNA synthesis and quantitative real-time PCR
2.3.1. qPCR for mRNA quantification
RNA was prepared for cDNA synthesis by performing an additional DNaseI digest (Life Tech-
nologies, Carlsbad, USA) using 1 µg RNA per reaction as given in the manufacturer’s protocol.
Reaction was incubated for 30 min at 37 ◦C and stopped by adding 1 µl 100 mM EDTA and heat
inactivation at 72 ◦C for 10 min. The complete 1 µg RNA reaction was used for cDNA synthesis
using First Strand cDNA Synthesis Kit (Thermo Scientific, Rockford, USA). RNA was mixed with 1
µl random hexamer primer, filled up to 11 µl with H2O and incubated for 65 ◦C for 5 min. Samples
were chilled on ice and mixed with 4 µl 5 x reaction buffer, 1 µl 2 U/µl RiboLock RNase inhibitor,
2 µl 1 mM dNTP mix and 2 µl 20 U/µl M-MuLV reverse transcriptase. Reaction was mixed, in-
cubated for 5 min at 25 ◦C and subsequently 60 min at 37 ◦C. Reaction was then terminated by
heating to 70 ◦C for 5 min.
qPCR was done with Sso Fast Eva Green Mix (Bio-Rad, Hercules, USA), 0,4 µM forward and
0,4 µM reverse primer and cDNA from 50 ng RNA as template. qPCR primer sequences are
shown in table 1.2. qPCRs were run on a CFX96 cycler (Bio-Rad, Hercules, USA) using stan-
dard program as given in the SsoFast EvaGreen SuperMix manual with denaturation and an-
nealing/extension times of 5 sec, 40 cycles and a 65-95 ◦C melt courve. Data were evaluated
using ∆∆Ct method (Livak and Schmittgen, 2001) with GAPDH or β-Actin as reference mRNA
and normalized to control sample. Error bars were calculated from three biological replicates.
2.3.2. qPCR for miRNA quantification
For miRNA quantification, DNaseI treated RNA samples were poly(A)-tailed using Poly(A) Tailing
Kit (Life Technologies, Carlsbad, USA) according to the manufacturer’s protocol. Samples were
then reverse transcribed with First Strand cDNA Synthesis Kit (Thermo Scientific, Rockford, USA)
using URT primer (1.2, Hurteau et al., 2006).
2.4. miRNA target identification
miRNA target identification has been done as described previously in Beitzinger et al., 2007 and
Schraivogel et al., 2011. The experimental procedure described here has been taken in parts
from Schraivogel et al., 2011. In short, RNA from anti-Ago2 IP and input samples was extracted
as described in section 2.2.1. RNA was further processed using the SuperAmp RNA amplification
protocol (Miltenyi, Bergisch Gladbach, Germany). cDNA integrity was checked via Bioanalyzer.
250 ng of each cDNA was labelled with Cy3 dye (Miltenyi, Bergisch Gladbach, Germany) accord-
ing to the manufacturer’s protocol. Samples were then hybridized to Whole Human Genome 4x44
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K Oligo Microarrays (Agilent Technologies, Santa Clara, USA). Fluorescence signals for Cy3 were
detected using Microarray Scanner System (Agilent Technologies, Santa Clara, USA).
Microarray data were analyzed using Genespring software (Agilent Technologies, Santa Clara,
USA) and further processed using Excel. Expression values < 0,01 were set to 0,01. Each
measurement was divided by the 50th percentile of all measurements in that sample. All IP
samples were normalized to the corresponding input RNA samples. The IP sample from control
and miR-9* inhibitor transfected cells was normalized against the median of the corresponding
input RNA samples. For normalization, each measurement for each gene in the IP samples was
divided by the median of that gene’s measurements in the corresponding input RNA samples. IP
to input ratios from miR-9* inhibitor transfected samples were then divided by the IP to input ratios
from control transfected sample.
Using this normalization procedure, the normalized expression value of each transcript in the IP
samples reflects its fold enrichment in the immunoprecipitated transcript pool relative to the input
RNA pool. All transcripts that were more than 5-fold enriched in IPs from control inhibitor trans-
fected cells were isolated to filter for potential miRNA target mRNAs bound by Ago2. Transcripts
with a > 10-fold decrease in miR-9* inhibitor transfected cells compared to control-transfected
cells were selected as potential targets of miR-9*.
2.5. Transcriptome analysis after CAMTA1 overexpression
To analyze transcriptome response after CAMTA1 overexpression, LN-229 cells were transfected
with pIRES-CAMTA or pIRES using Lipofectamine 2000 as described in section 4.3. RNA was
prepared using column-based preparation with NucleoSpin RNA Kit (Macherey-Nagel) and RNA
quality was determined by measuring A260/A280 ratio with NanoDrop (Thermo Scientific). RNA
samples were processed and hybridized on GeneChip Human Gene 1.1 ST Arrays (Affymetrix) at
KFB Regensburg in biological duplicates. Those arrays are designed to cover the whole human
transcriptome with probes against about 30000 protein-coding and 11000 long intergenic non-
coding RNA transcripts (lincRNAs). Fold change for each biological duplicate was calculated.
Heat map was built with GiTools 2.2.1.
2.6. Generation of small RNA libraries and Deep sequencing
2.6.1. Small RNA libraries and Deep sequencing from CD133-sorted R11
cells
The following procedure has been previously reported in Schraivogel et al., 2011 and partially
adopted. Small RNA libraries were generated by Vertis Biotechnology (Freising, Germany) and
sequenced by 454 pyrosequencing as previously described (Tarasov et al., 2007). Known miRNAs
were identified by comparing the sequencing results with annotated miRNAs from the H. sapiens
miRBase release 10.0 (08/2007) using Microsoft Excel software. Several miRNA reads were
found to contain sequencing errors, typically starting from nucleotides 18 to 25 that were possibly
due to the procedure of library preparation and/or pyrosequencing. Most errors were poly(A)
insertions at the 3’-end of the reads. Therefore, those reads that were fully complementary to a
known miRNAs from nucleotides 1 to 18 but had additional poly(A) insertions at the 3’-end were
re-annotated as miRNAs. Read numbers for each miRNA were normalized to the total number
134 PART IV. MATERIALS AND METHODS
of reads of the corresponding library. For calculation of miRNA expression, the normalized read
numbers from the CD133-negative cell library were divided by the normalized read numbers from
the CD133-negative library.
2.6.2. Generation of small RNA libraries from cells with DNA damages
Nuclear RNAs were isolated from cells and cloned essentially as described in Dueck et al., 2012
without size selection for 21 nt small RNAs prior to RNA cloning. 2 µg RNA were used as in-
put material for 3’-adapter and 5’-adapter ligation. After cloning and extraction from gel, cluster
generation, sequencing and FastQ file generation were carried out at sequencing core facility at
Center of Excellence for Fluorescent Bioanalytics (KFB) at Regensburg University. Datasets were
analyzed in the department of Rainer Spang at Regensburg University.
3. Proteinbiochemical methods
3.1. Immunoprecipitations
3.1.1. Ago2 immunoprecipitation for miRNA target identification
To identify miR-9* target mRNAs, immunoprecipitation of Ago2 for enrichment of Ago2-associated
mRNAs was done as described in Schraivogel et al., 2011. R11 cells were transfected with miR-9*
and control inhibitors for 2 days in four 10 cm plates per inhibitor. Cells were then lyzed in 2 ml IP
lysis buffer supplemented with 1 µl/ml Ribolock (Life Technologies, Carlsbad, USA) by incubation
for 20 min at 4 ◦C. Lysate was cleared by centrifugation at 16000 g for 10 min. In advance, 3 ml of
anti-Ago2 11A9 hybridoma supernatant was coupled to 100 µl Protein-G Sepharose beads (GE
Healthcare, Little Chalfont, UK) for over night at 4 ◦C. All centrifugation steps with beads were
done for 1 min at 1000 g. Coupled beads were washed twice with PBS. Beads were subsequently
incubated with cell lysate for 4 h at 4 ◦C. All IP samples were washed twice with IP wash buffer,
transferred into a new 1,5 ml tube and washed again once with IP wash buffer and once with PBS.
3.2. Protein expression, purification and antibody production
3.2.1. Proteins for immunization of rats and rabbits
CAMTA1 fragments were expressed in BL21 as N-terminal GST fusions and directly used for
immunization of rabbits. TNRC6A, B and C RRM domains were expressed in E. coli and used for
immunization of rats.
3.2.2. HA-tagged Ago2
Human HA-tagged Ago2 was expressed in Sf-21 cells as described in section 4.2. Purification
has essentially been done as described in Pfaff et al., 2013. pFastBac-HTa-HA-Ago2 was used
for virus production. Purification was done from 2,5 l culture infected with viral stock and cultivated
for 72 hours at 27,5 ◦C. Cells were harvested at 300 g for 10 min at RT and lyzed using 120 ml
Buffer A and additional sonification. Lysate was cleared by centrifugation at 40.000 g for 60 min
at 4 ◦C. Cleared lysate was filtered through a 45 µm filter and loaded onto a Ni-loaded HiTrap
IMAC FF 5 ml column (GE Healthcare, Little Chalfont, UK). After binding, column was washed
extensively with 10 column volumes of Buffer A and 5 column volumes 5 % Buffer B. Elution
was done with 100 % Buffer B and eluate was collected from peak fractions, supplemented with
tobacco etch virus (TEV) protease (kindly provided by Leonhard Jakob) and incubated over night.
Sample was loaded on a HiPrep 26/60 desalting column (GE Healthcare, Little Chalfont, UK)
using desalting buffer to increase salt concentration. Peak fractions were collected and applied
again onto Ni-loaded HiTrap IMAC FF 5 ml column and unbound flow-through was collected.
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Two different Ago2 stocks were produced with different properties: Flow through from second
IMAC was collected, concentrated and resolved by size-exclusion chromatography with a HiLoad
Superdex 200 26/60 column (GE Healthcare, Little Chalfont, UK) in gelfiltration buffer. Fractions
corresponding to HA-Ago2 were collected, pooled and concentrated (Stock I). Due to incom-
plete TEV cleavage, TEV cleavage was repeated from bound fractions of second IMAC. All steps
after TEV cleavage were repeated as described above. However, as TEV cleavage was again
incomplete, bound and unbound peak fractions were collected after elution from second IMAC.
Bound and unbound peak fractions were pooled, concentrated and resolved by size-exclusion
chromatography as described above. Fractions corresponding to His-HA-Ago2 and HA-Ago2
were collected, pooled and concentrated (Stock II).
Stock I containing pure HA-Ago2 was used for anti-Flag-pulldowns from Xenopus laevis oocytes.
Stock II containin HA-Ago2 as well as His-HA-Ago2 was used for GST-pulldowns with TNRC6A
and Import factors.
3.2.3. GST- and His-tagged Importins and Nucleoplasmin
Recombinant human Importin α subtypes were expressed as GST- and His-fusion proteins and
purified as described in Depping et al., 2008. Proteins were expressed in E. coli BL21. Cells were
grown and expression was induced by IPTG for 4 h at 25 ◦C. Cells were harvested and lyzed
in a French Press. Lysate was cleared for 1 h at 22.000 rpm in a SS-34 rotor. Cleared lysate
was incubated for 2-3 h at 4 ◦C with glutathion sepharose beads (GE Healthcare, Little Chal-
font, UK). Beads were washed 3 times and protein was subsequently eluted with elution buffer.
Protein samples were dialyzed against dialysis buffer and concentrated if necessary. His-tagged
Importins and Nucleoplasmin were purified by metal affinity chromatography using BD TALON
metal affinity resin (Clontech-Takara Bio Europe, Saint-Germain-en-Laye, France) according to
the manufacturer’s instructions and as described in Depping et al., 2008.
3.2.4. His-tagged Ran and Ran mutants
His-tagged human Ran and GTPase defective mutant RanQ69L were expressed in E. coli BL21.
Cells were grown to OD600 = 0,5 and expression was induced adding IPTG for 13 h at 37 ◦C. Cells
were harvested and lyzed in 100 ml Buffer A and additional sonification. Lysates were cleared
for 40 min at 22.000 rpm, supernatant was filtered through a 45 µm filter and applied onto a Ni-
loaded HiTrap IMAC FF 5 ml column (GE Healthcare, Little Chalfont, UK). Column was washed
with mixed buffer A and B resulting in 22 mM Imidazole. Elution was done with 100 % Buffer B.
Fractions containing Ran were pooled, dialyzed against 2 l Dialysis buffer over night in a dialysis
tube with a MWCO of 12 kDa (Carl Roth, Karlsruhe, Germany). Dialysate was concentrated in a
Centricon 10k (Merck Millipore, Darmstadt, Germany) and protein concentration was determined
using Bradford assay (Bio-Rad, Hercules, USA). Dialysis was set up to largely match IP lysis
buffer.
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3.3. Antibody production and purification
3.3.1. Antibody production from immunized rats and rabbits
Immunization of rats and production of hybridoma clones was done as described in Beitzinger
et al., 2007. All steps were done by Elisabeth Kremmer at Helmholtz Zentrum Munich and pro-
vided as hybridoma supernatants. Polyclonal antibodies were generated by immunization of rab-
bits as described in Weinmann et al., 2009. All steps were done at core facility of Max-Planck-
Institute of Biochemistry Martinsried/Munich and provided as blood serum.
3.3.2. Antibody purification
Monoclonal antibodies were purified with CnBr activated sepharose 4 fast flow (GE Healthcare,
Little Chalfont, UK) coupled recombinant antigen used for immunization. Sepharose columns
were prepared by swelling 300 mg sepharose powder in 1 mM HCl for 30 min on ice. 300 mg
sepharose was directly transferred into 10 ml gravity flow columns (Bio-Rad, Hercules, USA).
Column was allowed to empty by gravity flow and washed once with about 10 ml coupling buffer
until flow through was at pH 8,4. In advance, purified recombinant antigen was dialyzed against 1
l of coupling buffer over night at 4 ◦C. Dialysate was applied to column and incubated over night
at 4 ◦C or for 4 h at RT on turning wheel. After incubation, column was emptied by gravity flow
and washed with 5 packed column volumes (pcv) coupling buffer. Sepharose was resuspended
in 1 M ethanolamine pH 8,0 and incubated for 2 h at room temperature to block unused activated
CnBr. Column was washed 8 x with 3 pcv wash buffer using alternate low and high pH wash
buffer. Column was then washed once with 10 ml PBS and completely emptied by gravity flow.
Hybridoma supernatant or rabbit blood serum was freed from debris by centrifugation at 4000 rpm
for 5 min and supernatant was added to coupled sepharose. Coupling was done by incubation
over night at 4 ◦C. After incubation, column was emptied by gravity flow and washed two times
with 1 pcv PBS. Coupled antibody was eluted with elution buffer and immediately mixed with 100
µl 1 M Tris pH 8,8 per 1 ml eluate. Antibody, yield and concentration was checked by Coomassie
staining and NanoDrop measurment.
Polyclonal antibodies were purified by HiTrap Protein A FF columns by affinity purification. Pu-
rification was done by Nicholas Putz.
3.4. in vitro transcription/translation
Coupled in vitro transcription/translation of human GW182 proteins were performed using TNT
Coupled Reticulocyte Lysate System (Promega, Madison, USA) according to the manufacturer’s
protocol. pET28a plasmids were used for T7-dependent transcription containing TNRC6A, TNRC6B,
TNRC6C wildtype and mutant coding sequences. Sequences were transcribed and translated in
vitro in the presence of [35S]-methionine (Hartmann Analytics, Braunschweig, Germany).
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3.5. Preparation of cell extracts
3.5.1. Preparation of whole cell extracts
Cell extracts for analysis of Ago2 and TNRC6A and corresponding controls, cells were lyzed with
IP lysis buffer. About 1 x 106 cells were thoroughly resuspended in 100 µl IP lysis buffer by
pipetting and incubated on ice for 20 min with vortexing time by time. Lysates were then cleared
by centrifugation at highest speed for 15 min at 4 ◦C in a table top centrifuge. Supernatant was
supplemented with Laemmli buffer or used for Immunoprecipitations.
Whole cell extracts for analysis of CAMTA1 and corresponding controls were generated by cell
lysis in nuclear lysis buffer for 20 min and subsequent sonification for 10 s using a Sonopuls
HD2070 sonifier (Bandelin Electronic, Berlin, Germany). SDS and other components of nuclear
lysis buffer ensure complete dissociation of the cell. Lysates were then cleared by centrifugation
at highest speed for 15 min at 4 ◦C in a table top centrifuge. Supernatant was supplemented with
Laemmli buffer.
For direct and fast lysis of whole cells, cells were scraped off the wells in PBS, centrifuged for
4 min at 100-200 g and resuspended in 1 x Laemmli buffer. After sonification for 15 sec, samples
were loaded on Western Blot.
3.5.2. Preparation of subcellular extracts
Nucleo-cytoplasmic fractionations were done from HeLa S3 suspension cultures according to Dig-
nam et al., 1983 with some slight modifications. Cells were harvested for 20 min at 500 g, washed
once with PBS and packed cell volume (pcv) was detected (1 l HeLa S3 suspension culture at
1 x 106 cells/ml gives a pcv of about 2,5 ml). Cells washed once carefully with 5 pcv Roeder A,
centrifuged for 5 min at 1000 g and resuspended in 3 pcv Roeder A. Cells were incubated for 15
min on ice for sweelling and transfered into a douncer with a Type B pestle. Cells were dounced
until Trypan-blue exclusion staining revealed 90 to 95 % positive cells. Lysate was centrifuged for
10 min at 3000 g. Supernatant was taken, volume was determined and supplemented with 0,1 vol
Roeder B which gave the raw cytoplasmic extract. Raw cytoplasmic extract was cleared by high
speed centrifugation for 60 min at 100000 g, lipid film was completely taken off from the top of
the supernatant and remaining supernatant was saved as cleared cytoplasmic extract. Nucleus
pellet was washed twice with 5 pcv Roeder A and resuspended in 3 ml/109 cells Roeder C. Nuclei
were lyzed by 10 strokes with type B pestle and 30 min incubation at 4 ◦C on a magnetic stirrer.
Extract was crude nuclear extract. Soluble and insoluble nuclear extracts were generated from
crude nuclear extract by centrifugation for 20 min at 25000 g. Supernatant and pellet were seper-
ated, pellet was resuspended in 3 ml/109 cells Roeder C and sonified. Both fractions were cleared
by high speed centrifugation for 20 min at 25000 g and declared as cleared nuclear soluble and
insoluble extract. Samples were analyzed by Western Blot and detection of nuclear Lamin A/C
and cytoplasmic αTubulin.
3.6. GST pulldowns
GST pulldowns were done essentially as described in Steinhoff et al., 2009. Proteins were
expressed and purified as described in section 3.2.3 and 3.2.2. Coupled in vitro transcrip-
tion/translation was described in section 3.4.
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Purified His-Importin β, HA-Ago2 or Nucleoplasmin was added to Importin α if needed. [35S]-
labelled protein was added to the reaction and incubated at 4 ◦C for 1 h with GST pulldown
buffer pre-equilibrated glutathion sepharose beads (GE Healthcare, Little Chalfont, UK). After
incubation, samples were washed three times with GST pulldown buffer and elution was done by
adding 1 x Laemmli buffer. To detect [35S]-labeled proteins, the dried gels were autoradiographed
and binding was visualized by analyzing the data with a CR 35 BIO (Dürr Medical, Bietigheim-
Bissingen, Germany) and the Aida Image Analyser v 4.27 (Raytest, Straubenhardt, Germany).
3.7. SDS-PAGE and Western-Blot
SDS-PAGE gels were prepared with a 10 % separation gel and 5 % stacking gel. After poly-
merization, gels were stored at 4 ◦C until use. Samples were mixed with 4x Laemmli buffer and
heated for 5 min at 95 ◦C. After gel run with SDS running buffer, proteins were blotted semi-dry
onto a Hybond-ECL membrane (GE Healthcare, Little Chalfont, UK) using Towbin buffer for 2 h
at 13 V. Membrane was blocked using Western Blot blocking buffer. Antibodies were incubated
using Western Blot wash buffer. Between 1st and 2nd antibody, membrane was washed trice
for 10 min with Western Blot wash buffer. After 2nd antibody, membrane was washed once with
Western blot wash buffer and twice for 10 min with PBS. Antibodies are listed in table 1.8. 2nd
antibody was peroxidase coupled and signal was produced using enhanced chemiluminescence
(ECL) substrate as described in Sambrook et al., 1989.
4. Cell Biological Methods
4.1. Cultivation of mammalian cells
All cells except for HeLa S3 spinner cultures were cultivated at 37 ◦C in a humidified chamber
with air atmosphere and addition of 5 % CO2. HeLa spinner cultures were cultivated at 37 ◦C in
air atmosphere. HPAEC were grown on gelatine coated surface, all other cell lines were cultivated
on uncoated plastic surface.
Human glioblastoma cell lines (except for immortal glioblastoma cell lines) were cultivated in
6-well formate with 2 ml neural stem cell medium complete per well. Cells were passaged all 3
to 5 days by detaching with a pipette. In all, 50 % of the medium was substituted twice weekly
and cells were transfered into new wells after each passage. Cell lines were not used for exper-
iments directly after isolation from patients but were passaged frequently before. The number of
passages is not known.
HeLa, HEK 293T, NIH 3T3, U-2 OS, HCT116, Hep G2, HuH-7, A549, H1299, MCF7, T-47D,
NCCIT, MRC-5, DU 145, GM5756, Ntera2, LN-229, U87MG, T98G, SMA-560 and Sk-Mel-28
were cultivated in standard cell culture medium. Arpe-19 was cultivated in DMEM-F12 complete
medium. DLD-1 and LNCaP were cultivated in RPMI complete medium. Cells were passaged
twice weekly using trypsinization. Trypsin was purchased as 1x solution from Sigma Aldrich (Mu-
nich, Germany).
Human pulmonary artery smooth muscle cells (HPASMC) were cultivated in SmBM complete
and human pulmonary artery endothelial cells (HPAEC) were cultivated in EBM-2 complete. Pri-
mary keratinocytes were cultivated in Keratinocyte medium. Cells were passaged twice weekly
using trypsinization.
For growing HeLa S3 cells in suspension cultures, 10 15 cm plates of adherent HeLa S3 were
detached by trypsinization, pelleted by centrifugation at 200 g for 5 min and used to inoculate 150
of Joklik’s medium in a spinner flask (Corning). Suspension culture adapted cells were then frozen
and new suspension cultures were directly inoculated from frozen cells. Cells were cultivated
with closed lids, allowing atmosphere to refresh every 48 h. Cells were diluted twice weekly to
concentrations of 0,5 x 106 cells/ml and maximum cell density before splitting was 1,0 to 1,2 x 106
cells/ml.
For transfections with Lipofectamine 2000 or Nucleofection, cells were cultivated without peni-
cillin/streptomycin 1 d before transfection.
4.2. Cultivation of insect cells and baculovirus production
Recombinant baculovirus production and cultivation of insect cells was done as described in the
Bac-to-Bac manual and guide to baculovirus expression vector systems and insect cell culture
techniques manual provided by Life Technologies (Carlsbad, USA).
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4.3. Cell transfections
R11 and R8 were transfected with 2’-O-methylated miRNA inhibitors, miRNA mimics and siRNAs
using Lipofectamine 2000 (Life Technologies, Carlsbad, USA). 4 x 105 cells were used per trans-
fection and final concentrations of 100 nM for 2’-O-methylated miRNA inhibitors or 40 nM for
siRNAs and miRNA mimics were used. Transfections were done in 6-well format using 5 µl
Lipofectamine 2000, 10 cm format using 25 µl Lipofectamine 2000 or T75 flasks using 60 µl
Lipofectamine 2000. Transfection premixes containing OptiMEM with siRNA/miRNA/inhibitor and
OptiMEM with Lipofectamine 2000 were prepared and incubated for 5 min, mixed and incubated
for further 20 min before cells were added. For cotransfection of two different 2’-O-methylated
miRNA inhibitors into R11, each oligo was added to 50 nM final concentration, to give an overall
concentration of 100 nM. Transfection mix was removed 24 h post-transfection and fresh SCM
was added.
R28, R11, LN-229 and SMA-560 were transfected with plasmids by electroporation using Nu-
cleofector Device I and Nucleofector Kit R (both from Lonza, Basel, Switzerland). 3 Mio cells
LN-229 and SMA-560 and 100.000 cells R28 and R11 were used per transfection. 5 µg plasmid
were transfected using program A-33 and cells were plated out on 10 cm plates. For nucleo-
fection, plasmids were prepared using EndoFree Plasmid Midi Kit (Qiagen, Hilden, Germany) to
ensure optimal cell viability after transfection.
T98G was cotransfected with plasmids and 2’-O-methylated miRNA inhibitors using Lipofec-
tamine 2000 (Life Technologies, Carlsbad, USA) as given by the manufacturer’s forward protocol.
Inhibitors were used at 80 nM final concentration, siRNAs at 40 nM final concentration and pMIR-
RL plasmids were transfected with 100 ng/48-well well. All transfections were done in 48-well
format.
HEK 293T was transfected with plasmids using Lipofectamine 2000 (Life Technologies, Carls-
bad, USA) according to the manufacturer’s forward protocol and 90 % confluent cells in different
plate formats.
4.4. Preparation of stable cell lines
4.4.1. Generation of stable HeLa cell lines
For generation of stable HeLa cell line expressing FH-SV40NLS-Ago2, HeLa was transfected with
pIRES-Flag/HA-SV40NLS-Ago2 in 6-well format. Cells were split one day post transfection into
one 15 cm plate and selection was started with 400 µg/ml G418 (GE Healthcare/PAA). Clones
were picked 4 weeks after transfection and tested for expression by Western and Immunofluores-
cence. Stable clones were maintained in the same medium as used for selection.
4.4.2. Generation of stable inducible HEK 293T cell lines
For generation of stable inducible Flp-In T-REx 293 cell lines, cells were grown for 24 h without
Zeocin and Blasticidin until transfection. Cells were cotransfected with pOG44 and pcDNA5-
FRT/TO in a 9:1 ratio in 6-well format and split to one 10 cm plate one day post-transfection.
Selection was started two days post-transfection by splitting cells into two 15 cm plates and addi-
tion of 15 µg/ml Blasticidin and 200 µg/ml Hygromycin B (Life Technologies). Clones were picked
two weeks later and tested for Zeocin sensitivity, inducibility and expression levels. Expression
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was induced for 24 h with 1 µg/ml Tetracycline (Sigma Aldrich). Stable clones were maintained
in the same medium as used for selection. Stable T-REx 293 cell lines were generated by Kerrin
Hansen Intana.
4.4.3. Generation of a stable Luciferase expressing R28 cell line
Third-generation packaging, VSV-pseudotyped, self-inactivating lentiviral vectors were produced
by transient transfection of HEK 293T cells using standard protocols (Wübbenhorst et al., 2010).
Medium was changed to stem cell medium after 24 h. Supernatants were filtered through 0,45
µm filter and used for spin infection (Leisegang et al., 2008). Individual wells of a 24-well plate
were coated with 400 µl RetroNectin (Takara Bio, Otsu, Japan) at 12,5 mg/ml final concentration
for 2 h at room temperature, subsequently incubated for 30 min at 37 ◦C with bovine serum
albumine (2 % in PBS) and washed with PBS prior to addition of cells. 1x105 cells/ml suspension
cells were added onto RetroNectin coated wells. 1 ml virus containing supernatant supplemented
with protamine sulphate at 4 mg/ml final concentration was added to each well and infection was
enhanced by 90 min centrifugation at 32 ◦C and 800 g. Cells were incubated at 37 ◦C. The next
day, cells were washed off the wells, spun down, resuspended in 5 ml fresh SCM and further
cultivated.
Cell line was tested by detection of Luciferase activity on a Mithras LB 940 luminometer (Berthold
Technologies, Bad Wildbad, Germany). Luciferase substrate reagents were purchased from PJK
(Kleinbittersdorf, Germany).
4.5. Investigation of nucleocytoplasmic transport processes
4.5.1. Heterokaryon Assay
2 x 105 HeLa cells, stable monoclonal HeLa or HEK 293T TRex FLP/IN were plated out on cover
slips in 24-well plates one day before assay. HEK TRex FLP/IN cell lines were induced 24 h
before addition of NIH 3T3 cells. 2 h before addition of NIH 3T3 cells, medium was changed
to DMEM/CHX solution. 4 x 104 cells NIH 3T3 were added to wells and cocultured with HeLa
for 2 to 4 h until attachment of NIH 3T3. Cells were then treated with 1 ml PEG solution for 2
min at room temperature followed by 5 washing steps with PBS-A. Then, DMEM/CHX solution
was added again to cells for 4 hours. Assay was stopped by adding IF Fixation solution. For
detection of endogenous Ago2 or FH-NLS-Ago2, cells were used for immunofluorescence staining
as described in section 5.1. For detection of eGFP-Ago2 or eGFP-Ago2 Y529E, cells were directly
mounted after Fixation solution, Stopping solution and one PBS-A wash.
4.5.2. Leptomycin B treatments
Leptomycin B was purchased from Cayman Chemicals (Ann Arbor, USA) as 0,1 mg/ml solution in
Ethanol. Leptomycin B was added to cells to 10 ng/ml final concentration in standard cultivation
medium. Ethanol was added to control cells without Leptomycin B. Treatments were done for 4 h
and stopped by addition of Fixation solution for IF and subsequent immunofluorescence staining
as described in section 5.1.
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4.6. Flow cytometry
4.6.1. Fluorescence-activated cell sorting and analysis
Cells were trypsinized and washed with DMEM-F12 and FACS buffer. FACS staining has essen-
tially been done as described in anti-CD133-PE manual (Miltenyi, Bergisch Gladbach, Germany).
In short, 107 cells were resuspended in 80 ml FACS buffer containing 10 % FcR blocking reagent
(Miltenyi, Bergisch Gladbach, Germany) and incubated for 5 min on ice. In all, 10 µl anti-CD133-
PE was added, and cells were incubated for 10 min on ice in the dark. Cells were pelleted and
washed once with FACS buffer. Stained cells were sorted on an FACS Aria system (BD Bio-
sciences, Franklin Lakes, USA). Cell debris were gated out using a forward scatter/sideward scat-
ter dot plot. CD133-negative and CD133-positive cell populations were identified using unstained
cells as control.
4.6.2. Cell cycle progression analysis
Cells were harvested by trypsinization, Trypsin was neutralized with standard cell culture medium
and 2 x 106 cells were collected by centrifugation at 200 g for 5 min at 4 ◦C. Cells were washed
once with 4 ◦C PBS and resuspended in 300 µl 4 ◦C PBS. Cells were fixed by dropwise addition
of 700 µl ice cold 70 % EtOH while gently vortexing and subsequently incubated for 1 h at 4 ◦C.
Cells were collected again by centrifugation, washed once with 1 ml PBS and resuspended in 1
ml PBS with 100 µg/ml RNase A. After incubation for 1 h at 4 ◦C, 50 µl 1 mg/ml Propidium Iodide
(Sigma Aldrich, Munich, Germany) was added to cells. Cells were then stored in the dark at 4 ◦C
and analyzed using CyFlow Space (Partec, Münster, Germany) at 488 nm.
4.7. Neurosphere-formation assays
Analysis of neurosphere-formation in primary glioblastoma cell lines have been done following
transfection with miRNA inhibitors, miRNA mimics or siRNAs using Lipofectamine 2000 or plas-
mids using Nucleofection. Transfections have been done as described in section 4.3. For effects
of miRNA mimics, inhibitors and siRNAs, cell were transfected twice with 7 d between 1st and
2nd transfection. Single transfections did not lead to significant effects by miRNA inhibitors and
miRNA mimics, presumably due to transient activity of the transfected RNA. Plasmid transfection
have been done only once.
1 x 105 cells R11 were transfected in 6-well plates. For the second transfection, cells in control
transfected sample was counted and again 1 x 105 cells were used for transfection. From non-
control samples, the same proportion of cells as in the control sample was used.
1 to 4 weeks after the last transfection or as soon as clear neurospheres (clearly distinguishable
from not growing cell clumps) appeared, spheres were counted under inverted microscope. For
each 6-well well, cells were counted as follows: Cells in the microscope field of view were counted
throughout a complete well diameter and diameters were counted in duplicates per well with 90◦
between the two diameter lines. The ratio of spheres in control versus non-control samples was
constant during late and early timepoints of counting.
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4.8. Luciferase Reporter Assays
Dual luciferase reporter assays have been done with T98G and HeLa cells. pMIR-RL encodes
for firefly (Photinus pyralis) and renilla (Renilla reniformis) luciferases. Firefly luciferase expres-
sion is initiated from constitutive CMV promoter and a 3’-UTR was cloned downstream of firefly
open reading frame, which controls expression of firefly. Renilla is under control of constitutive
SV40 promoter. Cells were cotransfected with 250 ng pMIR-RL and miRNA inhibitors, siRNAs
and siPools. For cotransfection with other plasmids, 125 ng of each plasmid was transfected.
Transfections have been done in 48-well format as described in section 4.3. T98G was analyzed
24 h post-transfection. HeLa was analyzed 48 or 72 h post-transfection. T98G was used as it
was the glioblastoma cell line with highest transfection efficiency and high firefly and renilla ex-
pression levels. Cells were lyzed in passive lysis buffer (Promega, Madison, USA). Luciferase
activities were measured on a Mithras LB 940 luminometer (Berthold Technologies, Bad Wildbad,
Germany). Luciferase substrate reagents were purchased from PJK (Kleinbittersdorf, Germany).
Coelenterazine and DTT were added freshly before use. All samples were assayed in 3 technical
and 3-6 biological replicates. Data were analyzed by calculating firefly/renilla ratio for each well
and normalization of the ratios to control transfected samples.
5. Microscopy
5.1. Immunofluorescence stainings
Fixation solution was prepared as 1x stock and frozen at -20 ◦C until use. PBS-A, Fixation solution
and Stopping solution were prewarmed to 37 ◦C before addition to cells to prevent damage of cell
morphology prior to fixation. For immunofluorescence stainings, cells were cultivated 1 day before
staining in 24-well plates with 12 mm diameter cover slips of thickness #1,5 (0,15-0,19 mm) for
confocal microscopy (Carl Roth, Karlsruhe, Germany). All steps were done in 24-well format
with 500 µl volumes for all washing steps or 300 µl for antibody containing solutions. During all
wash steps, the time in which sample was exposed to air was minimized by addition of new wash
solution directly after aspirating the wash step before.
Cells were washed once with PBS-A and fixed with Fixation solution for 10 min at 37 ◦C. Fixa-
tion of cells expressing eGFP or related fluorescent proteins which will be detected later on was
reduced to 8 min at 37 ◦C to prevent protein damage. Fixation was stopped adding Stopping so-
lution for 5 min. All following steps were done at room temperature. Cells were washed once with
PBS-A and permeabilized with Permeabilization solution for 30 min. Permeabilization solution
was thoroughly vortexed before adding to cell in order to reduce detergent micelle size allowing
consistent and efficient permeabilization while preventing morphology changes. After washing off
detergent by one wash step with PBS-A, cells were blocked with Wash solution containing 5 %
BSA for 30 min. First antibody incubation was done in Wash solution for 1 h at room temperature
or over night at 4 ◦C. After three washing steps with Wash solution and incubation for 5 min at RT
between wash step 2 and 3, secondary antibody was added for 1 h at room temperature or 4 ◦C
over night. Cells were then washed once with Wash solution and trice with PBS-A and incubated
for 5 min between PBS-A wash 2 and 3 and between 3 and 4. Cells were then mounted using
Prolong Gold with 4’,6-diamidino-2-phenylindole (DAPI) (Life Technologies, Carlsbad, USA): 11 µl
mounting medium was placed on a microscope slide, excess liquid was removed from cover slip
by dipping on paper and cover slip was placed inverted on the mounting medium drop. Mouting
medium was allowed to dry for minimum 12 h.
5.2. Microscopy
Confocal microscopy has been done with a TCS SP8 (Leica Microsystems, Mannheim, Germany)
inverted microscope equipped with acousto-optical beam splitter, 405 nm laser (for DAPI), Argon
laser (488 nm for Alexa 488 and GFP) and DPSS laser 561 nm (for Alexa 555). All confocal
images were recorded using objective HC PL APO 63x/1,30 GLYC CORR CS2 and focusing to the
z section with the biggest nucleus diameter. Images for quantifications have been recorded with
HyD SP GaAsP detectors (Leica Microsystems, Mannheim, Germany). Images were recorded
using following microscope and scanning settings: Format 1024 x 1024; scan speed 700, 1000 or
1400 Hz; unidirectional scanning; pinhole size of 1 AU calculated by LAS AF for emission λ = 580
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Figure 4.5.1. Schematic demonstration of CellProfiler pipeline generated for measurement of cytoplasmic to
nuclear protein distribution. Pipeline is shown using the example of an Ago2 staining with anti-Ago2 11A9 antibody and
HeLa cells.
nm; 3 line averages. PMT detector gain was set to 750 V and offset was reduced until 50 % of all
image background pixels showed no signal. HyD detectors were set to standard mode and were
not changed from initial company settings. Scan speed and not the zoom mode was changed
to record either large or small field of views. Following procedures were done to prevent cross
talk between dyes: Dye combinations were chosen which show clearly seperated extinction and
emission spectra (Alexa Fluor 488, 555 and 594); all channels were recorded separately using
sequential scanning mode. Cross talk was controled by recording samples without primary or
secondary antibodies. Background detection was reduced by initial adjustment of laser power
and detector gain to detect minimal or no signal from samples without primary antibody.
Fluorescence microscopy was done with a Axiovert 200 inverse microsope (Zeiss Microscopy,
Jena, Germany) with Axiovision software (Zeiss Microscopy, Jena, Germany) or on a Eclipse
TE2000 inverted microscope (Nikon Instruments, Düsseldorf, Germany) equipped with a Zeiss
camera and Axiovision software.
5.3. Microscopy data analysis and quantifications
Quantifications were done from tif files exported from LAS AF software (Leica Microsystems,
Mannheim, Germany). Quantification was automated using CellProfiler v. 2.1.0 (Carpenter et al.,
2006). CellProfiler pipeline is shown in Figure 4.5.1. In a first step, the pipeline detects nuclei
from DAPI pictures. Cytoplasm was detected from anti-Ago2 or anti-TNRC6B antibody staining
around nucleus objects. Then nuclear and cytoplasmic objects were separated with a margin of 10
pixels around the nuclear envelope from where no signal was included into analysis. Signal from
antibody staining was then measured as a mean pixel value from nuclear and cytoplasmic objects
and exported to a Excel file. Nucleo-cytoplasmic ratio was calculated with excel and normalized
to control sample or shown as absolute ratios. The nucleo-cytoplasmic ratio does represent the
ratio in the recorded z section and should therefore also represent the mean ratio of the whole
cell. However, due to the detection of mean signal intensities this method does not measure total
protein levels and does not normalize to different nuclear and cytoplasmic compartment volumes
and therefore does not show total nucleo-cytoplasmic ratios of proteins.
Nuclear and cytoplasmic TNRC6A foci were manually counted from 100 randomly picked cells
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per sample and cells were classified into cells with nuclear, intermediate and cytoplasmic foci. A
cell is classified as ”nuclear” (”cytoplasmic”), if more than 80 % of the foci are nuclear (cytoplas-
mic). Cells which show 21 to 79 % foci in the nucleus or cytoplasm are classified as ”intermediate”.
For figure images, representative cells were selected, picture was cropped and contrast was
increased to the same extend for all pictures of one panel.
6. In vivo Experiments
6.1. Mouse strains
Following mouse strains were used or generated during this study:
C57BL/6 obtained from local ZTL maintained stock.
NMRI:nu/nu full name Crl:NMRI-Foxn1nu was obtained from Charles River.
Nes-Cre/ERT2+/0 full name C57BL/6-Tg(Nes-cre/ERT2)KEisc/J was obtained from Jackson Lab-
oratories, stock number 016261 (Lagace et al., 2007).
CAMTA1fl/fl full name not known but has mixed genetic background of 129 and C57BL/6. Ob-
tained and previously characterized in Long et al., 2014.
CAMTA1fl/fl / Nes-Cre/ERT2+/0 was generated by crossing Nes-Cre/ERT2+/0 and CAMTA1fl/fl. F1
animals were genotyped and Nes-Cre/ERT2+/0 and CAMTA1fl/0 animals were selected and
paired again to obtain CAMTA1fl/fl / Nes-Cre/ERT2+/0.
6.2. Murine xenograft model for CAMTA1 overexpression
Transfection of R28-luc was done by Nucleofection as described in section 4.3. 1 day before, cells
were cultivated in SCM without penicillin/streptomycin. Three hours after transfection, cell viability
was determined by trypan blue exclusion and 140.000 viable cells were resuspended in PBS to
give total concentration of 140.000 viable cells in 3 µl PBS.
Intracranial glioblastoma xenografts were established in 10 week old male NMRI:nu/nu mice
(Charles River, Wilmington, USA) essentially as described in Beier et al., 2007. All experimental
procedures were conducted in accordance with German laws governing animal care. Group size
was 15 mice, i.e. 15 mice were injected per sample. A burr hole was drilled 2 mm dorsal to the
midline and 4 mm anterior to bregma. Transfected tumour cells were stereotactically injected to a
depth of 3 mm from the dura, using a manual Hamilton syringe and an injection volume of about
3 µl over 1 min. The burr hole was closed with cement.
Tumor size was analyzed 15 days after implantation by bioluminescence detection. 15 days
were chosen as successfully developed tumors show stable growth after 15 days without severely
affecting the animal. Mice were observed continuously after injection and animal was killed as
soon as clear pain expression was observed. 1 min after injection of 150 mg/kg D-luciferin
(Biosynth, Staad, Switzerland), mice were anaesthetized and emitted photons were registered for
5 min using Xenogen IVIS Lumina Imaging System (Caliper Life Sciences, Hopkinton, USA). The
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signal was corrected to background signal and mice without detectable tumours were excluded
from the analysis.
6.3. Isolation of neural stem cells
For isolation of neural stem cells, mice were killed with CO2. Mice were decapitated and brain
was isolated and stored in PBS on ice. Dissection was done under dissection microscope as
described in Walker and Kempermann, 2014 to isolate subventricular zone (SVZ), dentate gyrus
(DG), cortex and cerebellum. Tissue samples of approximately similar size were minced using a
scalpel for 1 min and transfered into 3 ml 0,05 % Trypsin-EDTA or Accutase (Life Technologies)
followed by 20 min incubation at 37 ◦C in water bath. Cells were pipetted time by time with 1 ml
pipet. Cells were then filled up to 15 ml with SCM incomplete and spin down at 300 g for 5 min at
RT. Supernatant was discarded and pellet thoroughly resuspended in 10 ml SCM complete. Cells
were finally passaged through a 70 µm filter and plated on 10 cm plates. Neurospheres started to
develop 5 to 7 days post isolation and continued to increase in sice rapidly. Cells were passaged
every five days with 50 % medium exchange and singularization by pipetting. Short spins at
very low g-force were done to separate spheres from dead cells that remained from isolation if
necessary. Pure isolation of brain regions was not controlled but neurospheres only developed
from SVZ samples.
6.4. Mouse genotyping
Genomic DNA preparation by NaOH extraction was done as follows from mouse tail tip biopsies
or brain tissue samples. Brain tissue samples were snap frozen with liquid nitrogen and sheared
with a mortar in liquid nitrogen in advance. Tail or mortared tissue was mixed with 75 µl 25 mM
NaOH / 0,2 mM EDTA and placed in a thermocycler at 98 ◦C for 1 hour. Then temperature was
reduced to 15 ◦C. 75 µl 40 mM Tris pH 5,5 were added and mixed. After centrifugation at 4000
rpm for 3 min, an aliquot of 1 µl was used as template for genotyping PCR. Multiplexed PCR
for detection of Cre-allel and various CAMTA1 allels was set up using Taq DNA polymerase (Life
Technologies) in the following reaction:
2,5 µl 10 x Taq buffer with (NH4)2SO4 without MgCl2
0,125 µl 10 mM dNTP mix
0,125 µl A1CKOsLA Seq
0,125 µl A1CKOASeq-6
0,125 µl A1CKOfP-1
0,125 µl oIMR1084 cre fwd
0,125 µl oIMR1085 cre rev
2 µl 25 mM MgCl2
1 µl template DNA from NaOH extraction
18,625 µl H2O
0,125 µl 5 U/µl recombinant Taq DNA Polymerase
PCR was done as follows:
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95 ◦C 2 min
95 ◦C 30 sec
55 ◦C 30 sec
72 ◦C 45 sec
72 ◦C 7 min
4 ◦C infinite
Following bands correspond to either Cre or CAMTA1 alleles and were analyzed by agarose gel
electrophoresis on a 1 % agarose gel:
390 nt CAMTA1wt (C57BL/6 were used)
390 + 495 nt CAMTA1fl/wt
495 nt CAMTA1fl/fl
700 nt CAMTA1fl/fl floxed allel
no band Nes-Cre/ERT20/0
100 nt Nes-Cre/ERT2+/0
Of note, in some cases multiplexing of Cre and CAMTA1 specific primers resulted in a decrease
in CAMTA1 specific bands. If this was observed, two separate PCRs were set up, one with
A1CKOsLA Seq/A1CKOASeq-6/A1CKOfP-1, the second with oIMR1084 cre fwd/oIMR1085 cre
rev.
7. Computational methods and statistical
analyses
7.1. Analysis of glioblastoma patient data
7.1.1. GBM patient data copy number variation analysis
For genomic copy number variation analyses around CAMTA1 genomic locus in patients suffering
from Glioblastoma multiforme, a published dataset from 587 Glioblastoma multiforme samples
(TCGA, 2008) was accessed via the UCSC Cancer Browser. Copy number profile was determined
by analyzing SNP and copy-number markers from an Affymetrix Genome-Wide Human SNP Array
6.0 (TCGA, 2008).
7.1.2. GBM patient data gene expression and survival analysis
Repository for Molecular Brain Neoplasia Data (REMBRANDT) is a publicly available brain tumor
dataset managed by the National Cancer Institute. REMBRANDT contains clinical and molecular
data from clinical trial patients suffering from grade II, III and IV gliomas, i.e. not only high grade
Glioblastoma multiforme but also lower grade gliomas.
Analysis of CAMTA1 expression in glioma patients and analysis of survival data have been done
with REMBRANDT (June 2009). Higher order analysis was performed and patients suffering from
Glioblastoma multiforme, oligodendroglioma and astrocytoma have been included into analysis.
Analysis with Glioblastoma multiforme alone was not informative due to low number of patients
with differential expression of CAMTA1. P values, gene expression data for box-whisker plot and
Kaplan-Meier survival curves were generated by REMBRANDT.
For analysis of natriuretic peptide hormone system components in glioma patients, query search
function was used with REMBRANDT version 1.5.9 (November 2013) and patients with Glioblas-
toma multiformeonly were included into analysis. P values and Kaplan-Meier survival curves were
generated by REMBRANDT.
7.2. Prediction of classical NLS and NES sequences
Prediction of classical nuclear localization sequences (NLS) and nuclear expor sequences (NES)
have been performed using eukaryotic linear motif resource (ELM) tool (Dinkel et al., 2014).
ELM contains a collection of short linear motifs analyzed against input protein sequences. NLS
identifiers look for monopartite (TRG_NLS_MonoCore_2, TRG_NLS_MonoExtC_3, TRG_NLS_-
MonoExtN_4) or bipartite (TRG_NLS_Bipartite_1) basically charged NLSs which are typical sub-
strates for import factor Impα. NES identifiers (TRG_NES_CRM1_1) looks for Leucine-rich motifs
that are binding substrates to the export factor Crm1 (Exp1). Other NLS and NES sequences
which are used by non-classical import and export pathways can not be solidly predicted.
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7.3. Statistical analyses
All experiments were performed in minimum 3 biological replicates. Error bars represent the
plus/minus standard error of the mean calculated from biological replicates. Significance was
calculated from biological replicates using two-sided Student’s t-test for unequal sample variance.
P values were classified into ”∗” for P < 0,05, ”∗∗” for P < 0,005, ”∗ ∗ ∗” for P < 0,0005 and ”n.s.”
for P > 0,05.
Appendix
Figure A1 CAMTA1 multiple sequence alignment. Alignment was done with Clustal W2 includ-
ing human and mouse CAMTA1 and CAMTA2. JNet secondary structure prediction is indicated in
the lower row for hsCAMTA1. Color scheme represents percentage of conservation between all
four sequences. Figure is split in three parts 1-3. hs, Homo sapiens mm; Mus musculus.
Figure A2 Generation of the CAMTA1 conditional knockout mouse. Schematic representa-
tion the knockout strategy for CAMTA1fl/fl from Long et al., 2014. Domain organization of CAMTA1
protein is shown on the top, below the CAMTA1 locus on mouse chr 4. Exon 9, directly upstream
of the TIG domain was flanked with loxP sites for Cre-mediated recombination. Recombination
generates a premature stop codon within Exon 10. The mutant allele can generate a truncated
protein product with the N-terminal CG-1 domain. CAMTA1fl/fl mice were used for experiments
described in this study. Figure adapted from Long et al., 2014.
Figure A3 Ago2 localization in 26 different human cell lines from various tissue origins.
Confocal microscopy with anti-Ago2 antibody was done in 26 different cell lines from different
tissue origins. Figure contains two parts. Scale bar represents 20 µm.
Figure A4 Colocalization of the nuclear trapped TNRC6A NES mut with various factors. A
to E, Confocal microscopy with HEK cells stably expressing TNRC6A NES mut. TNRC6A NES
mut was detected via its GFP tag, the different factors were costained by secondary immunoflu-
orescence. These factors include components of cytoplasmic P-bodies (A and E), protein degra-
dation machinery (B), nuclear compartments (C), RNA polymerases (D). Figure contains three
parts. Scale bar represents 10 µm.
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Contributions
Part I: miR-9/9* regulate CAMTA1 in glioblastoma stem cells
The results of part I of this work have been published in parts in Schraivogel et al., 2011. Figures
of section 3 were partially adapted from Schraivogel et al., 2011 I contributed to experiments
presented in Figures 2.3.3, 2.3.4, 2.3.7, 2.3.9C, 2.3.11, 2.3.12C, 2.3.13, 2.3.14 and 2.3.15 and
analyzed data in Figures 2.3.2 and 2.3.6.
Part II: Nuclear transport of Argonaute and TNRC6 proteins
In part II of this work, I contributed all data except for pulldowns from oocyte extracts presented
in Figure 3.3.8D where I analyzed data and the GST-pulldown experiments in Figures 3.3.13 and
3.3.18B-D.
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